#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Schizotypy-Related Magnetization of Cortex in Healthy Adolescence Is Colocated With Expression of Schizophrenia-Related Genes
#Text=Background
#Text=Genetic risk is thought to drive clinical variation on a spectrum of schizophrenia-like traits, but the underlying changes in brain structure that mechanistically link genomic variation to schizotypal experience and behavior are unclear.
1-1	0-18	Schizotypy-Related	_	
1-2	19-32	Magnetization	_	
1-3	33-35	of	_	
1-4	36-42	Cortex	_	
1-5	43-45	in	_	
1-6	46-53	Healthy	_	
1-7	54-65	Adolescence	_	
1-8	66-68	Is	_	
1-9	69-78	Colocated	_	
1-10	79-83	With	_	
1-11	84-94	Expression	_	
1-12	95-97	of	_	
1-13	98-119	Schizophrenia-Related	_	
1-14	120-125	Genes	_	
1-15	126-136	Background	_	
1-16	137-144	Genetic	_	
1-17	145-149	risk	_	
1-18	150-152	is	_	
1-19	153-160	thought	_	
1-20	161-163	to	_	
1-21	164-169	drive	_	
1-22	170-178	clinical	_	
1-23	179-188	variation	_	
1-24	189-191	on	_	
1-25	192-193	a	_	
1-26	194-202	spectrum	_	
1-27	203-205	of	_	
1-28	206-224	schizophrenia-like	_	
1-29	225-231	traits	_	
1-30	231-232	,	_	
1-31	233-236	but	_	
1-32	237-240	the	_	
1-33	241-251	underlying	_	
1-34	252-259	changes	_	
1-35	260-262	in	_	
1-36	263-268	brain	_	
1-37	269-278	structure	_	
1-38	279-283	that	_	
1-39	284-299	mechanistically	_	
1-40	300-304	link	_	
1-41	305-312	genomic	_	
1-42	313-322	variation	_	
1-43	323-325	to	_	
1-44	326-337	schizotypal	_	
1-45	338-348	experience	_	
1-46	349-352	and	_	
1-47	353-361	behavior	_	
1-48	362-365	are	_	
1-49	366-373	unclear	_	
1-50	373-374	.	_	

#Text=Methods
#Text=We assessed schizotypy using a self-reported questionnaire and measured magnetization transfer as a putative microstructural magnetic resonance imaging marker of intracortical myelination in 68 brain regions in 248 healthy young people (14–25 years of age).
2-1	375-382	Methods	_	
2-2	383-385	We	_	
2-3	386-394	assessed	_	
2-4	395-405	schizotypy	_	
2-5	406-411	using	_	
2-6	412-413	a	_	
2-7	414-427	self-reported	_	
2-8	428-441	questionnaire	_	
2-9	442-445	and	_	
2-10	446-454	measured	_	
2-11	455-468	magnetization	_	
2-12	469-477	transfer	_	
2-13	478-480	as	_	
2-14	481-482	a	_	
2-15	483-491	putative	_	
2-16	492-507	microstructural	_	
2-17	508-516	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[1]	
2-18	517-526	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[1]	
2-19	527-534	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[1]	
2-20	535-541	marker	_	
2-21	542-544	of	_	
2-22	545-558	intracortical	_	
2-23	559-570	myelination	_	
2-24	571-573	in	_	
2-25	574-576	68	_	
2-26	577-582	brain	_	
2-27	583-590	regions	_	
2-28	591-593	in	_	
2-29	594-597	248	_	
2-30	598-605	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
2-31	606-611	young	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
2-32	612-618	people	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
2-33	619-620	(	_	
2-34	620-622	14	_	
2-35	622-623	–	_	
2-36	623-625	25	_	
2-37	626-631	years	_	
2-38	632-634	of	_	
2-39	635-638	age	_	
2-40	638-639	)	_	
2-41	639-640	.	_	

#Text=We used normative adult brain gene expression data and partial least squares analysis to find the weighted gene expression pattern that was most colocated with the cortical map of schizotypy-related magnetization.
3-1	641-643	We	_	
3-2	644-648	used	_	
3-3	649-658	normative	_	
3-4	659-664	adult	_	
3-5	665-670	brain	_	
3-6	671-675	gene	_	
3-7	676-686	expression	_	
3-8	687-691	data	_	
3-9	692-695	and	_	
3-10	696-703	partial	_	
3-11	704-709	least	_	
3-12	710-717	squares	_	
3-13	718-726	analysis	_	
3-14	727-729	to	_	
3-15	730-734	find	_	
3-16	735-738	the	_	
3-17	739-747	weighted	_	
3-18	748-752	gene	_	
3-19	753-763	expression	_	
3-20	764-771	pattern	_	
3-21	772-776	that	_	
3-22	777-780	was	_	
3-23	781-785	most	_	
3-24	786-795	colocated	_	
3-25	796-800	with	_	
3-26	801-804	the	_	
3-27	805-813	cortical	_	
3-28	814-817	map	_	
3-29	818-820	of	_	
3-30	821-839	schizotypy-related	_	
3-31	840-853	magnetization	_	
3-32	853-854	.	_	

#Text=Results
#Text=Magnetization was significantly correlated with schizotypy in the bilateral posterior cingulate cortex and precuneus (and for disorganized schizotypy, also in medial prefrontal cortex; all false discovery rate–corrected ps < .05), which are regions of the default mode network specialized for social and memory functions.
4-1	855-862	Results	_	
4-2	863-876	Magnetization	_	
4-3	877-880	was	_	
4-4	881-894	significantly	_	
4-5	895-905	correlated	_	
4-6	906-910	with	_	
4-7	911-921	schizotypy	_	
4-8	922-924	in	_	
4-9	925-928	the	_	
4-10	929-938	bilateral	_	
4-11	939-948	posterior	_	
4-12	949-958	cingulate	_	
4-13	959-965	cortex	_	
4-14	966-969	and	_	
4-15	970-979	precuneus	_	
4-16	980-981	(	_	
4-17	981-984	and	_	
4-18	985-988	for	_	
4-19	989-1001	disorganized	_	
4-20	1002-1012	schizotypy	_	
4-21	1012-1013	,	_	
4-22	1014-1018	also	_	
4-23	1019-1021	in	_	
4-24	1022-1028	medial	_	
4-25	1029-1039	prefrontal	_	
4-26	1040-1046	cortex	_	
4-27	1046-1047	;	_	
4-28	1048-1051	all	_	
4-29	1052-1057	false	_	
4-30	1058-1067	discovery	_	
4-31	1068-1082	rate–corrected	_	
4-32	1083-1085	ps	_	
4-33	1085-1086	 	_	
4-34	1086-1087	<	_	
4-35	1087-1088	 	_	
4-36	1088-1091	.05	_	
4-37	1091-1092	)	_	
4-38	1092-1093	,	_	
4-39	1094-1099	which	_	
4-40	1100-1103	are	_	
4-41	1104-1111	regions	_	
4-42	1112-1114	of	_	
4-43	1115-1118	the	_	
4-44	1119-1126	default	_	
4-45	1127-1131	mode	_	
4-46	1132-1139	network	_	
4-47	1140-1151	specialized	_	
4-48	1152-1155	for	_	
4-49	1156-1162	social	_	
4-50	1163-1166	and	_	
4-51	1167-1173	memory	_	
4-52	1174-1183	functions	_	
4-53	1183-1184	.	_	

#Text=The genes most positively weighted on the whole-genome expression map colocated with schizotypy-related magnetization were enriched for genes that were significantly downregulated in two prior case-control histological studies of brain gene expression in schizophrenia.
5-1	1185-1188	The	_	
5-2	1189-1194	genes	_	
5-3	1195-1199	most	_	
5-4	1200-1210	positively	_	
5-5	1211-1219	weighted	_	
5-6	1220-1222	on	_	
5-7	1223-1226	the	_	
5-8	1227-1239	whole-genome	_	
5-9	1240-1250	expression	_	
5-10	1251-1254	map	_	
5-11	1255-1264	colocated	_	
5-12	1265-1269	with	_	
5-13	1270-1288	schizotypy-related	_	
5-14	1289-1302	magnetization	_	
5-15	1303-1307	were	_	
5-16	1308-1316	enriched	_	
5-17	1317-1320	for	_	
5-18	1321-1326	genes	_	
5-19	1327-1331	that	_	
5-20	1332-1336	were	_	
5-21	1337-1350	significantly	_	
5-22	1351-1364	downregulated	_	
5-23	1365-1367	in	_	
5-24	1368-1371	two	_	
5-25	1372-1377	prior	_	
5-26	1378-1390	case-control	_	
5-27	1391-1403	histological	_	
5-28	1404-1411	studies	_	
5-29	1412-1414	of	_	
5-30	1415-1420	brain	_	
5-31	1421-1425	gene	_	
5-32	1426-1436	expression	_	
5-33	1437-1439	in	_	
5-34	1440-1453	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
5-35	1453-1454	.	_	

#Text=Conversely, the most negatively weighted genes were enriched for genes that were transcriptionally upregulated in schizophrenia.
6-1	1455-1465	Conversely	_	
6-2	1465-1466	,	_	
6-3	1467-1470	the	_	
6-4	1471-1475	most	_	
6-5	1476-1486	negatively	_	
6-6	1487-1495	weighted	_	
6-7	1496-1501	genes	_	
6-8	1502-1506	were	_	
6-9	1507-1515	enriched	_	
6-10	1516-1519	for	_	
6-11	1520-1525	genes	_	
6-12	1526-1530	that	_	
6-13	1531-1535	were	_	
6-14	1536-1553	transcriptionally	_	
6-15	1554-1565	upregulated	_	
6-16	1566-1568	in	_	
6-17	1569-1582	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
6-18	1582-1583	.	_	

#Text=Positively weighted (downregulated) genes were enriched for neuronal, specifically interneuronal, affiliations and coded a network of proteins comprising a few highly interactive “hubs” such as parvalbumin and calmodulin.
7-1	1584-1594	Positively	_	
7-2	1595-1603	weighted	_	
7-3	1604-1605	(	_	
7-4	1605-1618	downregulated	_	
7-5	1618-1619	)	_	
7-6	1620-1625	genes	_	
7-7	1626-1630	were	_	
7-8	1631-1639	enriched	_	
7-9	1640-1643	for	_	
7-10	1644-1652	neuronal	_	
7-11	1652-1653	,	_	
7-12	1654-1666	specifically	_	
7-13	1667-1680	interneuronal	_	
7-14	1680-1681	,	_	
7-15	1682-1694	affiliations	_	
7-16	1695-1698	and	_	
7-17	1699-1704	coded	_	
7-18	1705-1706	a	_	
7-19	1707-1714	network	_	
7-20	1715-1717	of	_	
7-21	1718-1726	proteins	_	
7-22	1727-1737	comprising	_	
7-23	1738-1739	a	_	
7-24	1740-1743	few	_	
7-25	1744-1750	highly	_	
7-26	1751-1762	interactive	_	
7-27	1763-1764	“	_	
7-28	1764-1768	hubs	_	
7-29	1768-1769	”	_	
7-30	1770-1774	such	_	
7-31	1775-1777	as	_	
7-32	1778-1789	parvalbumin	_	
7-33	1790-1793	and	_	
7-34	1794-1804	calmodulin	_	
7-35	1804-1805	.	_	

#Text=Conclusions
#Text=Microstructural magnetic resonance imaging maps of intracortical magnetization can be linked to both the behavioral traits of schizotypy and prior histological data on dysregulated gene expression in schizophrenia.
8-1	1806-1817	Conclusions	_	
8-2	1818-1833	Microstructural	_	
8-3	1834-1842	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[3]	
8-4	1843-1852	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[3]	
8-5	1853-1860	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[3]	
8-6	1861-1865	maps	_	
8-7	1866-1868	of	_	
8-8	1869-1882	intracortical	_	
8-9	1883-1896	magnetization	_	
8-10	1897-1900	can	_	
8-11	1901-1903	be	_	
8-12	1904-1910	linked	_	
8-13	1911-1913	to	_	
8-14	1914-1918	both	_	
8-15	1919-1922	the	_	
8-16	1923-1933	behavioral	_	
8-17	1934-1940	traits	_	
8-18	1941-1943	of	_	
8-19	1944-1954	schizotypy	_	
8-20	1955-1958	and	_	
8-21	1959-1964	prior	_	
8-22	1965-1977	histological	_	
8-23	1978-1982	data	_	
8-24	1983-1985	on	_	
8-25	1986-1998	dysregulated	_	
8-26	1999-2003	gene	_	
8-27	2004-2014	expression	_	
8-28	2015-2017	in	_	
8-29	2018-2031	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
8-30	2031-2032	.	_	

#Text=SEE COMMENTARY ON PAGE 212
#Text=The genetic architecture of schizophrenia spectrum disorders assumes many independent allelic variations, each of small effect, contributing to the probability of diagnosis.
9-1	2033-2036	SEE	_	
9-2	2037-2047	COMMENTARY	_	
9-3	2048-2050	ON	_	
9-4	2051-2055	PAGE	_	
9-5	2056-2059	212	_	
9-6	2060-2063	The	_	
9-7	2064-2071	genetic	_	
9-8	2072-2084	architecture	_	
9-9	2085-2087	of	_	
9-10	2088-2101	schizophrenia	_	
9-11	2102-2110	spectrum	_	
9-12	2111-2120	disorders	_	
9-13	2121-2128	assumes	_	
9-14	2129-2133	many	_	
9-15	2134-2145	independent	_	
9-16	2146-2153	allelic	_	
9-17	2154-2164	variations	_	
9-18	2164-2165	,	_	
9-19	2166-2170	each	_	
9-20	2171-2173	of	_	
9-21	2174-2179	small	_	
9-22	2180-2186	effect	_	
9-23	2186-2187	,	_	
9-24	2188-2200	contributing	_	
9-25	2201-2203	to	_	
9-26	2204-2207	the	_	
9-27	2208-2219	probability	_	
9-28	2220-2222	of	_	
9-29	2223-2232	diagnosis	_	
9-30	2232-2233	.	_	

#Text=Individuals with the greatest accumulation of genetic risk have the more severe psychotic disorder; individuals with a lower genetic risk may have less severe, nonpsychotic schizotypal personality disorder, characterized by social eccentricity and unusual beliefs.
10-1	2234-2245	Individuals	_	
10-2	2246-2250	with	_	
10-3	2251-2254	the	_	
10-4	2255-2263	greatest	_	
10-5	2264-2276	accumulation	_	
10-6	2277-2279	of	_	
10-7	2280-2287	genetic	_	
10-8	2288-2292	risk	_	
10-9	2293-2297	have	_	
10-10	2298-2301	the	_	
10-11	2302-2306	more	_	
10-12	2307-2313	severe	_	
10-13	2314-2323	psychotic	_	
10-14	2324-2332	disorder	_	
10-15	2332-2333	;	_	
10-16	2334-2345	individuals	_	
10-17	2346-2350	with	_	
10-18	2351-2352	a	_	
10-19	2353-2358	lower	_	
10-20	2359-2366	genetic	_	
10-21	2367-2371	risk	_	
10-22	2372-2375	may	_	
10-23	2376-2380	have	_	
10-24	2381-2385	less	_	
10-25	2386-2392	severe	_	
10-26	2392-2393	,	_	
10-27	2394-2406	nonpsychotic	_	
10-28	2407-2418	schizotypal	_	
10-29	2419-2430	personality	_	
10-30	2431-2439	disorder	_	
10-31	2439-2440	,	_	
10-32	2441-2454	characterized	_	
10-33	2455-2457	by	_	
10-34	2458-2464	social	_	
10-35	2465-2477	eccentricity	_	
10-36	2478-2481	and	_	
10-37	2482-2489	unusual	_	
10-38	2490-2497	beliefs	_	
10-39	2497-2498	.	_	

#Text=The genetic risk for schizophrenia has been resolved more clearly by recent genome-wide association studies and postmortem human brain transcriptional studies.
11-1	2499-2502	The	_	
11-2	2503-2510	genetic	_	
11-3	2511-2515	risk	_	
11-4	2516-2519	for	_	
11-5	2520-2533	schizophrenia	_	
11-6	2534-2537	has	_	
11-7	2538-2542	been	_	
11-8	2543-2551	resolved	_	
11-9	2552-2556	more	_	
11-10	2557-2564	clearly	_	
11-11	2565-2567	by	_	
11-12	2568-2574	recent	_	
11-13	2575-2586	genome-wide	_	
11-14	2587-2598	association	_	
11-15	2599-2606	studies	_	
11-16	2607-2610	and	_	
11-17	2611-2621	postmortem	_	
11-18	2622-2627	human	_	
11-19	2628-2633	brain	_	
11-20	2634-2649	transcriptional	_	
11-21	2650-2657	studies	_	
11-22	2657-2658	.	_	

#Text=However, it remains unclear how expression of these schizophrenia-related genes might be related to neuroimaging markers of schizophrenia spectrum disorders.
12-1	2659-2666	However	_	
12-2	2666-2667	,	_	
12-3	2668-2670	it	_	
12-4	2671-2678	remains	_	
12-5	2679-2686	unclear	_	
12-6	2687-2690	how	_	
12-7	2691-2701	expression	_	
12-8	2702-2704	of	_	
12-9	2705-2710	these	_	
12-10	2711-2732	schizophrenia-related	_	
12-11	2733-2738	genes	_	
12-12	2739-2744	might	_	
12-13	2745-2747	be	_	
12-14	2748-2755	related	_	
12-15	2756-2758	to	_	
12-16	2759-2771	neuroimaging	_	
12-17	2772-2779	markers	_	
12-18	2780-2782	of	_	
12-19	2783-2796	schizophrenia	_	
12-20	2797-2805	spectrum	_	
12-21	2806-2815	disorders	_	
12-22	2815-2816	.	_	

#Text=Previous Studies Relating Schizotypal Traits and Macrostructural Magnetic Resonance Imaging Metrics
#Text=Study\tSample Size, n\tMean Age, Years\tExperimental Design\tBrain Coverage\tSchizotypy Measure\tType I Error Control\tStructural Index\tDirectionality\tBrain Regions\t \tEvans et al., 2016 \t28\t11\tVBM\tWhole brain\tPSI-C\tBonferroni\tVolume\t−\tCaudate, amygdala, hippocampal gyrus, middle temporal\t \tNenadic et al., 2015 \t59\t31\tVBM / positive and negative factor of schizotypy\tWhole brain\tCAPE\tFWE\tVolume\t−\tR precuneus\t \tWang et al., 2015 \t69\t19\tVBM / dividing subjects with high/low schizotypy\tWhole brain\tSPQ\tAlphaSim permutation\tVolume\t−\tDorsolateral prefrontal cortex, insula, posterior temporal, cerebellum\t \tDeRosse et al., 2015 \t138\t36\tANCOVA / dividing subjects with high/low schizotypy\tROIs\tSPQ\tNone\tThickness/GM and WM volume\t−\tFrontal, temporal\t \tKühn et al., 2012 \t34\t36\tVertexwise / positive and negative factor of schizotypy\tWhole cortex/thalamus\tSPQ\tFDR\tThickness/thalamus volume\t+\tR dorsolateral prefrontal cortex, R dorsal premotor\t \tEttinger et al., 2012 \t55\t27\tVBM\tWhole brain\tRISC\tFWE cluster\tVolume\t−\tMedial prefrontal, orbitofrontal, temporal\t \tModinos et al., 2010 \t38\t20\tVBM / dividing subjects with high/low schizotypy\tWhole brain\tCAPE\tFDR\tVolume\t+\tMedial posterior cingulate, precuneus\t \tMoorhead et al., 2009 \t98\t16\tVBM / longitudinal study\tWhole brain\tSIS\tUnspecified multiple comparison correction\tVolume\t−\tL medial temporal, L amygdala, L parahippocampal gyrus\t \tStanfield et al., 2008 \t143\t16\tANCOVA\tWhole brain\tSIS\tNone\tFolding\t+\tR prefrontal\t \t
#Text=Directionality refers to whether the study reports a positive (+) or negative (−) association between a schizotypy measure and a structural metric.
13-1	2817-2825	Previous	_	
13-2	2826-2833	Studies	_	
13-3	2834-2842	Relating	_	
13-4	2843-2854	Schizotypal	_	
13-5	2855-2861	Traits	_	
13-6	2862-2865	and	_	
13-7	2866-2881	Macrostructural	_	
13-8	2882-2890	Magnetic	_	
13-9	2891-2900	Resonance	_	
13-10	2901-2908	Imaging	_	
13-11	2909-2916	Metrics	_	
13-12	2917-2922	Study	_	
13-13	2923-2929	Sample	_	
13-14	2930-2934	Size	_	
13-15	2934-2935	,	_	
13-16	2936-2937	n	_	
13-17	2938-2942	Mean	_	
13-18	2943-2946	Age	_	
13-19	2946-2947	,	_	
13-20	2948-2953	Years	_	
13-21	2954-2966	Experimental	_	
13-22	2967-2973	Design	_	
13-23	2974-2979	Brain	_	
13-24	2980-2988	Coverage	_	
13-25	2989-2999	Schizotypy	_	
13-26	3000-3007	Measure	_	
13-27	3008-3012	Type	_	
13-28	3013-3014	I	_	
13-29	3015-3020	Error	_	
13-30	3021-3028	Control	_	
13-31	3029-3039	Structural	_	
13-32	3040-3045	Index	_	
13-33	3046-3060	Directionality	_	
13-34	3061-3066	Brain	_	
13-35	3067-3074	Regions	_	
13-36	3077-3082	Evans	_	
13-37	3083-3085	et	_	
13-38	3085-3086	 	_	
13-39	3086-3088	al	_	
13-40	3088-3089	.	_	
13-41	3089-3090	,	_	
13-42	3091-3095	2016	_	
13-43	3097-3099	28	_	
13-44	3100-3102	11	_	
13-45	3103-3106	VBM	_	
13-46	3107-3112	Whole	_	
13-47	3113-3118	brain	_	
13-48	3119-3124	PSI-C	_	
13-49	3125-3135	Bonferroni	_	
13-50	3136-3142	Volume	_	
13-51	3143-3144	−	_	
13-52	3145-3152	Caudate	_	
13-53	3152-3153	,	_	
13-54	3154-3162	amygdala	_	
13-55	3162-3163	,	_	
13-56	3164-3175	hippocampal	_	
13-57	3176-3181	gyrus	_	
13-58	3181-3182	,	_	
13-59	3183-3189	middle	_	
13-60	3190-3198	temporal	_	
13-61	3201-3208	Nenadic	_	
13-62	3209-3211	et	_	
13-63	3211-3212	 	_	
13-64	3212-3214	al	_	
13-65	3214-3215	.	_	
13-66	3215-3216	,	_	
13-67	3217-3221	2015	_	
13-68	3223-3225	59	_	
13-69	3226-3228	31	_	
13-70	3229-3232	VBM	_	
13-71	3233-3234	/	_	
13-72	3235-3243	positive	_	
13-73	3244-3247	and	_	
13-74	3248-3256	negative	_	
13-75	3257-3263	factor	_	
13-76	3264-3266	of	_	
13-77	3267-3277	schizotypy	_	
13-78	3278-3283	Whole	_	
13-79	3284-3289	brain	_	
13-80	3290-3294	CAPE	_	
13-81	3295-3298	FWE	_	
13-82	3299-3305	Volume	_	
13-83	3306-3307	−	_	
13-84	3308-3309	R	_	
13-85	3310-3319	precuneus	_	
13-86	3322-3326	Wang	_	
13-87	3327-3329	et	_	
13-88	3329-3330	 	_	
13-89	3330-3332	al	_	
13-90	3332-3333	.	_	
13-91	3333-3334	,	_	
13-92	3335-3339	2015	_	
13-93	3341-3343	69	_	
13-94	3344-3346	19	_	
13-95	3347-3350	VBM	_	
13-96	3351-3352	/	_	
13-97	3353-3361	dividing	_	
13-98	3362-3370	subjects	_	
13-99	3371-3375	with	_	
13-100	3376-3380	high	_	
13-101	3380-3381	/	_	
13-102	3381-3384	low	_	
13-103	3385-3395	schizotypy	_	
13-104	3396-3401	Whole	_	
13-105	3402-3407	brain	_	
13-106	3408-3411	SPQ	_	
13-107	3412-3420	AlphaSim	_	
13-108	3421-3432	permutation	_	
13-109	3433-3439	Volume	_	
13-110	3440-3441	−	_	
13-111	3442-3454	Dorsolateral	_	
13-112	3455-3465	prefrontal	_	
13-113	3466-3472	cortex	_	
13-114	3472-3473	,	_	
13-115	3474-3480	insula	_	
13-116	3480-3481	,	_	
13-117	3482-3491	posterior	_	
13-118	3492-3500	temporal	_	
13-119	3500-3501	,	_	
13-120	3502-3512	cerebellum	_	
13-121	3515-3522	DeRosse	_	
13-122	3523-3525	et	_	
13-123	3525-3526	 	_	
13-124	3526-3528	al	_	
13-125	3528-3529	.	_	
13-126	3529-3530	,	_	
13-127	3531-3535	2015	_	
13-128	3537-3540	138	_	
13-129	3541-3543	36	_	
13-130	3544-3550	ANCOVA	_	
13-131	3551-3552	/	_	
13-132	3553-3561	dividing	_	
13-133	3562-3570	subjects	_	
13-134	3571-3575	with	_	
13-135	3576-3580	high	_	
13-136	3580-3581	/	_	
13-137	3581-3584	low	_	
13-138	3585-3595	schizotypy	_	
13-139	3596-3600	ROIs	_	
13-140	3601-3604	SPQ	_	
13-141	3605-3609	None	_	
13-142	3610-3619	Thickness	_	
13-143	3619-3620	/	_	
13-144	3620-3622	GM	_	
13-145	3623-3626	and	_	
13-146	3627-3629	WM	_	
13-147	3630-3636	volume	_	
13-148	3637-3638	−	_	
13-149	3639-3646	Frontal	_	
13-150	3646-3647	,	_	
13-151	3648-3656	temporal	_	
13-152	3659-3663	Kühn	_	
13-153	3664-3666	et	_	
13-154	3666-3667	 	_	
13-155	3667-3669	al	_	
13-156	3669-3670	.	_	
13-157	3670-3671	,	_	
13-158	3672-3676	2012	_	
13-159	3678-3680	34	_	
13-160	3681-3683	36	_	
13-161	3684-3694	Vertexwise	_	
13-162	3695-3696	/	_	
13-163	3697-3705	positive	_	
13-164	3706-3709	and	_	
13-165	3710-3718	negative	_	
13-166	3719-3725	factor	_	
13-167	3726-3728	of	_	
13-168	3729-3739	schizotypy	_	
13-169	3740-3745	Whole	_	
13-170	3746-3752	cortex	_	
13-171	3752-3753	/	_	
13-172	3753-3761	thalamus	_	
13-173	3762-3765	SPQ	_	
13-174	3766-3769	FDR	_	
13-175	3770-3779	Thickness	_	
13-176	3779-3780	/	_	
13-177	3780-3788	thalamus	_	
13-178	3789-3795	volume	_	
13-179	3796-3797	+	_	
13-180	3798-3799	R	_	
13-181	3800-3812	dorsolateral	_	
13-182	3813-3823	prefrontal	_	
13-183	3824-3830	cortex	_	
13-184	3830-3831	,	_	
13-185	3832-3833	R	_	
13-186	3834-3840	dorsal	_	
13-187	3841-3849	premotor	_	
13-188	3852-3860	Ettinger	_	
13-189	3861-3863	et	_	
13-190	3863-3864	 	_	
13-191	3864-3866	al	_	
13-192	3866-3867	.	_	
13-193	3867-3868	,	_	
13-194	3869-3873	2012	_	
13-195	3875-3877	55	_	
13-196	3878-3880	27	_	
13-197	3881-3884	VBM	_	
13-198	3885-3890	Whole	_	
13-199	3891-3896	brain	_	
13-200	3897-3901	RISC	_	
13-201	3902-3905	FWE	_	
13-202	3906-3913	cluster	_	
13-203	3914-3920	Volume	_	
13-204	3921-3922	−	_	
13-205	3923-3929	Medial	_	
13-206	3930-3940	prefrontal	_	
13-207	3940-3941	,	_	
13-208	3942-3955	orbitofrontal	_	
13-209	3955-3956	,	_	
13-210	3957-3965	temporal	_	
13-211	3968-3975	Modinos	_	
13-212	3976-3978	et	_	
13-213	3978-3979	 	_	
13-214	3979-3981	al	_	
13-215	3981-3982	.	_	
13-216	3982-3983	,	_	
13-217	3984-3988	2010	_	
13-218	3990-3992	38	_	
13-219	3993-3995	20	_	
13-220	3996-3999	VBM	_	
13-221	4000-4001	/	_	
13-222	4002-4010	dividing	_	
13-223	4011-4019	subjects	_	
13-224	4020-4024	with	_	
13-225	4025-4029	high	_	
13-226	4029-4030	/	_	
13-227	4030-4033	low	_	
13-228	4034-4044	schizotypy	_	
13-229	4045-4050	Whole	_	
13-230	4051-4056	brain	_	
13-231	4057-4061	CAPE	_	
13-232	4062-4065	FDR	_	
13-233	4066-4072	Volume	_	
13-234	4073-4074	+	_	
13-235	4075-4081	Medial	_	
13-236	4082-4091	posterior	_	
13-237	4092-4101	cingulate	_	
13-238	4101-4102	,	_	
13-239	4103-4112	precuneus	_	
13-240	4115-4123	Moorhead	_	
13-241	4124-4126	et	_	
13-242	4126-4127	 	_	
13-243	4127-4129	al	_	
13-244	4129-4130	.	_	
13-245	4130-4131	,	_	
13-246	4132-4136	2009	_	
13-247	4138-4140	98	_	
13-248	4141-4143	16	_	
13-249	4144-4147	VBM	_	
13-250	4148-4149	/	_	
13-251	4150-4162	longitudinal	_	
13-252	4163-4168	study	_	
13-253	4169-4174	Whole	_	
13-254	4175-4180	brain	_	
13-255	4181-4184	SIS	_	
13-256	4185-4196	Unspecified	_	
13-257	4197-4205	multiple	_	
13-258	4206-4216	comparison	_	
13-259	4217-4227	correction	_	
13-260	4228-4234	Volume	_	
13-261	4235-4236	−	_	
13-262	4237-4238	L	_	
13-263	4239-4245	medial	_	
13-264	4246-4254	temporal	_	
13-265	4254-4255	,	_	
13-266	4256-4257	L	_	
13-267	4258-4266	amygdala	_	
13-268	4266-4267	,	_	
13-269	4268-4269	L	_	
13-270	4270-4285	parahippocampal	_	
13-271	4286-4291	gyrus	_	
13-272	4294-4303	Stanfield	_	
13-273	4304-4306	et	_	
13-274	4306-4307	 	_	
13-275	4307-4309	al	_	
13-276	4309-4310	.	_	
13-277	4310-4311	,	_	
13-278	4312-4316	2008	_	
13-279	4318-4321	143	_	
13-280	4322-4324	16	_	
13-281	4325-4331	ANCOVA	_	
13-282	4332-4337	Whole	_	
13-283	4338-4343	brain	_	
13-284	4344-4347	SIS	_	
13-285	4348-4352	None	_	
13-286	4353-4360	Folding	_	
13-287	4361-4362	+	_	
13-288	4363-4364	R	_	
13-289	4365-4375	prefrontal	_	
13-290	4379-4393	Directionality	_	
13-291	4394-4400	refers	_	
13-292	4401-4403	to	_	
13-293	4404-4411	whether	_	
13-294	4412-4415	the	_	
13-295	4416-4421	study	_	
13-296	4422-4429	reports	_	
13-297	4430-4431	a	_	
13-298	4432-4440	positive	_	
13-299	4441-4442	(	_	
13-300	4442-4443	+	_	
13-301	4443-4444	)	_	
13-302	4445-4447	or	_	
13-303	4448-4456	negative	_	
13-304	4457-4458	(	_	
13-305	4458-4459	−	_	
13-306	4459-4460	)	_	
13-307	4461-4472	association	_	
13-308	4473-4480	between	_	
13-309	4481-4482	a	_	
13-310	4483-4493	schizotypy	_	
13-311	4494-4501	measure	_	
13-312	4502-4505	and	_	
13-313	4506-4507	a	_	
13-314	4508-4518	structural	_	
13-315	4519-4525	metric	_	
13-316	4525-4526	.	_	

#Text=ANCOVA, analysis of covariance; CAPE, Community Assessment of Psychic Experience; FDR, false discovery rate; FWE, familywise error; GM, gray matter; L, left; PSI-C: Psychiatric and Schizotypal Inventory for Children; R, right; RISC, Rust Inventory of Schizotypal Cognitions; ROI, region of interest; SIS, Structured Interview for Schizotypy; SPQ, Schizotypal Personality Questionnaire; VBM, voxel-based morphometry; WM, white matter.
14-1	4527-4533	ANCOVA	_	
14-2	4533-4534	,	_	
14-3	4535-4543	analysis	_	
14-4	4544-4546	of	_	
14-5	4547-4557	covariance	_	
14-6	4557-4558	;	_	
14-7	4559-4563	CAPE	_	
14-8	4563-4564	,	_	
14-9	4565-4574	Community	_	
14-10	4575-4585	Assessment	_	
14-11	4586-4588	of	_	
14-12	4589-4596	Psychic	_	
14-13	4597-4607	Experience	_	
14-14	4607-4608	;	_	
14-15	4609-4612	FDR	_	
14-16	4612-4613	,	_	
14-17	4614-4619	false	_	
14-18	4620-4629	discovery	_	
14-19	4630-4634	rate	_	
14-20	4634-4635	;	_	
14-21	4636-4639	FWE	_	
14-22	4639-4640	,	_	
14-23	4641-4651	familywise	_	
14-24	4652-4657	error	_	
14-25	4657-4658	;	_	
14-26	4659-4661	GM	_	
14-27	4661-4662	,	_	
14-28	4663-4667	gray	_	
14-29	4668-4674	matter	_	
14-30	4674-4675	;	_	
14-31	4676-4677	L	_	
14-32	4677-4678	,	_	
14-33	4679-4683	left	_	
14-34	4683-4684	;	_	
14-35	4685-4690	PSI-C	_	
14-36	4690-4691	:	_	
14-37	4692-4703	Psychiatric	_	
14-38	4704-4707	and	_	
14-39	4708-4719	Schizotypal	_	
14-40	4720-4729	Inventory	_	
14-41	4730-4733	for	_	
14-42	4734-4742	Children	_	
14-43	4742-4743	;	_	
14-44	4744-4745	R	_	
14-45	4745-4746	,	_	
14-46	4747-4752	right	_	
14-47	4752-4753	;	_	
14-48	4754-4758	RISC	_	
14-49	4758-4759	,	_	
14-50	4760-4764	Rust	_	
14-51	4765-4774	Inventory	_	
14-52	4775-4777	of	_	
14-53	4778-4789	Schizotypal	_	
14-54	4790-4800	Cognitions	_	
14-55	4800-4801	;	_	
14-56	4802-4805	ROI	_	
14-57	4805-4806	,	_	
14-58	4807-4813	region	_	
14-59	4814-4816	of	_	
14-60	4817-4825	interest	_	
14-61	4825-4826	;	_	
14-62	4827-4830	SIS	_	
14-63	4830-4831	,	_	
14-64	4832-4842	Structured	_	
14-65	4843-4852	Interview	_	
14-66	4853-4856	for	_	
14-67	4857-4867	Schizotypy	_	
14-68	4867-4868	;	_	
14-69	4869-4872	SPQ	_	
14-70	4872-4873	,	_	
14-71	4874-4885	Schizotypal	_	
14-72	4886-4897	Personality	_	
14-73	4898-4911	Questionnaire	_	
14-74	4911-4912	;	_	
14-75	4913-4916	VBM	_	
14-76	4916-4917	,	_	
14-77	4918-4929	voxel-based	_	
14-78	4930-4941	morphometry	_	
14-79	4941-4942	;	_	
14-80	4943-4945	WM	_	
14-81	4945-4946	,	_	
14-82	4947-4952	white	_	
14-83	4953-4959	matter	_	
14-84	4959-4960	.	_	

#Text=Macrostructural magnetic resonance imaging (MRI) studies—which measure anatomical parameters like cortical thickness—have collectively provided robust evidence for reduced volume or thickness in a network of interconnected cortical areas in patients with schizophrenia.
15-1	4961-4976	Macrostructural	_	
15-2	4977-4985	magnetic	_	
15-3	4986-4995	resonance	_	
15-4	4996-5003	imaging	_	
15-5	5004-5005	(	_	
15-6	5005-5008	MRI	_	
15-7	5008-5009	)	_	
15-8	5010-5023	studies—which	_	
15-9	5024-5031	measure	_	
15-10	5032-5042	anatomical	_	
15-11	5043-5053	parameters	_	
15-12	5054-5058	like	_	
15-13	5059-5067	cortical	_	
15-14	5068-5082	thickness—have	_	
15-15	5083-5095	collectively	_	
15-16	5096-5104	provided	_	
15-17	5105-5111	robust	_	
15-18	5112-5120	evidence	_	
15-19	5121-5124	for	_	
15-20	5125-5132	reduced	_	
15-21	5133-5139	volume	_	
15-22	5140-5142	or	_	
15-23	5143-5152	thickness	_	
15-24	5153-5155	in	_	
15-25	5156-5157	a	_	
15-26	5158-5165	network	_	
15-27	5166-5168	of	_	
15-28	5169-5183	interconnected	_	
15-29	5184-5192	cortical	_	
15-30	5193-5198	areas	_	
15-31	5199-5201	in	_	
15-32	5202-5210	patients	_	
15-33	5211-5215	with	_	
15-34	5216-5229	schizophrenia	_	
15-35	5229-5230	.	_	

#Text=There have been fewer MRI studies of schizotypy, and the pattern of macrostructural results has not been consistent, perhaps reflecting their relatively small sample sizes (Table 1).
16-1	5231-5236	There	_	
16-2	5237-5241	have	_	
16-3	5242-5246	been	_	
16-4	5247-5252	fewer	_	
16-5	5253-5256	MRI	_	
16-6	5257-5264	studies	_	
16-7	5265-5267	of	_	
16-8	5268-5278	schizotypy	_	
16-9	5278-5279	,	_	
16-10	5280-5283	and	_	
16-11	5284-5287	the	_	
16-12	5288-5295	pattern	_	
16-13	5296-5298	of	_	
16-14	5299-5314	macrostructural	_	
16-15	5315-5322	results	_	
16-16	5323-5326	has	_	
16-17	5327-5330	not	_	
16-18	5331-5335	been	_	
16-19	5336-5346	consistent	_	
16-20	5346-5347	,	_	
16-21	5348-5355	perhaps	_	
16-22	5356-5366	reflecting	_	
16-23	5367-5372	their	_	
16-24	5373-5383	relatively	_	
16-25	5384-5389	small	_	
16-26	5390-5396	sample	_	
16-27	5397-5402	sizes	_	
16-28	5403-5404	(	_	
16-29	5404-5409	Table	_	
16-30	5409-5410	 	_	
16-31	5410-5411	1	_	
16-32	5411-5412	)	_	
16-33	5412-5413	.	_	

#Text=Microstructural MRI provides information about the composition of tissue within a voxel.
17-1	5414-5429	Microstructural	_	
17-2	5430-5433	MRI	_	
17-3	5434-5442	provides	_	
17-4	5443-5454	information	_	
17-5	5455-5460	about	_	
17-6	5461-5464	the	_	
17-7	5465-5476	composition	_	
17-8	5477-5479	of	_	
17-9	5480-5486	tissue	_	
17-10	5487-5493	within	_	
17-11	5494-5495	a	_	
17-12	5496-5501	voxel	_	
17-13	5501-5502	.	_	

#Text=For example, magnetization transfer (MT) images and “myelin maps” derived from the ratio of conventional T1- and T2-weighted images are sensitive to the proportion of fatty brain tissue represented by each voxel, which, according to histological studies on animal models, is related to myelin content.
18-1	5503-5506	For	_	
18-2	5507-5514	example	_	
18-3	5514-5515	,	_	
18-4	5516-5529	magnetization	_	
18-5	5530-5538	transfer	_	
18-6	5539-5540	(	_	
18-7	5540-5542	MT	_	
18-8	5542-5543	)	_	
18-9	5544-5550	images	_	
18-10	5551-5554	and	_	
18-11	5555-5556	“	_	
18-12	5556-5562	myelin	_	
18-13	5563-5567	maps	_	
18-14	5567-5568	”	_	
18-15	5569-5576	derived	_	
18-16	5577-5581	from	_	
18-17	5582-5585	the	_	
18-18	5586-5591	ratio	_	
18-19	5592-5594	of	_	
18-20	5595-5607	conventional	_	
18-21	5608-5610	T1	_	
18-22	5610-5611	-	_	
18-23	5612-5615	and	_	
18-24	5616-5618	T2	_	
18-25	5618-5619	-	_	
18-26	5619-5627	weighted	_	
18-27	5628-5634	images	_	
18-28	5635-5638	are	_	
18-29	5639-5648	sensitive	_	
18-30	5649-5651	to	_	
18-31	5652-5655	the	_	
18-32	5656-5666	proportion	_	
18-33	5667-5669	of	_	
18-34	5670-5675	fatty	_	
18-35	5676-5681	brain	_	
18-36	5682-5688	tissue	_	
18-37	5689-5700	represented	_	
18-38	5701-5703	by	_	
18-39	5704-5708	each	_	
18-40	5709-5714	voxel	_	
18-41	5714-5715	,	_	
18-42	5716-5721	which	_	
18-43	5721-5722	,	_	
18-44	5723-5732	according	_	
18-45	5733-5735	to	_	
18-46	5736-5748	histological	_	
18-47	5749-5756	studies	_	
18-48	5757-5759	on	_	
18-49	5760-5766	animal	_	
18-50	5767-5773	models	_	
18-51	5773-5774	,	_	
18-52	5775-5777	is	_	
18-53	5778-5785	related	_	
18-54	5786-5788	to	_	
18-55	5789-5795	myelin	_	
18-56	5796-5803	content	_	
18-57	5803-5804	.	_	

#Text=MT maps have been used as markers of myelination in white matter and the cortex in healthy subjects and in demyelinating disorders such as multiple sclerosis.
19-1	5805-5807	MT	_	
19-2	5808-5812	maps	_	
19-3	5813-5817	have	_	
19-4	5818-5822	been	_	
19-5	5823-5827	used	_	
19-6	5828-5830	as	_	
19-7	5831-5838	markers	_	
19-8	5839-5841	of	_	
19-9	5842-5853	myelination	_	
19-10	5854-5856	in	_	
19-11	5857-5862	white	_	
19-12	5863-5869	matter	_	
19-13	5870-5873	and	_	
19-14	5874-5877	the	_	
19-15	5878-5884	cortex	_	
19-16	5885-5887	in	_	
19-17	5888-5895	healthy	_	
19-18	5896-5904	subjects	_	
19-19	5905-5908	and	_	
19-20	5909-5911	in	_	
19-21	5912-5925	demyelinating	_	
19-22	5926-5935	disorders	_	
19-23	5936-5940	such	_	
19-24	5941-5943	as	_	
19-25	5944-5952	multiple	_	
19-26	5953-5962	sclerosis	_	
19-27	5962-5963	.	_	

#Text=Schizophrenia has been associated with reduced MT in the frontal, temporal, and insular cortices, and the cortical expression of schizophrenia-related genes was (negatively) correlated with T1- and T2-weighted maps.
20-1	5964-5977	Schizophrenia	_	
20-2	5978-5981	has	_	
20-3	5982-5986	been	_	
20-4	5987-5997	associated	_	
20-5	5998-6002	with	_	
20-6	6003-6010	reduced	_	
20-7	6011-6013	MT	_	
20-8	6014-6016	in	_	
20-9	6017-6020	the	_	
20-10	6021-6028	frontal	_	
20-11	6028-6029	,	_	
20-12	6030-6038	temporal	_	
20-13	6038-6039	,	_	
20-14	6040-6043	and	_	
20-15	6044-6051	insular	_	
20-16	6052-6060	cortices	_	
20-17	6060-6061	,	_	
20-18	6062-6065	and	_	
20-19	6066-6069	the	_	
20-20	6070-6078	cortical	_	
20-21	6079-6089	expression	_	
20-22	6090-6092	of	_	
20-23	6093-6114	schizophrenia-related	_	
20-24	6115-6120	genes	_	
20-25	6121-6124	was	_	
20-26	6125-6126	(	_	
20-27	6126-6136	negatively	_	
20-28	6136-6137	)	_	
20-29	6138-6148	correlated	_	
20-30	6149-6153	with	_	
20-31	6154-6156	T1	_	
20-32	6156-6157	-	_	
20-33	6158-6161	and	_	
20-34	6162-6164	T2	_	
20-35	6164-6165	-	_	
20-36	6165-6173	weighted	_	
20-37	6174-6178	maps	_	
20-38	6178-6179	.	_	

#Text=In this context, we measured schizotypy, using the Schizotypal Personality Questionnaire (SPQ), and MT, using a multiparameter MRI scanning procedure, in a sample of 248 healthy young people (14–25 years of age) (Table S1).
21-1	6180-6182	In	_	
21-2	6183-6187	this	_	
21-3	6188-6195	context	_	
21-4	6195-6196	,	_	
21-5	6197-6199	we	_	
21-6	6200-6208	measured	_	
21-7	6209-6219	schizotypy	_	
21-8	6219-6220	,	_	
21-9	6221-6226	using	_	
21-10	6227-6230	the	_	
21-11	6231-6242	Schizotypal	_	
21-12	6243-6254	Personality	_	
21-13	6255-6268	Questionnaire	_	
21-14	6269-6270	(	_	
21-15	6270-6273	SPQ	_	
21-16	6273-6274	)	_	
21-17	6274-6275	,	_	
21-18	6276-6279	and	_	
21-19	6280-6282	MT	_	
21-20	6282-6283	,	_	
21-21	6284-6289	using	_	
21-22	6290-6291	a	_	
21-23	6292-6306	multiparameter	_	
21-24	6307-6310	MRI	_	
21-25	6311-6319	scanning	_	
21-26	6320-6329	procedure	_	
21-27	6329-6330	,	_	
21-28	6331-6333	in	_	
21-29	6334-6335	a	_	
21-30	6336-6342	sample	_	
21-31	6343-6345	of	_	
21-32	6346-6349	248	_	
21-33	6350-6357	healthy	_	
21-34	6358-6363	young	_	
21-35	6364-6370	people	_	
21-36	6371-6372	(	_	
21-37	6372-6374	14	_	
21-38	6374-6375	–	_	
21-39	6375-6377	25	_	
21-40	6378-6383	years	_	
21-41	6384-6386	of	_	
21-42	6387-6390	age	_	
21-43	6390-6391	)	_	
21-44	6392-6393	(	_	
21-45	6393-6398	Table	_	
21-46	6398-6399	 	_	
21-47	6399-6401	S1	_	
21-48	6401-6402	)	_	
21-49	6402-6403	.	_	

#Text=We tested 3 key hypotheses in a logical sequence: 1) that intracortical MT was correlated with the SPQ total score (and subscale scores), 2) that the cortical pattern of schizotypy-related magnetization (SRM) was colocated with a cortical map of weighted whole-genome expression, and 3) that the gene transcripts most strongly coupled to SRM were enriched for genes that were transcriptionally dysregulated in histological case-control studies of schizophrenia.
22-1	6404-6406	We	_	
22-2	6407-6413	tested	_	
22-3	6414-6415	3	_	
22-4	6416-6419	key	_	
22-5	6420-6430	hypotheses	_	
22-6	6431-6433	in	_	
22-7	6434-6435	a	_	
22-8	6436-6443	logical	_	
22-9	6444-6452	sequence	_	
22-10	6452-6453	:	_	
22-11	6454-6455	1	_	
22-12	6455-6456	)	_	
22-13	6457-6461	that	_	
22-14	6462-6475	intracortical	_	
22-15	6476-6478	MT	_	
22-16	6479-6482	was	_	
22-17	6483-6493	correlated	_	
22-18	6494-6498	with	_	
22-19	6499-6502	the	_	
22-20	6503-6506	SPQ	_	
22-21	6507-6512	total	_	
22-22	6513-6518	score	_	
22-23	6519-6520	(	_	
22-24	6520-6523	and	_	
22-25	6524-6532	subscale	_	
22-26	6533-6539	scores	_	
22-27	6539-6540	)	_	
22-28	6540-6541	,	_	
22-29	6542-6543	2	_	
22-30	6543-6544	)	_	
22-31	6545-6549	that	_	
22-32	6550-6553	the	_	
22-33	6554-6562	cortical	_	
22-34	6563-6570	pattern	_	
22-35	6571-6573	of	_	
22-36	6574-6592	schizotypy-related	_	
22-37	6593-6606	magnetization	_	
22-38	6607-6608	(	_	
22-39	6608-6611	SRM	_	
22-40	6611-6612	)	_	
22-41	6613-6616	was	_	
22-42	6617-6626	colocated	_	
22-43	6627-6631	with	_	
22-44	6632-6633	a	_	
22-45	6634-6642	cortical	_	
22-46	6643-6646	map	_	
22-47	6647-6649	of	_	
22-48	6650-6658	weighted	_	
22-49	6659-6671	whole-genome	_	
22-50	6672-6682	expression	_	
22-51	6682-6683	,	_	
22-52	6684-6687	and	_	
22-53	6688-6689	3	_	
22-54	6689-6690	)	_	
22-55	6691-6695	that	_	
22-56	6696-6699	the	_	
22-57	6700-6704	gene	_	
22-58	6705-6716	transcripts	_	
22-59	6717-6721	most	_	
22-60	6722-6730	strongly	_	
22-61	6731-6738	coupled	_	
22-62	6739-6741	to	_	
22-63	6742-6745	SRM	_	
22-64	6746-6750	were	_	
22-65	6751-6759	enriched	_	
22-66	6760-6763	for	_	
22-67	6764-6769	genes	_	
22-68	6770-6774	that	_	
22-69	6775-6779	were	_	
22-70	6780-6797	transcriptionally	_	
22-71	6798-6810	dysregulated	_	
22-72	6811-6813	in	_	
22-73	6814-6826	histological	_	
22-74	6827-6839	case-control	_	
22-75	6840-6847	studies	_	
22-76	6848-6850	of	_	
22-77	6851-6864	schizophrenia	_	
22-78	6864-6865	.	_	

#Text=Methods and Materials
#Text=Participants
#Text=A total of 2135 healthy young people, 14 to 25 years of age, were recruited from schools, colleges, National Health Service primary care services, and direct advertisement in north London and Cambridgeshire, United Kingdom.
23-1	6866-6873	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
23-2	6874-6877	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
23-3	6878-6887	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
23-4	6888-6900	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-5	6901-6902	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-6	6903-6908	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-7	6909-6911	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-8	6912-6916	2135	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-9	6917-6924	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
23-10	6925-6930	young	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
23-11	6931-6937	people	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
23-12	6937-6938	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-13	6939-6941	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-14	6942-6944	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-15	6945-6947	25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-16	6948-6953	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-17	6954-6956	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-18	6957-6960	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-19	6960-6961	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-20	6962-6966	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-21	6967-6976	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-22	6977-6981	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-23	6982-6989	schools	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-24	6989-6990	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-25	6991-6999	colleges	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-26	6999-7000	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-27	7001-7009	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-28	7010-7016	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-29	7017-7024	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-30	7025-7032	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-31	7033-7037	care	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-32	7038-7046	services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-33	7046-7047	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-34	7048-7051	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-35	7052-7058	direct	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-36	7059-7072	advertisement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-37	7073-7075	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-38	7076-7081	north	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-39	7082-7088	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-40	7089-7092	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-41	7093-7107	Cambridgeshire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-42	7107-7108	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-43	7109-7115	United	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-44	7116-7123	Kingdom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-45	7123-7124	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=This primary cohort was stratified into 5 contiguous age-related strata, balanced for gender and ethnicity.
24-1	7125-7129	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-2	7130-7137	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-3	7138-7144	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-4	7145-7148	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-5	7149-7159	stratified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-6	7160-7164	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-7	7165-7166	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-8	7167-7177	contiguous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-9	7178-7189	age-related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-10	7190-7196	strata	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-11	7196-7197	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-12	7198-7206	balanced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-13	7207-7210	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-14	7211-7217	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-15	7218-7221	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-16	7222-7231	ethnicity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-17	7231-7232	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=A secondary cohort of 297 individuals was recruited by randomly subsampling the primary cohort so that ∼60 participants were assigned to each of the same age-related strata, balanced for gender and ethnicity, as in the primary cohort.
25-1	7233-7234	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-2	7235-7244	secondary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-3	7245-7251	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-4	7252-7254	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-5	7255-7258	297	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-6	7259-7270	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-7	7271-7274	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-8	7275-7284	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-9	7285-7287	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-10	7288-7296	randomly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-11	7297-7308	subsampling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-12	7309-7312	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-13	7313-7320	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-14	7321-7327	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-15	7328-7330	so	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-16	7331-7335	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-17	7336-7337	∼	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-18	7337-7339	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-19	7340-7352	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-20	7353-7357	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-21	7358-7366	assigned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-22	7367-7369	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-23	7370-7374	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-24	7375-7377	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-25	7378-7381	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-26	7382-7386	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-27	7387-7398	age-related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-28	7399-7405	strata	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-29	7405-7406	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-30	7407-7415	balanced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-31	7416-7419	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-32	7420-7426	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-33	7427-7430	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-34	7431-7440	ethnicity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-35	7440-7441	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-36	7442-7444	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-37	7445-7447	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-38	7448-7451	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-39	7452-7459	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-40	7460-7466	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-41	7466-7467	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Participants were excluded if they had a current or past history of clinical treatment for a psychiatric disorder, drug or alcohol dependence, neurological disorder including epilepsy, head injury causing loss of consciousness, or learning disability (see Supplement for details).
26-1	7468-7480	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-2	7481-7485	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-3	7486-7494	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-4	7495-7497	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-5	7498-7502	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-6	7503-7506	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-7	7507-7508	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-8	7509-7516	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-9	7517-7519	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-10	7520-7524	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-11	7525-7532	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-12	7533-7535	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-13	7536-7544	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-14	7545-7554	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-15	7555-7558	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-16	7559-7560	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-17	7561-7572	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-18	7573-7581	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-19	7581-7582	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-20	7583-7587	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-21	7588-7590	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-22	7591-7598	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-23	7599-7609	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-24	7609-7610	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-25	7611-7623	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-26	7624-7632	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-27	7633-7642	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-28	7643-7651	epilepsy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-29	7651-7652	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-30	7653-7657	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-31	7658-7664	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-32	7665-7672	causing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-33	7673-7677	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-34	7678-7680	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-35	7681-7694	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-36	7694-7695	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-37	7696-7698	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-38	7699-7707	learning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-39	7708-7718	disability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-40	7719-7720	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-41	7720-7723	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-42	7724-7734	Supplement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-43	7735-7738	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-44	7739-7746	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-45	7746-7747	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-46	7747-7748	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Written informed consent was provided by all participants as well as written parental assent for participants less than 16 years of age.
27-1	7749-7756	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-2	7757-7765	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-3	7766-7773	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-4	7774-7777	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-5	7778-7786	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-6	7787-7789	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-7	7790-7793	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-8	7794-7806	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-9	7807-7809	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-10	7810-7814	well	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-11	7815-7817	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-12	7818-7825	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-13	7826-7834	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-14	7835-7841	assent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-15	7842-7845	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-16	7846-7858	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-17	7859-7863	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-18	7864-7868	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-19	7869-7871	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-20	7872-7877	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-21	7878-7880	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-22	7881-7884	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-23	7884-7885	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=The study was approved by the National Research Ethics Service and conducted in accordance with National Health Service research governance standards.
28-1	7886-7889	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-2	7890-7895	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-3	7896-7899	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-4	7900-7908	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-5	7909-7911	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-6	7912-7915	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-7	7916-7924	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-8	7925-7933	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-9	7934-7940	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-10	7941-7948	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-11	7949-7952	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-12	7953-7962	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-13	7963-7965	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-14	7966-7976	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-15	7977-7981	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-16	7982-7990	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-17	7991-7997	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-18	7998-8005	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-19	8006-8014	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-20	8015-8025	governance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-21	8026-8035	standards	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-22	8035-8036	.	_	

#Text=Schizotypy Assessment
#Text=The SPQ is a self-report scale, comprising 74 dichotomous items that are grouped on 9 subscales, measuring the complex trait of schizotypy.
29-1	8037-8047	Schizotypy	_	
29-2	8048-8058	Assessment	_	
29-3	8059-8062	The	_	
29-4	8063-8066	SPQ	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire	
29-5	8067-8069	is	_	
29-6	8070-8071	a	_	
29-7	8072-8083	self-report	_	
29-8	8084-8089	scale	_	
29-9	8089-8090	,	_	
29-10	8091-8101	comprising	_	
29-11	8102-8104	74	_	
29-12	8105-8116	dichotomous	_	
29-13	8117-8122	items	_	
29-14	8123-8127	that	_	
29-15	8128-8131	are	_	
29-16	8132-8139	grouped	_	
29-17	8140-8142	on	_	
29-18	8143-8144	9	_	
29-19	8145-8154	subscales	_	
29-20	8154-8155	,	_	
29-21	8156-8165	measuring	_	
29-22	8166-8169	the	_	
29-23	8170-8177	complex	_	
29-24	8178-8183	trait	_	
29-25	8184-8186	of	_	
29-26	8187-8197	schizotypy	_	
29-27	8197-8198	.	_	

#Text=Participants completed the SPQ on 2 assessments, separated by 6 to 18 months, so that traitlike scores on total and subscale SPQ metrics could be estimated by the number of questionnaire items positively endorsed by each participant on average over time.
30-1	8199-8211	Participants	_	
30-2	8212-8221	completed	_	
30-3	8222-8225	the	_	
30-4	8226-8229	SPQ	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire	
30-5	8230-8232	on	_	
30-6	8233-8234	2	_	
30-7	8235-8246	assessments	_	
30-8	8246-8247	,	_	
30-9	8248-8257	separated	_	
30-10	8258-8260	by	_	
30-11	8261-8262	6	_	
30-12	8263-8265	to	_	
30-13	8266-8268	18	_	
30-14	8269-8275	months	_	
30-15	8275-8276	,	_	
30-16	8277-8279	so	_	
30-17	8280-8284	that	_	
30-18	8285-8294	traitlike	_	
30-19	8295-8301	scores	_	
30-20	8302-8304	on	_	
30-21	8305-8310	total	_	
30-22	8311-8314	and	_	
30-23	8315-8323	subscale	_	
30-24	8324-8327	SPQ	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire	
30-25	8328-8335	metrics	_	
30-26	8336-8341	could	_	
30-27	8342-8344	be	_	
30-28	8345-8354	estimated	_	
30-29	8355-8357	by	_	
30-30	8358-8361	the	_	
30-31	8362-8368	number	_	
30-32	8369-8371	of	_	
30-33	8372-8385	questionnaire	_	
30-34	8386-8391	items	_	
30-35	8392-8402	positively	_	
30-36	8403-8411	endorsed	_	
30-37	8412-8414	by	_	
30-38	8415-8419	each	_	
30-39	8420-8431	participant	_	
30-40	8432-8434	on	_	
30-41	8435-8442	average	_	
30-42	8443-8447	over	_	
30-43	8448-8452	time	_	
30-44	8452-8453	.	_	

#Text=MRI Data Acquisition
#Text=Structural MRI scans were acquired on 1 of 3 identical 3T MRI systems in London or Cambridge, United Kingdom (Magnetom TIM Trio [Siemens Healthcare, Erlangen, Germany], software version VB17).
31-1	8454-8457	MRI	_	
31-2	8458-8462	Data	_	
31-3	8463-8474	Acquisition	_	
31-4	8475-8485	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[7]	
31-5	8486-8489	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[7]	
31-6	8490-8495	scans	_	
31-7	8496-8500	were	_	
31-8	8501-8509	acquired	_	
31-9	8510-8512	on	_	
31-10	8513-8514	1	_	
31-11	8515-8517	of	_	
31-12	8518-8519	3	_	
31-13	8520-8529	identical	_	
31-14	8530-8532	3T	_	
31-15	8533-8536	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
31-16	8537-8544	systems	_	
31-17	8545-8547	in	_	
31-18	8548-8554	London	_	
31-19	8555-8557	or	_	
31-20	8558-8567	Cambridge	_	
31-21	8567-8568	,	_	
31-22	8569-8575	United	_	
31-23	8576-8583	Kingdom	_	
31-24	8584-8585	(	_	
31-25	8585-8593	Magnetom	_	
31-26	8594-8597	TIM	_	
31-27	8598-8602	Trio	_	
31-28	8603-8604	[	_	
31-29	8604-8611	Siemens	_	
31-30	8612-8622	Healthcare	_	
31-31	8622-8623	,	_	
31-32	8624-8632	Erlangen	_	
31-33	8632-8633	,	_	
31-34	8634-8641	Germany	_	
31-35	8641-8642	]	_	
31-36	8642-8643	,	_	
31-37	8644-8652	software	_	
31-38	8653-8660	version	_	
31-39	8661-8665	VB17	_	
31-40	8665-8666	)	_	
31-41	8666-8667	.	_	

#Text=The multiparametric mapping protocol yielded 3 multiecho fast low-angle shot scans with variable excitation flip angles.
32-1	8668-8671	The	_	
32-2	8672-8687	multiparametric	_	
32-3	8688-8695	mapping	_	
32-4	8696-8704	protocol	_	
32-5	8705-8712	yielded	_	
32-6	8713-8714	3	_	
32-7	8715-8724	multiecho	_	
32-8	8725-8729	fast	_	
32-9	8730-8739	low-angle	_	
32-10	8740-8744	shot	_	
32-11	8745-8750	scans	_	
32-12	8751-8755	with	_	
32-13	8756-8764	variable	_	
32-14	8765-8775	excitation	_	
32-15	8776-8780	flip	_	
32-16	8781-8787	angles	_	
32-17	8787-8788	.	_	

#Text=By appropriate choice of repetition time and flip angle α, acquisitions were predominantly weighted by T1 (repetition time = 18.7 ms, α = 20°), proton density, or MT (repetition time = 23.7 ms, α = 6°).
33-1	8789-8791	By	_	
33-2	8792-8803	appropriate	_	
33-3	8804-8810	choice	_	
33-4	8811-8813	of	_	
33-5	8814-8824	repetition	_	
33-6	8825-8829	time	_	
33-7	8830-8833	and	_	
33-8	8834-8838	flip	_	
33-9	8839-8844	angle	_	
33-10	8845-8846	α	_	
33-11	8846-8847	,	_	
33-12	8848-8860	acquisitions	_	
33-13	8861-8865	were	_	
33-14	8866-8879	predominantly	_	
33-15	8880-8888	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[8]	
33-16	8889-8891	by	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[8]	
33-17	8892-8894	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[8]	
33-18	8895-8896	(	_	
33-19	8896-8906	repetition	_	
33-20	8907-8911	time	_	
33-21	8911-8912	 	_	
33-22	8912-8913	=	_	
33-23	8914-8918	18.7	_	
33-24	8919-8921	ms	_	
33-25	8921-8922	,	_	
33-26	8923-8924	α	_	
33-27	8924-8925	 	_	
33-28	8925-8926	=	_	
33-29	8927-8929	20	_	
33-30	8929-8930	°	_	
33-31	8930-8931	)	_	
33-32	8931-8932	,	_	
33-33	8933-8939	proton	_	
33-34	8940-8947	density	_	
33-35	8947-8948	,	_	
33-36	8949-8951	or	_	
33-37	8952-8954	MT	_	
33-38	8955-8956	(	_	
33-39	8956-8966	repetition	_	
33-40	8967-8971	time	_	
33-41	8971-8972	 	_	
33-42	8972-8973	=	_	
33-43	8974-8978	23.7	_	
33-44	8979-8981	ms	_	
33-45	8981-8982	,	_	
33-46	8983-8984	α	_	
33-47	8984-8985	 	_	
33-48	8985-8986	=	_	
33-49	8987-8988	6	_	
33-50	8988-8989	°	_	
33-51	8989-8990	)	_	
33-52	8990-8991	.	_	

#Text=Other acquisition parameters were 1-mm3 voxel resolution, 176 sagittal slices, and a field of view of 256 × 240 mm.
34-1	8992-8997	Other	_	
34-2	8998-9009	acquisition	_	
34-3	9010-9020	parameters	_	
34-4	9021-9025	were	_	
34-5	9026-9027	1	_	
34-6	9027-9028	-	_	
34-7	9028-9031	mm3	_	
34-8	9032-9037	voxel	_	
34-9	9038-9048	resolution	_	
34-10	9048-9049	,	_	
34-11	9050-9053	176	_	
34-12	9054-9062	sagittal	_	
34-13	9063-9069	slices	_	
34-14	9069-9070	,	_	
34-15	9071-9074	and	_	
34-16	9075-9076	a	_	
34-17	9077-9082	field	_	
34-18	9083-9085	of	_	
34-19	9086-9090	view	_	
34-20	9091-9093	of	_	
34-21	9094-9097	256	_	
34-22	9097-9098	 	_	
34-23	9098-9099	×	_	
34-24	9100-9103	240	_	
34-25	9104-9106	mm	_	
34-26	9106-9107	.	_	

#Text=A pilot study demonstrated satisfactory levels of between-site reliability in multiparametric mapping data acquisition.
35-1	9108-9109	A	_	
35-2	9110-9115	pilot	_	
35-3	9116-9121	study	_	
35-4	9122-9134	demonstrated	_	
35-5	9135-9147	satisfactory	_	
35-6	9148-9154	levels	_	
35-7	9155-9157	of	_	
35-8	9158-9170	between-site	_	
35-9	9171-9182	reliability	_	
35-10	9183-9185	in	_	
35-11	9186-9201	multiparametric	_	
35-12	9202-9209	mapping	_	
35-13	9210-9214	data	_	
35-14	9215-9226	acquisition	_	
35-15	9226-9227	.	_	

#Text=MT images and T1 images from this sample have been previously reported.
36-1	9228-9230	MT	_	
36-2	9231-9237	images	_	
36-3	9238-9241	and	_	
36-4	9242-9244	T1	_	
36-5	9245-9251	images	_	
36-6	9252-9256	from	_	
36-7	9257-9261	this	_	
36-8	9262-9268	sample	_	
36-9	9269-9273	have	_	
36-10	9274-9278	been	_	
36-11	9279-9289	previously	_	
36-12	9290-9298	reported	_	
36-13	9298-9299	.	_	

#Text=MRI Reconstruction, Cortical Parcellation, and Estimation of SRM
#Text=We used a standard automated processing pipeline for skull stripping, tissue classiﬁcation, surface extraction, and cortical parcellation (FreeSurfer [http://surfer.nmr.mgh.harvard.edu]) applied to longitudinal relaxation rate (R1) maps (R1 = 1/T1).
37-1	9300-9303	MRI	_	
37-2	9304-9318	Reconstruction	_	
37-3	9318-9319	,	_	
37-4	9320-9328	Cortical	_	
37-5	9329-9341	Parcellation	_	
37-6	9341-9342	,	_	
37-7	9343-9346	and	_	
37-8	9347-9357	Estimation	_	
37-9	9358-9360	of	_	
37-10	9361-9364	SRM	_	
37-11	9365-9367	We	_	
37-12	9368-9372	used	_	
37-13	9373-9374	a	_	
37-14	9375-9383	standard	_	
37-15	9384-9393	automated	_	
37-16	9394-9404	processing	_	
37-17	9405-9413	pipeline	_	
37-18	9414-9417	for	_	
37-19	9418-9423	skull	_	
37-20	9424-9433	stripping	_	
37-21	9433-9434	,	_	
37-22	9435-9441	tissue	_	
37-23	9442-9455	classiﬁcation	_	
37-24	9455-9456	,	_	
37-25	9457-9464	surface	_	
37-26	9465-9475	extraction	_	
37-27	9475-9476	,	_	
37-28	9477-9480	and	_	
37-29	9481-9489	cortical	_	
37-30	9490-9502	parcellation	_	
37-31	9503-9504	(	_	
37-32	9504-9514	FreeSurfer	_	
37-33	9515-9516	[	_	
37-34	9516-9520	http	_	
37-35	9520-9521	:	_	
37-36	9521-9522	/	_	
37-37	9522-9523	/	_	
37-38	9523-9549	surfer.nmr.mgh.harvard.edu	_	
37-39	9549-9550	]	_	
37-40	9550-9551	)	_	
37-41	9552-9559	applied	_	
37-42	9560-9562	to	_	
37-43	9563-9575	longitudinal	_	
37-44	9576-9586	relaxation	_	
37-45	9587-9591	rate	_	
37-46	9592-9593	(	_	
37-47	9593-9595	R1	_	
37-48	9595-9596	)	_	
37-49	9597-9601	maps	_	
37-50	9602-9603	(	_	
37-51	9603-9605	R1	_	
37-52	9605-9606	 	_	
37-53	9606-9607	=	_	
37-54	9608-9609	1	_	
37-55	9609-9610	/	_	
37-56	9610-9612	T1	_	
37-57	9612-9613	)	_	
37-58	9613-9614	.	_	

#Text=Expert visual quality control ensured accurate segmentation of pial and gray/white matter boundaries.
38-1	9615-9621	Expert	_	
38-2	9622-9628	visual	_	
38-3	9629-9636	quality	_	
38-4	9637-9644	control	_	
38-5	9645-9652	ensured	_	
38-6	9653-9661	accurate	_	
38-7	9662-9674	segmentation	_	
38-8	9675-9677	of	_	
38-9	9678-9682	pial	_	
38-10	9683-9686	and	_	
38-11	9687-9691	gray	_	
38-12	9691-9692	/	_	
38-13	9692-9697	white	_	
38-14	9698-9704	matter	_	
38-15	9705-9715	boundaries	_	
38-16	9715-9716	.	_	

#Text=Regional MT values were estimated at each of 68 cortical regions for each subject, resulting in a 248 × 68 regional MT data matrix.
39-1	9717-9725	Regional	_	
39-2	9726-9728	MT	_	
39-3	9729-9735	values	_	
39-4	9736-9740	were	_	
39-5	9741-9750	estimated	_	
39-6	9751-9753	at	_	
39-7	9754-9758	each	_	
39-8	9759-9761	of	_	
39-9	9762-9764	68	_	
39-10	9765-9773	cortical	_	
39-11	9774-9781	regions	_	
39-12	9782-9785	for	_	
39-13	9786-9790	each	_	
39-14	9791-9798	subject	_	
39-15	9798-9799	,	_	
39-16	9800-9809	resulting	_	
39-17	9810-9812	in	_	
39-18	9813-9814	a	_	
39-19	9815-9818	248	_	
39-20	9818-9819	 	_	
39-21	9819-9820	×	_	
39-22	9821-9823	68	_	
39-23	9824-9832	regional	_	
39-24	9833-9835	MT	_	
39-25	9836-9840	data	_	
39-26	9841-9847	matrix	_	
39-27	9847-9848	.	_	

#Text=The Euler number for the R1 images was calculated as a proxy measure of image quality in the simultaneously acquired MT images.
40-1	9849-9852	The	_	
40-2	9853-9858	Euler	_	
40-3	9859-9865	number	_	
40-4	9866-9869	for	_	
40-5	9870-9873	the	_	
40-6	9874-9876	R1	_	
40-7	9877-9883	images	_	
40-8	9884-9887	was	_	
40-9	9888-9898	calculated	_	
40-10	9899-9901	as	_	
40-11	9902-9903	a	_	
40-12	9904-9909	proxy	_	
40-13	9910-9917	measure	_	
40-14	9917-9918	 	_	
40-15	9918-9920	of	_	
40-16	9921-9926	image	_	
40-17	9927-9934	quality	_	
40-18	9935-9937	in	_	
40-19	9938-9941	the	_	
40-20	9942-9956	simultaneously	_	
40-21	9957-9965	acquired	_	
40-22	9966-9968	MT	_	
40-23	9968-9969	 	_	
40-24	9969-9975	images	_	
40-25	9975-9976	.	_	

#Text=A simple linear model of age-related change in MT was used to estimate two key parameters for each region: baseline MT at 14 years of age and age-related rate of change in the period from 14 to 24 years of age.
41-1	9977-9978	A	_	
41-2	9979-9985	simple	_	
41-3	9986-9992	linear	_	
41-4	9993-9998	model	_	
41-5	9999-10001	of	_	
41-6	10002-10013	age-related	_	
41-7	10014-10020	change	_	
41-8	10021-10023	in	_	
41-9	10024-10026	MT	_	
41-10	10027-10030	was	_	
41-11	10031-10035	used	_	
41-12	10036-10038	to	_	
41-13	10039-10047	estimate	_	
41-14	10048-10051	two	_	
41-15	10052-10055	key	_	
41-16	10056-10066	parameters	_	
41-17	10067-10070	for	_	
41-18	10071-10075	each	_	
41-19	10076-10082	region	_	
41-20	10082-10083	:	_	
41-21	10084-10092	baseline	_	
41-22	10093-10095	MT	_	
41-23	10096-10098	at	_	
41-24	10099-10101	14	_	
41-25	10102-10107	years	_	
41-26	10108-10110	of	_	
41-27	10111-10114	age	_	
41-28	10115-10118	and	_	
41-29	10119-10130	age-related	_	
41-30	10131-10135	rate	_	
41-31	10136-10138	of	_	
41-32	10139-10145	change	_	
41-33	10146-10148	in	_	
41-34	10149-10152	the	_	
41-35	10153-10159	period	_	
41-36	10160-10164	from	_	
41-37	10165-10167	14	_	
41-38	10168-10170	to	_	
41-39	10171-10173	24	_	
41-40	10174-10179	years	_	
41-41	10180-10182	of	_	
41-42	10183-10186	age	_	
41-43	10186-10187	.	_	

#Text=For the principal analyses, effects of age on MT were controlled by regression before estimating the correlation of the age-corrected MT residuals with SPQ total score.
42-1	10188-10191	For	_	
42-2	10192-10195	the	_	
42-3	10196-10205	principal	_	
42-4	10206-10214	analyses	_	
42-5	10214-10215	,	_	
42-6	10216-10223	effects	_	
42-7	10224-10226	of	_	
42-8	10227-10230	age	_	
42-9	10231-10233	on	_	
42-10	10234-10236	MT	_	
42-11	10237-10241	were	_	
42-12	10242-10252	controlled	_	
42-13	10253-10255	by	_	
42-14	10256-10266	regression	_	
42-15	10267-10273	before	_	
42-16	10274-10284	estimating	_	
42-17	10285-10288	the	_	
42-18	10289-10300	correlation	_	
42-19	10301-10303	of	_	
42-20	10304-10307	the	_	
42-21	10308-10321	age-corrected	_	
42-22	10322-10324	MT	_	
42-23	10325-10334	residuals	_	
42-24	10335-10339	with	_	
42-25	10340-10343	SPQ	_	
42-26	10344-10349	total	_	
42-27	10350-10355	score	_	
42-28	10355-10356	.	_	

#Text=The Kolmogorov-Smirnov normality test was used to determine the appropriate correlation estimator (Pearson’s or Spearman’s).
43-1	10357-10360	The	_	
43-2	10361-10379	Kolmogorov-Smirnov	_	
43-3	10380-10389	normality	_	
43-4	10390-10394	test	_	
43-5	10395-10398	was	_	
43-6	10399-10403	used	_	
43-7	10404-10406	to	_	
43-8	10407-10416	determine	_	
43-9	10417-10420	the	_	
43-10	10421-10432	appropriate	_	
43-11	10433-10444	correlation	_	
43-12	10445-10454	estimator	_	
43-13	10455-10456	(	_	
43-14	10456-10463	Pearson	_	
43-15	10463-10464	’	_	
43-16	10464-10465	s	_	
43-17	10466-10468	or	_	
43-18	10469-10477	Spearman	_	
43-19	10477-10478	’	_	
43-20	10478-10479	s	_	
43-21	10479-10480	)	_	
43-22	10480-10481	.	_	

#Text=Estimation of Regional Gene Expression
#Text=We used the Allen Human Brain Atlas (AHBA), a whole-genome expression atlas of the adult human brain created by the Allen Institute for Brain Sciences using 6 donors 24 to 57 years of age (http://human.brain-map.org).
44-1	10482-10492	Estimation	_	
44-2	10493-10495	of	_	
44-3	10496-10504	Regional	_	
44-4	10505-10509	Gene	_	
44-5	10510-10520	Expression	_	
44-6	10521-10523	We	_	
44-7	10524-10528	used	_	
44-8	10529-10532	the	_	
44-9	10533-10538	Allen	_	
44-10	10539-10544	Human	_	
44-11	10545-10550	Brain	_	
44-12	10551-10556	Atlas	_	
44-13	10557-10558	(	_	
44-14	10558-10562	AHBA	_	
44-15	10562-10563	)	_	
44-16	10563-10564	,	_	
44-17	10565-10566	a	_	
44-18	10567-10579	whole-genome	_	
44-19	10580-10590	expression	_	
44-20	10591-10596	atlas	_	
44-21	10597-10599	of	_	
44-22	10600-10603	the	_	
44-23	10604-10609	adult	_	
44-24	10610-10615	human	_	
44-25	10616-10621	brain	_	
44-26	10622-10629	created	_	
44-27	10630-10632	by	_	
44-28	10633-10636	the	_	
44-29	10637-10642	Allen	_	
44-30	10643-10652	Institute	_	
44-31	10653-10656	for	_	
44-32	10657-10662	Brain	_	
44-33	10663-10671	Sciences	_	
44-34	10672-10677	using	_	
44-35	10678-10679	6	_	
44-36	10680-10686	donors	_	
44-37	10687-10689	24	_	
44-38	10690-10692	to	_	
44-39	10693-10695	57	_	
44-40	10696-10701	years	_	
44-41	10702-10704	of	_	
44-42	10705-10708	age	_	
44-43	10709-10710	(	_	
44-44	10710-10714	http	_	
44-45	10714-10715	:	_	
44-46	10715-10716	/	_	
44-47	10716-10717	/	_	
44-48	10717-10736	human.brain-map.org	_	
44-49	10736-10737	)	_	
44-50	10737-10738	.	_	

#Text=Probe-to-gene and sample-to-region mapping strategies can have a major impact on regional gene expression estimation.
45-1	10739-10752	Probe-to-gene	_	
45-2	10753-10756	and	_	
45-3	10757-10773	sample-to-region	_	
45-4	10774-10781	mapping	_	
45-5	10782-10792	strategies	_	
45-6	10793-10796	can	_	
45-7	10797-10801	have	_	
45-8	10802-10803	a	_	
45-9	10804-10809	major	_	
45-10	10810-10816	impact	_	
45-11	10817-10819	on	_	
45-12	10820-10828	regional	_	
45-13	10829-10833	gene	_	
45-14	10834-10844	expression	_	
45-15	10845-10855	estimation	_	
45-16	10855-10856	.	_	

#Text=Here, we used the genome assembly hg19 (http://sourceforge.net/projects/reannotator/) to reannotate the probe sequences into genes.
46-1	10857-10861	Here	_	
46-2	10861-10862	,	_	
46-3	10863-10865	we	_	
46-4	10866-10870	used	_	
46-5	10871-10874	the	_	
46-6	10875-10881	genome	_	
46-7	10882-10890	assembly	_	
46-8	10891-10895	hg19	_	
46-9	10896-10897	(	_	
46-10	10897-10901	http	_	
46-11	10901-10902	:	_	
46-12	10902-10903	/	_	
46-13	10903-10904	/	_	
46-14	10904-10919	sourceforge.net	_	
46-15	10919-10920	/	_	
46-16	10920-10928	projects	_	
46-17	10928-10929	/	_	
46-18	10929-10940	reannotator	_	
46-19	10940-10941	/	_	
46-20	10941-10942	)	_	
46-21	10943-10945	to	_	
46-22	10946-10956	reannotate	_	
46-23	10957-10960	the	_	
46-24	10961-10966	probe	_	
46-25	10967-10976	sequences	_	
46-26	10977-10981	into	_	
46-27	10982-10987	genes	_	
46-28	10987-10988	.	_	

#Text=When genes were mapped by multiple complementary RNA hybridization probes, the probe showing the highest average expression across samples was selected.
47-1	10989-10993	When	_	
47-2	10994-10999	genes	_	
47-3	11000-11004	were	_	
47-4	11005-11011	mapped	_	
47-5	11012-11014	by	_	
47-6	11015-11023	multiple	_	
47-7	11024-11037	complementary	_	
47-8	11038-11041	RNA	_	
47-9	11042-11055	hybridization	_	
47-10	11056-11062	probes	_	
47-11	11062-11063	,	_	
47-12	11064-11067	the	_	
47-13	11068-11073	probe	_	
47-14	11074-11081	showing	_	
47-15	11082-11085	the	_	
47-16	11086-11093	highest	_	
47-17	11094-11101	average	_	
47-18	11102-11112	expression	_	
47-19	11113-11119	across	_	
47-20	11120-11127	samples	_	
47-21	11128-11131	was	_	
47-22	11132-11140	selected	_	
47-23	11140-11141	.	_	

#Text=MRI images of the AHBA donors were parcellated using the Desikan-Killiany atlas, and each cortical tissue sample was assigned to an anatomical structure.
48-1	11142-11145	MRI	_	
48-2	11146-11152	images	_	
48-3	11153-11155	of	_	
48-4	11156-11159	the	_	
48-5	11160-11164	AHBA	_	
48-6	11165-11171	donors	_	
48-7	11172-11176	were	_	
48-8	11177-11188	parcellated	_	
48-9	11189-11194	using	_	
48-10	11195-11198	the	_	
48-11	11199-11215	Desikan-Killiany	_	
48-12	11216-11221	atlas	_	
48-13	11221-11222	,	_	
48-14	11223-11226	and	_	
48-15	11227-11231	each	_	
48-16	11232-11240	cortical	_	
48-17	11241-11247	tissue	_	
48-18	11248-11254	sample	_	
48-19	11255-11258	was	_	
48-20	11259-11267	assigned	_	
48-21	11268-11270	to	_	
48-22	11271-11273	an	_	
48-23	11274-11284	anatomical	_	
48-24	11285-11294	structure	_	
48-25	11294-11295	.	_	

#Text=Regional expression levels were compiled to form a 68 × 20,647 regional transcription matrix (see Supplement).
49-1	11296-11304	Regional	_	
49-2	11305-11315	expression	_	
49-3	11316-11322	levels	_	
49-4	11323-11327	were	_	
49-5	11328-11336	compiled	_	
49-6	11337-11339	to	_	
49-7	11340-11344	form	_	
49-8	11345-11346	a	_	
49-9	11347-11349	68	_	
49-10	11349-11350	 	_	
49-11	11350-11351	×	_	
49-12	11352-11358	20,647	_	
49-13	11359-11367	regional	_	
49-14	11368-11381	transcription	_	
49-15	11382-11388	matrix	_	
49-16	11389-11390	(	_	
49-17	11390-11393	see	_	
49-18	11394-11404	Supplement	_	
49-19	11404-11405	)	_	
49-20	11405-11406	.	_	

#Text=SRM and Human Brain Gene Expression
#Text=We used partial least squares (PLS) to analyze covariation between SRM and gene expression because it is technically well suited to the high collinearity of the gene expression data, and because PLS and the related multivariate method of canonical correlation analysis have been extensively developed and used for neuroimaging and transcriptional data analysis.
50-1	11407-11410	SRM	_	
50-2	11411-11414	and	_	
50-3	11415-11420	Human	_	
50-4	11421-11426	Brain	_	
50-5	11427-11431	Gene	_	
50-6	11432-11442	Expression	_	
50-7	11443-11445	We	_	
50-8	11446-11450	used	_	
50-9	11451-11458	partial	_	
50-10	11459-11464	least	_	
50-11	11465-11472	squares	_	
50-12	11473-11474	(	_	
50-13	11474-11477	PLS	_	
50-14	11477-11478	)	_	
50-15	11479-11481	to	_	
50-16	11482-11489	analyze	_	
50-17	11490-11501	covariation	_	
50-18	11502-11509	between	_	
50-19	11510-11513	SRM	_	
50-20	11514-11517	and	_	
50-21	11518-11522	gene	_	
50-22	11523-11533	expression	_	
50-23	11534-11541	because	_	
50-24	11542-11544	it	_	
50-25	11545-11547	is	_	
50-26	11548-11559	technically	_	
50-27	11560-11564	well	_	
50-28	11565-11571	suited	_	
50-29	11572-11574	to	_	
50-30	11575-11578	the	_	
50-31	11579-11583	high	_	
50-32	11584-11596	collinearity	_	
50-33	11597-11599	of	_	
50-34	11600-11603	the	_	
50-35	11604-11608	gene	_	
50-36	11609-11619	expression	_	
50-37	11620-11624	data	_	
50-38	11624-11625	,	_	
50-39	11626-11629	and	_	
50-40	11630-11637	because	_	
50-41	11638-11641	PLS	_	
50-42	11642-11645	and	_	
50-43	11646-11649	the	_	
50-44	11650-11657	related	_	
50-45	11658-11670	multivariate	_	
50-46	11671-11677	method	_	
50-47	11678-11680	of	_	
50-48	11681-11690	canonical	_	
50-49	11691-11702	correlation	_	
50-50	11703-11711	analysis	_	
50-51	11712-11716	have	_	
50-52	11717-11721	been	_	
50-53	11722-11733	extensively	_	
50-54	11734-11743	developed	_	
50-55	11744-11747	and	_	
50-56	11748-11752	used	_	
50-57	11753-11756	for	_	
50-58	11757-11769	neuroimaging	_	
50-59	11770-11773	and	_	
50-60	11774-11789	transcriptional	_	
50-61	11790-11794	data	_	
50-62	11795-11803	analysis	_	
50-63	11803-11804	.	_	

#Text=Specifically, we used PLS to analyze the relationship between the vector of 68 regional measures of SRM and the 68 × 20,647 matrix of 68 regional messenger RNA measurements for 20,647 genes.
51-1	11805-11817	Specifically	_	
51-2	11817-11818	,	_	
51-3	11819-11821	we	_	
51-4	11822-11826	used	_	
51-5	11827-11830	PLS	_	
51-6	11831-11833	to	_	
51-7	11834-11841	analyze	_	
51-8	11842-11845	the	_	
51-9	11846-11858	relationship	_	
51-10	11859-11866	between	_	
51-11	11867-11870	the	_	
51-12	11871-11877	vector	_	
51-13	11878-11880	of	_	
51-14	11881-11883	68	_	
51-15	11884-11892	regional	_	
51-16	11893-11901	measures	_	
51-17	11902-11904	of	_	
51-18	11905-11908	SRM	_	
51-19	11909-11912	and	_	
51-20	11913-11916	the	_	
51-21	11917-11919	68	_	
51-22	11919-11920	 	_	
51-23	11920-11921	×	_	
51-24	11922-11928	20,647	_	
51-25	11929-11935	matrix	_	
51-26	11936-11938	of	_	
51-27	11939-11941	68	_	
51-28	11942-11950	regional	_	
51-29	11951-11960	messenger	_	
51-30	11961-11964	RNA	_	
51-31	11965-11977	measurements	_	
51-32	11978-11981	for	_	
51-33	11982-11988	20,647	_	
51-34	11989-11994	genes	_	
51-35	11994-11995	.	_	

#Text=The first PLS component (PLS1) was defined as the weighted sum of whole-genome expression that was most strongly correlated, or most closely colocated, with the anatomical map of SRM.
52-1	11996-11999	The	_	
52-2	12000-12005	first	_	
52-3	12006-12009	PLS	_	
52-4	12010-12019	component	_	
52-5	12020-12021	(	_	
52-6	12021-12025	PLS1	_	
52-7	12025-12026	)	_	
52-8	12027-12030	was	_	
52-9	12031-12038	defined	_	
52-10	12039-12041	as	_	
52-11	12042-12045	the	_	
52-12	12046-12054	weighted	_	
52-13	12055-12058	sum	_	
52-14	12059-12061	of	_	
52-15	12062-12074	whole-genome	_	
52-16	12075-12085	expression	_	
52-17	12086-12090	that	_	
52-18	12091-12094	was	_	
52-19	12095-12099	most	_	
52-20	12100-12108	strongly	_	
52-21	12109-12119	correlated	_	
52-22	12119-12120	,	_	
52-23	12121-12123	or	_	
52-24	12124-12128	most	_	
52-25	12129-12136	closely	_	
52-26	12137-12146	colocated	_	
52-27	12146-12147	,	_	
52-28	12148-12152	with	_	
52-29	12153-12156	the	_	
52-30	12157-12167	anatomical	_	
52-31	12168-12171	map	_	
52-32	12172-12174	of	_	
52-33	12175-12178	SRM	_	
52-34	12178-12179	.	_	

#Text=Permutation testing based on spherical rotations or “spins” of the spatially correlated SRM map was used to test the null hypothesis that PLS1 explained no more covariance between SRM and whole-genome expression than expected by chance.
53-1	12180-12191	Permutation	_	
53-2	12192-12199	testing	_	
53-3	12200-12205	based	_	
53-4	12206-12208	on	_	
53-5	12209-12218	spherical	_	
53-6	12219-12228	rotations	_	
53-7	12229-12231	or	_	
53-8	12232-12233	“	_	
53-9	12233-12238	spins	_	
53-10	12238-12239	”	_	
53-11	12240-12242	of	_	
53-12	12243-12246	the	_	
53-13	12247-12256	spatially	_	
53-14	12257-12267	correlated	_	
53-15	12268-12271	SRM	_	
53-16	12272-12275	map	_	
53-17	12276-12279	was	_	
53-18	12280-12284	used	_	
53-19	12285-12287	to	_	
53-20	12288-12292	test	_	
53-21	12293-12296	the	_	
53-22	12297-12301	null	_	
53-23	12302-12312	hypothesis	_	
53-24	12313-12317	that	_	
53-25	12318-12322	PLS1	_	
53-26	12323-12332	explained	_	
53-27	12333-12335	no	_	
53-28	12336-12340	more	_	
53-29	12341-12351	covariance	_	
53-30	12352-12359	between	_	
53-31	12360-12363	SRM	_	
53-32	12364-12367	and	_	
53-33	12368-12380	whole-genome	_	
53-34	12381-12391	expression	_	
53-35	12392-12396	than	_	
53-36	12397-12405	expected	_	
53-37	12406-12408	by	_	
53-38	12409-12415	chance	_	
53-39	12415-12416	.	_	

#Text=Bootstrapping was used to estimate the variability of each gene’s positive or negative weight on PLS1, and we tested the null hypothesis of zero weight for each gene with a false discovery rate (FDR) of 5%.
54-1	12417-12430	Bootstrapping	_	
54-2	12431-12434	was	_	
54-3	12435-12439	used	_	
54-4	12440-12442	to	_	
54-5	12443-12451	estimate	_	
54-6	12452-12455	the	_	
54-7	12456-12467	variability	_	
54-8	12468-12470	of	_	
54-9	12471-12475	each	_	
54-10	12476-12480	gene	_	
54-11	12480-12481	’	_	
54-12	12481-12482	s	_	
54-13	12483-12491	positive	_	
54-14	12492-12494	or	_	
54-15	12495-12503	negative	_	
54-16	12504-12510	weight	_	
54-17	12511-12513	on	_	
54-18	12514-12518	PLS1	_	
54-19	12518-12519	,	_	
54-20	12520-12523	and	_	
54-21	12524-12526	we	_	
54-22	12527-12533	tested	_	
54-23	12534-12537	the	_	
54-24	12538-12542	null	_	
54-25	12543-12553	hypothesis	_	
54-26	12554-12556	of	_	
54-27	12557-12561	zero	_	
54-28	12562-12568	weight	_	
54-29	12569-12572	for	_	
54-30	12573-12577	each	_	
54-31	12578-12582	gene	_	
54-32	12583-12587	with	_	
54-33	12588-12589	a	_	
54-34	12590-12595	false	_	
54-35	12596-12605	discovery	_	
54-36	12606-12610	rate	_	
54-37	12611-12612	(	_	
54-38	12612-12615	FDR	_	
54-39	12615-12616	)	_	
54-40	12617-12619	of	_	
54-41	12620-12622	5%	_	
54-42	12622-12623	.	_	

#Text=The set of genes that were significantly (positively or negatively) weighted on PLS1 was called the SRM gene list or set.
55-1	12624-12627	The	_	
55-2	12628-12631	set	_	
55-3	12632-12634	of	_	
55-4	12635-12640	genes	_	
55-5	12641-12645	that	_	
55-6	12646-12650	were	_	
55-7	12651-12664	significantly	_	
55-8	12665-12666	(	_	
55-9	12666-12676	positively	_	
55-10	12677-12679	or	_	
55-11	12680-12690	negatively	_	
55-12	12690-12691	)	_	
55-13	12692-12700	weighted	_	
55-14	12701-12703	on	_	
55-15	12704-12708	PLS1	_	
55-16	12709-12712	was	_	
55-17	12713-12719	called	_	
55-18	12720-12723	the	_	
55-19	12724-12727	SRM	_	
55-20	12728-12732	gene	_	
55-21	12733-12737	list	_	
55-22	12738-12740	or	_	
55-23	12741-12744	set	_	
55-24	12744-12745	.	_	

#Text=Enrichment Analysis
#Text=We assigned a cellular affiliation score to each gene in the SRM gene list according to prior criteria for 4 cell types—neuron, astrocyte, microglia, or oligodendroglia —and for a more fine-grained set of cell types (Table S2).
56-1	12746-12756	Enrichment	_	
56-2	12757-12765	Analysis	_	
56-3	12766-12768	We	_	
56-4	12769-12777	assigned	_	
56-5	12778-12779	a	_	
56-6	12780-12788	cellular	_	
56-7	12789-12800	affiliation	_	
56-8	12801-12806	score	_	
56-9	12807-12809	to	_	
56-10	12810-12814	each	_	
56-11	12815-12819	gene	_	
56-12	12820-12822	in	_	
56-13	12823-12826	the	_	
56-14	12827-12830	SRM	_	
56-15	12831-12835	gene	_	
56-16	12836-12840	list	_	
56-17	12841-12850	according	_	
56-18	12851-12853	to	_	
56-19	12854-12859	prior	_	
56-20	12860-12868	criteria	_	
56-21	12869-12872	for	_	
56-22	12873-12874	4	_	
56-23	12875-12879	cell	_	
56-24	12880-12892	types—neuron	_	
56-25	12892-12893	,	_	
56-26	12894-12903	astrocyte	_	
56-27	12903-12904	,	_	
56-28	12905-12914	microglia	_	
56-29	12914-12915	,	_	
56-30	12916-12918	or	_	
56-31	12919-12934	oligodendroglia	_	
56-32	12935-12936	—	_	
56-33	12936-12939	and	_	
56-34	12940-12943	for	_	
56-35	12944-12945	a	_	
56-36	12946-12950	more	_	
56-37	12951-12963	fine-grained	_	
56-38	12964-12967	set	_	
56-39	12968-12970	of	_	
56-40	12971-12975	cell	_	
56-41	12976-12981	types	_	
56-42	12982-12983	(	_	
56-43	12983-12988	Table	_	
56-44	12988-12989	 	_	
56-45	12989-12991	S2	_	
56-46	12991-12992	)	_	
56-47	12992-12993	.	_	

#Text=We used a data resampling procedure to test the null hypothesis that SRM genes were randomly assigned to different cell types.
57-1	12994-12996	We	_	
57-2	12997-13001	used	_	
57-3	13002-13003	a	_	
57-4	13004-13008	data	_	
57-5	13009-13019	resampling	_	
57-6	13020-13029	procedure	_	
57-7	13030-13032	to	_	
57-8	13033-13037	test	_	
57-9	13038-13041	the	_	
57-10	13042-13046	null	_	
57-11	13047-13057	hypothesis	_	
57-12	13058-13062	that	_	
57-13	13063-13066	SRM	_	
57-14	13067-13072	genes	_	
57-15	13073-13077	were	_	
57-16	13078-13086	randomly	_	
57-17	13087-13095	assigned	_	
57-18	13096-13098	to	_	
57-19	13099-13108	different	_	
57-20	13109-13113	cell	_	
57-21	13114-13119	types	_	
57-22	13119-13120	.	_	

#Text=We used 2 lists of genes that were differentially expressed, or transcriptionally dysregulated, in postmortem brain tissue measurements of messenger RNA from case-control studies of schizophrenia: 1) the list of genes reported by Gandal et al. as upregulated (n = 845) or downregulated (n = 1175) in the prefrontal and parietal brain regions in schizophrenia (n = 159); and 2) the list of genes reported by Fromer et al. as upregulated (n = 304) or downregulated (n = 345) in the dorsolateral prefrontal cortex in schizophrenia (n = 258).
58-1	13121-13123	We	_	
58-2	13124-13128	used	_	
58-3	13129-13130	2	_	
58-4	13131-13136	lists	_	
58-5	13137-13139	of	_	
58-6	13140-13145	genes	_	
58-7	13146-13150	that	_	
58-8	13151-13155	were	_	
58-9	13156-13170	differentially	_	
58-10	13171-13180	expressed	_	
58-11	13180-13181	,	_	
58-12	13182-13184	or	_	
58-13	13185-13202	transcriptionally	_	
58-14	13203-13215	dysregulated	_	
58-15	13215-13216	,	_	
58-16	13217-13219	in	_	
58-17	13220-13230	postmortem	_	
58-18	13231-13236	brain	_	
58-19	13237-13243	tissue	_	
58-20	13244-13256	measurements	_	
58-21	13257-13259	of	_	
58-22	13260-13269	messenger	_	
58-23	13270-13273	RNA	_	
58-24	13274-13278	from	_	
58-25	13279-13291	case-control	_	
58-26	13292-13299	studies	_	
58-27	13300-13302	of	_	
58-28	13303-13316	schizophrenia	_	
58-29	13316-13317	:	_	
58-30	13318-13319	1	_	
58-31	13319-13320	)	_	
58-32	13321-13324	the	_	
58-33	13325-13329	list	_	
58-34	13330-13332	of	_	
58-35	13333-13338	genes	_	
58-36	13339-13347	reported	_	
58-37	13348-13350	by	_	
58-38	13351-13357	Gandal	_	
58-39	13358-13360	et	_	
58-40	13360-13361	 	_	
58-41	13361-13363	al	_	
58-42	13363-13364	.	_	
58-43	13365-13367	as	_	
58-44	13368-13379	upregulated	_	
58-45	13380-13381	(	_	
58-46	13381-13382	n	_	
58-47	13382-13383	 	_	
58-48	13383-13384	=	_	
58-49	13385-13388	845	_	
58-50	13388-13389	)	_	
58-51	13390-13392	or	_	
58-52	13393-13406	downregulated	_	
58-53	13407-13408	(	_	
58-54	13408-13409	n	_	
58-55	13409-13410	 	_	
58-56	13410-13411	=	_	
58-57	13412-13416	1175	_	
58-58	13416-13417	)	_	
58-59	13418-13420	in	_	
58-60	13421-13424	the	_	
58-61	13425-13435	prefrontal	_	
58-62	13436-13439	and	_	
58-63	13440-13448	parietal	_	
58-64	13449-13454	brain	_	
58-65	13455-13462	regions	_	
58-66	13463-13465	in	_	
58-67	13466-13479	schizophrenia	_	
58-68	13480-13481	(	_	
58-69	13481-13482	n	_	
58-70	13482-13483	 	_	
58-71	13483-13484	=	_	
58-72	13485-13488	159	_	
58-73	13488-13489	)	_	
58-74	13489-13490	;	_	
58-75	13491-13494	and	_	
58-76	13495-13496	2	_	
58-77	13496-13497	)	_	
58-78	13498-13501	the	_	
58-79	13502-13506	list	_	
58-80	13507-13509	of	_	
58-81	13510-13515	genes	_	
58-82	13516-13524	reported	_	
58-83	13525-13527	by	_	
58-84	13528-13534	Fromer	_	
58-85	13535-13537	et	_	
58-86	13537-13538	 	_	
58-87	13538-13540	al	_	
58-88	13540-13541	.	_	
58-89	13542-13544	as	_	
58-90	13545-13556	upregulated	_	
58-91	13557-13558	(	_	
58-92	13558-13559	n	_	
58-93	13559-13560	 	_	
58-94	13560-13561	=	_	
58-95	13562-13565	304	_	
58-96	13565-13566	)	_	
58-97	13567-13569	or	_	
58-98	13570-13583	downregulated	_	
58-99	13584-13585	(	_	
58-100	13585-13586	n	_	
58-101	13586-13587	 	_	
58-102	13587-13588	=	_	
58-103	13589-13592	345	_	
58-104	13592-13593	)	_	
58-105	13594-13596	in	_	
58-106	13597-13600	the	_	
58-107	13601-13613	dorsolateral	_	
58-108	13614-13624	prefrontal	_	
58-109	13625-13631	cortex	_	
58-110	13632-13634	in	_	
58-111	13635-13648	schizophrenia	_	
58-112	13649-13650	(	_	
58-113	13650-13651	n	_	
58-114	13651-13652	 	_	
58-115	13652-13653	=	_	
58-116	13654-13657	258	_	
58-117	13657-13658	)	_	
58-118	13658-13659	.	_	

#Text=The 2 gene lists were partially overlapping (Table S3), and differential expression of all genes subsumed by the union of the 2 lists was strongly correlated between studies (ρ = .76, p < 10−129) (Figure S1).
59-1	13660-13663	The	_	
59-2	13664-13665	2	_	
59-3	13666-13670	gene	_	
59-4	13671-13676	lists	_	
59-5	13677-13681	were	_	
59-6	13682-13691	partially	_	
59-7	13692-13703	overlapping	_	
59-8	13704-13705	(	_	
59-9	13705-13710	Table	_	
59-10	13710-13711	 	_	
59-11	13711-13713	S3	_	
59-12	13713-13714	)	_	
59-13	13714-13715	,	_	
59-14	13716-13719	and	_	
59-15	13720-13732	differential	_	
59-16	13733-13743	expression	_	
59-17	13744-13746	of	_	
59-18	13747-13750	all	_	
59-19	13751-13756	genes	_	
59-20	13757-13765	subsumed	_	
59-21	13766-13768	by	_	
59-22	13769-13772	the	_	
59-23	13773-13778	union	_	
59-24	13779-13781	of	_	
59-25	13782-13785	the	_	
59-26	13786-13787	2	_	
59-27	13788-13793	lists	_	
59-28	13794-13797	was	_	
59-29	13798-13806	strongly	_	
59-30	13807-13817	correlated	_	
59-31	13818-13825	between	_	
59-32	13826-13833	studies	_	
59-33	13834-13835	(	_	
59-34	13835-13836	ρ	_	
59-35	13836-13837	 	_	
59-36	13837-13838	=	_	
59-37	13839-13842	.76	_	
59-38	13842-13843	,	_	
59-39	13844-13845	p	_	
59-40	13846-13847	<	_	
59-41	13848-13850	10	_	
59-42	13850-13851	−	_	
59-43	13851-13854	129	_	
59-44	13854-13855	)	_	
59-45	13856-13857	(	_	
59-46	13857-13863	Figure	_	
59-47	13863-13864	 	_	
59-48	13864-13866	S1	_	
59-49	13866-13867	)	_	
59-50	13867-13868	.	_	

#Text=We used repeated random relabeling of genes to test the null hypothesis that the SRM gene list included no more schizophrenia-related genes than expected by chance.
60-1	13869-13871	We	_	
60-2	13872-13876	used	_	
60-3	13877-13885	repeated	_	
60-4	13886-13892	random	_	
60-5	13893-13903	relabeling	_	
60-6	13904-13906	of	_	
60-7	13907-13912	genes	_	
60-8	13913-13915	to	_	
60-9	13916-13920	test	_	
60-10	13921-13924	the	_	
60-11	13925-13929	null	_	
60-12	13930-13940	hypothesis	_	
60-13	13941-13945	that	_	
60-14	13946-13949	the	_	
60-15	13950-13953	SRM	_	
60-16	13954-13958	gene	_	
60-17	13959-13963	list	_	
60-18	13964-13972	included	_	
60-19	13973-13975	no	_	
60-20	13976-13980	more	_	
60-21	13981-14002	schizophrenia-related	_	
60-22	14003-14008	genes	_	
60-23	14009-14013	than	_	
60-24	14014-14022	expected	_	
60-25	14023-14025	by	_	
60-26	14026-14032	chance	_	
60-27	14032-14033	.	_	

#Text=We also applied the same resampling procedures to comparable prior data on differential gene expression from case-control studies of inflammatory bowel disease, bipolar disorder (BPD), major depressive disorder, and autism spectrum disorder (ASD).
61-1	14034-14036	We	_	
61-2	14037-14041	also	_	
61-3	14042-14049	applied	_	
61-4	14050-14053	the	_	
61-5	14054-14058	same	_	
61-6	14059-14069	resampling	_	
61-7	14070-14080	procedures	_	
61-8	14081-14083	to	_	
61-9	14084-14094	comparable	_	
61-10	14095-14100	prior	_	
61-11	14101-14105	data	_	
61-12	14106-14108	on	_	
61-13	14109-14121	differential	_	
61-14	14122-14126	gene	_	
61-15	14127-14137	expression	_	
61-16	14138-14142	from	_	
61-17	14143-14155	case-control	_	
61-18	14156-14163	studies	_	
61-19	14164-14166	of	_	
61-20	14167-14179	inflammatory	_	
61-21	14180-14185	bowel	_	
61-22	14186-14193	disease	_	
61-23	14193-14194	,	_	
61-24	14195-14202	bipolar	_	
61-25	14203-14211	disorder	_	
61-26	14212-14213	(	_	
61-27	14213-14216	BPD	_	
61-28	14216-14217	)	_	
61-29	14217-14218	,	_	
61-30	14219-14224	major	_	
61-31	14225-14235	depressive	_	
61-32	14236-14244	disorder	_	
61-33	14244-14245	,	_	
61-34	14246-14249	and	_	
61-35	14250-14256	autism	_	
61-36	14257-14265	spectrum	_	
61-37	14266-14274	disorder	_	
61-38	14275-14276	(	_	
61-39	14276-14279	ASD	_	
61-40	14279-14280	)	_	
61-41	14280-14281	.	_	

#Text=Data and Code Sharing
#Text=Data
#Text=Regional MT for 68 cortical regions, schizotypy scores, age, gender, socioeconomic status, scanning site, total brain volume, and Euler values (for N = 248) are available at https://github.com/RafaelRomeroGarcia/Schizotypy_MT_geneExp.
62-1	14282-14286	Data	_	
62-2	14287-14290	and	_	
62-3	14291-14295	Code	_	
62-4	14296-14303	Sharing	_	
62-5	14304-14308	Data	_	
62-6	14309-14317	Regional	_	
62-7	14318-14320	MT	_	
62-8	14321-14324	for	_	
62-9	14325-14327	68	_	
62-10	14328-14336	cortical	_	
62-11	14337-14344	regions	_	
62-12	14344-14345	,	_	
62-13	14346-14356	schizotypy	_	
62-14	14357-14363	scores	_	
62-15	14363-14364	,	_	
62-16	14365-14368	age	_	
62-17	14368-14369	,	_	
62-18	14370-14376	gender	_	
62-19	14376-14377	,	_	
62-20	14378-14391	socioeconomic	_	
62-21	14392-14398	status	_	
62-22	14398-14399	,	_	
62-23	14400-14408	scanning	_	
62-24	14409-14413	site	_	
62-25	14413-14414	,	_	
62-26	14415-14420	total	_	
62-27	14421-14426	brain	_	
62-28	14427-14433	volume	_	
62-29	14433-14434	,	_	
62-30	14435-14438	and	_	
62-31	14439-14444	Euler	_	
62-32	14445-14451	values	_	
62-33	14452-14453	(	_	
62-34	14453-14456	for	_	
62-35	14457-14458	N	_	
62-36	14458-14459	 	_	
62-37	14459-14460	=	_	
62-38	14461-14464	248	_	
62-39	14464-14465	)	_	
62-40	14466-14469	are	_	
62-41	14470-14479	available	_	
62-42	14480-14482	at	_	
62-43	14483-14488	https	_	
62-44	14488-14489	:	_	
62-45	14489-14490	/	_	
62-46	14490-14491	/	_	
62-47	14491-14501	github.com	_	
62-48	14501-14502	/	_	
62-49	14502-14520	RafaelRomeroGarcia	_	
62-50	14520-14521	/	_	
62-51	14521-14542	Schizotypy_MT_geneExp	_	
62-52	14542-14543	.	_	

#Text=Code
#Text=Cortical parcellation of gene expression maps to estimate regional mean gene expression can be found at https://github.com/RafaelRomeroGarcia/geneExpression_Repository.
63-1	14544-14548	Code	_	
63-2	14549-14557	Cortical	_	
63-3	14558-14570	parcellation	_	
63-4	14571-14573	of	_	
63-5	14574-14578	gene	_	
63-6	14579-14589	expression	_	
63-7	14590-14594	maps	_	
63-8	14595-14597	to	_	
63-9	14598-14606	estimate	_	
63-10	14607-14615	regional	_	
63-11	14616-14620	mean	_	
63-12	14621-14625	gene	_	
63-13	14626-14636	expression	_	
63-14	14637-14640	can	_	
63-15	14641-14643	be	_	
63-16	14644-14649	found	_	
63-17	14650-14652	at	_	
63-18	14653-14658	https	_	
63-19	14658-14659	:	_	
63-20	14659-14660	/	_	
63-21	14660-14661	/	_	
63-22	14661-14671	github.com	_	
63-23	14671-14672	/	_	
63-24	14672-14690	RafaelRomeroGarcia	_	
63-25	14690-14691	/	_	
63-26	14691-14716	geneExpression_Repository	_	
63-27	14716-14717	.	_	

#Text=The rotate_parcellation code generates null models that preserve the spatial contiguity of cortical regions for permutation testing: https://github.com/frantisekvasa/rotate_parcellation.
64-1	14718-14721	The	_	
64-2	14722-14741	rotate_parcellation	_	
64-3	14742-14746	code	_	
64-4	14747-14756	generates	_	
64-5	14757-14761	null	_	
64-6	14762-14768	models	_	
64-7	14769-14773	that	_	
64-8	14774-14782	preserve	_	
64-9	14783-14786	the	_	
64-10	14787-14794	spatial	_	
64-11	14795-14805	contiguity	_	
64-12	14806-14808	of	_	
64-13	14809-14817	cortical	_	
64-14	14818-14825	regions	_	
64-15	14826-14829	for	_	
64-16	14830-14841	permutation	_	
64-17	14842-14849	testing	_	
64-18	14849-14850	:	_	
64-19	14851-14856	https	_	
64-20	14856-14857	:	_	
64-21	14857-14858	/	_	
64-22	14858-14859	/	_	
64-23	14859-14869	github.com	_	
64-24	14869-14870	/	_	
64-25	14870-14883	frantisekvasa	_	
64-26	14883-14884	/	_	
64-27	14884-14903	rotate_parcellation	_	
64-28	14903-14904	.	_	

#Text=PLS analysis and bootstrapping to estimate PLS weights can be found at https://github.com/KirstieJane/NSPN_WhitakerVertes_PNAS2016/tree/master/SCRIPTS.
65-1	14905-14908	PLS	_	
65-2	14909-14917	analysis	_	
65-3	14918-14921	and	_	
65-4	14922-14935	bootstrapping	_	
65-5	14936-14938	to	_	
65-6	14939-14947	estimate	_	
65-7	14948-14951	PLS	_	
65-8	14952-14959	weights	_	
65-9	14960-14963	can	_	
65-10	14964-14966	be	_	
65-11	14967-14972	found	_	
65-12	14973-14975	at	_	
65-13	14976-14981	https	_	
65-14	14981-14982	:	_	
65-15	14982-14983	/	_	
65-16	14983-14984	/	_	
65-17	14984-14994	github.com	_	
65-18	14994-14995	/	_	
65-19	14995-15006	KirstieJane	_	
65-20	15006-15007	/	_	
65-21	15007-15035	NSPN_WhitakerVertes_PNAS2016	_	
65-22	15035-15036	/	_	
65-23	15036-15040	tree	_	
65-24	15040-15041	/	_	
65-25	15041-15047	master	_	
65-26	15047-15048	/	_	
65-27	15048-15055	SCRIPTS	_	
65-28	15055-15056	.	_	

#Text=To generate Figure S1 from the raw Gandal et al. and Fromer et al. datasets, we used https://github.com/RafaelRomeroGarcia/Schizotypy_MT_geneExp.
66-1	15057-15059	To	_	
66-2	15060-15068	generate	_	
66-3	15069-15075	Figure	_	
66-4	15075-15076	 	_	
66-5	15076-15078	S1	_	
66-6	15079-15083	from	_	
66-7	15084-15087	the	_	
66-8	15088-15091	raw	_	
66-9	15092-15098	Gandal	_	
66-10	15099-15101	et	_	
66-11	15101-15102	 	_	
66-12	15102-15104	al	_	
66-13	15104-15105	.	_	
66-14	15106-15109	and	_	
66-15	15110-15116	Fromer	_	
66-16	15117-15119	et	_	
66-17	15119-15120	 	_	
66-18	15120-15122	al	_	
66-19	15122-15123	.	_	
66-20	15124-15132	datasets	_	
66-21	15132-15133	,	_	
66-22	15134-15136	we	_	
66-23	15137-15141	used	_	
66-24	15142-15147	https	_	
66-25	15147-15148	:	_	
66-26	15148-15149	/	_	
66-27	15149-15150	/	_	
66-28	15150-15160	github.com	_	
66-29	15160-15161	/	_	
66-30	15161-15179	RafaelRomeroGarcia	_	
66-31	15179-15180	/	_	
66-32	15180-15201	Schizotypy_MT_geneExp	_	
66-33	15201-15202	.	_	

#Text=For mapping regional values to the cortical surface for visualization (BrainsForPublication v0.2.1), see https://doi.org/10.5281/zenodo.1069156.
67-1	15203-15206	For	_	
67-2	15207-15214	mapping	_	
67-3	15215-15223	regional	_	
67-4	15224-15230	values	_	
67-5	15231-15233	to	_	
67-6	15234-15237	the	_	
67-7	15238-15246	cortical	_	
67-8	15247-15254	surface	_	
67-9	15255-15258	for	_	
67-10	15259-15272	visualization	_	
67-11	15273-15274	(	_	
67-12	15274-15294	BrainsForPublication	_	
67-13	15295-15301	v0.2.1	_	
67-14	15301-15302	)	_	
67-15	15302-15303	,	_	
67-16	15304-15307	see	_	
67-17	15308-15313	https	_	
67-18	15313-15314	:	_	
67-19	15314-15315	/	_	
67-20	15315-15316	/	_	
67-21	15316-15323	doi.org	_	
67-22	15323-15324	/	_	
67-23	15324-15331	10.5281	_	
67-24	15331-15332	/	_	
67-25	15332-15338	zenodo	_	
67-26	15338-15346	.1069156	_	
67-27	15346-15347	.	_	

#Text=Results
#Text=Sample Characteristics
#Text=After quality control checks, complete, evaluable MRI and behavioral data were available for analysis on 248 participants: mean age 19.11 ± 2.93 years; 123 (50%) female participants; 213 (86%) right-handed participants; IQ = 112.0 ± 10.5; and 214 (86%) white Caucasian, 10 Asian, 4 black/African American/Caribbean American, 17 mixed, and 3 other ethnic groups (see Table S1 for details).
68-1	15348-15355	Results	_	
68-2	15356-15362	Sample	_	
68-3	15363-15378	Characteristics	_	
68-4	15379-15384	After	_	
68-5	15385-15392	quality	_	
68-6	15393-15400	control	_	
68-7	15401-15407	checks	_	
68-8	15407-15408	,	_	
68-9	15409-15417	complete	_	
68-10	15417-15418	,	_	
68-11	15419-15428	evaluable	_	
68-12	15429-15432	MRI	_	
68-13	15433-15436	and	_	
68-14	15437-15447	behavioral	_	
68-15	15448-15452	data	_	
68-16	15453-15457	were	_	
68-17	15458-15467	available	_	
68-18	15468-15471	for	_	
68-19	15472-15480	analysis	_	
68-20	15481-15483	on	_	
68-21	15484-15487	248	_	
68-22	15488-15500	participants	_	
68-23	15500-15501	:	_	
68-24	15502-15506	mean	_	
68-25	15507-15510	age	_	
68-26	15511-15516	19.11	_	
68-27	15517-15518	±	_	
68-28	15519-15523	2.93	_	
68-29	15524-15529	years	_	
68-30	15529-15530	;	_	
68-31	15531-15534	123	_	
68-32	15535-15536	(	_	
68-33	15536-15539	50%	_	
68-34	15539-15540	)	_	
68-35	15541-15547	female	_	
68-36	15548-15560	participants	_	
68-37	15560-15561	;	_	
68-38	15562-15565	213	_	
68-39	15566-15567	(	_	
68-40	15567-15570	86%	_	
68-41	15570-15571	)	_	
68-42	15572-15584	right-handed	_	
68-43	15585-15597	participants	_	
68-44	15597-15598	;	_	
68-45	15599-15601	IQ	_	
68-46	15601-15602	 	_	
68-47	15602-15603	=	_	
68-48	15604-15609	112.0	_	
68-49	15610-15611	±	_	
68-50	15612-15616	10.5	_	
68-51	15616-15617	;	_	
68-52	15618-15621	and	_	
68-53	15622-15625	214	_	
68-54	15626-15627	(	_	
68-55	15627-15630	86%	_	
68-56	15630-15631	)	_	
68-57	15632-15637	white	_	
68-58	15638-15647	Caucasian	_	
68-59	15647-15648	,	_	
68-60	15649-15651	10	_	
68-61	15652-15657	Asian	_	
68-62	15657-15658	,	_	
68-63	15659-15660	4	_	
68-64	15661-15666	black	_	
68-65	15666-15667	/	_	
68-66	15667-15674	African	_	
68-67	15675-15683	American	_	
68-68	15683-15684	/	_	
68-69	15684-15693	Caribbean	_	
68-70	15694-15702	American	_	
68-71	15702-15703	,	_	
68-72	15704-15706	17	_	
68-73	15707-15712	mixed	_	
68-74	15712-15713	,	_	
68-75	15714-15717	and	_	
68-76	15718-15719	3	_	
68-77	15720-15725	other	_	
68-78	15726-15732	ethnic	_	
68-79	15733-15739	groups	_	
68-80	15740-15741	(	_	
68-81	15741-15744	see	_	
68-82	15745-15750	Table	_	
68-83	15750-15751	 	_	
68-84	15751-15753	S1	_	
68-85	15754-15757	for	_	
68-86	15758-15765	details	_	
68-87	15765-15766	)	_	
68-88	15766-15767	.	_	

#Text=Schizotypy and MT
#Text=Schizotypal personality scores in this healthy (nonpsychotic) sample followed a positively skewed distribution (mean = 0.23, median = 0.20) that was normalized by square root transformation prior to statistical analysis.
69-1	15768-15778	Schizotypy	_	
69-2	15779-15782	and	_	
69-3	15783-15785	MT	_	
69-4	15786-15797	Schizotypal	_	
69-5	15798-15809	personality	_	
69-6	15810-15816	scores	_	
69-7	15817-15819	in	_	
69-8	15820-15824	this	_	
69-9	15825-15832	healthy	_	
69-10	15833-15834	(	_	
69-11	15834-15846	nonpsychotic	_	
69-12	15846-15847	)	_	
69-13	15848-15854	sample	_	
69-14	15855-15863	followed	_	
69-15	15864-15865	a	_	
69-16	15866-15876	positively	_	
69-17	15877-15883	skewed	_	
69-18	15884-15896	distribution	_	
69-19	15897-15898	(	_	
69-20	15898-15902	mean	_	
69-21	15902-15903	 	_	
69-22	15903-15904	=	_	
69-23	15905-15909	0.23	_	
69-24	15909-15910	,	_	
69-25	15911-15917	median	_	
69-26	15917-15918	 	_	
69-27	15918-15919	=	_	
69-28	15920-15924	0.20	_	
69-29	15924-15925	)	_	
69-30	15926-15930	that	_	
69-31	15931-15934	was	_	
69-32	15935-15945	normalized	_	
69-33	15946-15948	by	_	
69-34	15949-15955	square	_	
69-35	15956-15960	root	_	
69-36	15961-15975	transformation	_	
69-37	15976-15981	prior	_	
69-38	15982-15984	to	_	
69-39	15985-15996	statistical	_	
69-40	15997-16005	analysis	_	
69-41	16005-16006	.	_	

#Text=There was no significant effect of age (R2 < .001, p = .69) (Figure S2), gender (R2 < .001, p = .77), or age-by-gender interaction (R2 < .001; p = .82) on SPQ total score or subscale scores.
70-1	16007-16012	There	_	
70-2	16013-16016	was	_	
70-3	16017-16019	no	_	
70-4	16020-16031	significant	_	
70-5	16032-16038	effect	_	
70-6	16039-16041	of	_	
70-7	16042-16045	age	_	
70-8	16046-16047	(	_	
70-9	16047-16049	R2	_	
70-10	16050-16051	<	_	
70-11	16052-16056	.001	_	
70-12	16056-16057	,	_	
70-13	16058-16059	p	_	
70-14	16059-16060	 	_	
70-15	16060-16061	=	_	
70-16	16062-16065	.69	_	
70-17	16065-16066	)	_	
70-18	16067-16068	(	_	
70-19	16068-16074	Figure	_	
70-20	16074-16075	 	_	
70-21	16075-16077	S2	_	
70-22	16077-16078	)	_	
70-23	16078-16079	,	_	
70-24	16080-16086	gender	_	
70-25	16087-16088	(	_	
70-26	16088-16090	R2	_	
70-27	16091-16092	<	_	
70-28	16093-16097	.001	_	
70-29	16097-16098	,	_	
70-30	16099-16100	p	_	
70-31	16100-16101	 	_	
70-32	16101-16102	=	_	
70-33	16103-16106	.77	_	
70-34	16106-16107	)	_	
70-35	16107-16108	,	_	
70-36	16109-16111	or	_	
70-37	16112-16125	age-by-gender	_	
70-38	16126-16137	interaction	_	
70-39	16138-16139	(	_	
70-40	16139-16141	R2	_	
70-41	16142-16143	<	_	
70-42	16144-16148	.001	_	
70-43	16148-16149	;	_	
70-44	16150-16151	p	_	
70-45	16151-16152	 	_	
70-46	16152-16153	=	_	
70-47	16154-16157	.82	_	
70-48	16157-16158	)	_	
70-49	16159-16161	on	_	
70-50	16162-16165	SPQ	_	
70-51	16166-16171	total	_	
70-52	16172-16177	score	_	
70-53	16178-16180	or	_	
70-54	16181-16189	subscale	_	
70-55	16190-16196	scores	_	
70-56	16196-16197	.	_	

#Text=Schizotypy-related magnetization (SRM): association between intracortical magnetization transfer (MT) and Schizotypal Personality Questionnaire (SPQ) score.
71-1	16198-16216	Schizotypy-related	_	
71-2	16217-16230	magnetization	_	
71-3	16231-16232	(	_	
71-4	16232-16235	SRM	_	
71-5	16235-16236	)	_	
71-6	16236-16237	:	_	
71-7	16238-16249	association	_	
71-8	16250-16257	between	_	
71-9	16258-16271	intracortical	_	
71-10	16272-16285	magnetization	_	
71-11	16286-16294	transfer	_	
71-12	16295-16296	(	_	
71-13	16296-16298	MT	_	
71-14	16298-16299	)	_	
71-15	16300-16303	and	_	
71-16	16304-16315	Schizotypal	_	
71-17	16316-16327	Personality	_	
71-18	16328-16341	Questionnaire	_	
71-19	16342-16343	(	_	
71-20	16343-16346	SPQ	_	
71-21	16346-16347	)	_	
71-22	16348-16353	score	_	
71-23	16353-16354	.	_	

#Text=(A) Cortical surface maps highlighting areas where SPQ total score was significantly positively correlated with regional MT after controlling for age by regression: pink regions had nominally significant SRM (2-tailed p < .05); red regions had significant SRM controlled for multiple comparisons over 68 cortical regions tested (false discovery rate < .05).
72-1	16355-16356	(	_	
72-2	16356-16357	A	_	
72-3	16357-16358	)	_	
72-4	16359-16367	Cortical	_	
72-5	16368-16375	surface	_	
72-6	16376-16380	maps	_	
72-7	16381-16393	highlighting	_	
72-8	16394-16399	areas	_	
72-9	16400-16405	where	_	
72-10	16406-16409	SPQ	_	
72-11	16410-16415	total	_	
72-12	16416-16421	score	_	
72-13	16422-16425	was	_	
72-14	16426-16439	significantly	_	
72-15	16440-16450	positively	_	
72-16	16451-16461	correlated	_	
72-17	16462-16466	with	_	
72-18	16467-16475	regional	_	
72-19	16476-16478	MT	_	
72-20	16479-16484	after	_	
72-21	16485-16496	controlling	_	
72-22	16497-16500	for	_	
72-23	16501-16504	age	_	
72-24	16505-16507	by	_	
72-25	16508-16518	regression	_	
72-26	16518-16519	:	_	
72-27	16520-16524	pink	_	
72-28	16525-16532	regions	_	
72-29	16533-16536	had	_	
72-30	16537-16546	nominally	_	
72-31	16547-16558	significant	_	
72-32	16559-16562	SRM	_	
72-33	16563-16564	(	_	
72-34	16564-16565	2	_	
72-35	16565-16566	-	_	
72-36	16566-16572	tailed	_	
72-37	16573-16574	p	_	
72-38	16575-16576	<	_	
72-39	16577-16580	.05	_	
72-40	16580-16581	)	_	
72-41	16581-16582	;	_	
72-42	16583-16586	red	_	
72-43	16587-16594	regions	_	
72-44	16595-16598	had	_	
72-45	16599-16610	significant	_	
72-46	16611-16614	SRM	_	
72-47	16615-16625	controlled	_	
72-48	16626-16629	for	_	
72-49	16630-16638	multiple	_	
72-50	16639-16650	comparisons	_	
72-51	16651-16655	over	_	
72-52	16656-16658	68	_	
72-53	16659-16667	cortical	_	
72-54	16668-16675	regions	_	
72-55	16676-16682	tested	_	
72-56	16683-16684	(	_	
72-57	16684-16689	false	_	
72-58	16690-16699	discovery	_	
72-59	16700-16704	rate	_	
72-60	16705-16706	<	_	
72-61	16707-16710	.05	_	
72-62	16710-16711	)	_	
72-63	16711-16712	.	_	

#Text=(B) Scatterplot of SPQ total score for each participant vs. mean MT in regions of significant SRM (R2246 = .04, p = .002); each dot represents 1 of 248 healthy people 14 to 25 years of age.
73-1	16713-16714	(	_	
73-2	16714-16715	B	_	
73-3	16715-16716	)	_	
73-4	16717-16728	Scatterplot	_	
73-5	16729-16731	of	_	
73-6	16732-16735	SPQ	_	
73-7	16736-16741	total	_	
73-8	16742-16747	score	_	
73-9	16748-16751	for	_	
73-10	16752-16756	each	_	
73-11	16757-16768	participant	_	
73-12	16769-16771	vs	_	
73-13	16771-16772	.	_	
73-14	16773-16777	mean	_	
73-15	16778-16780	MT	_	
73-16	16781-16783	in	_	
73-17	16784-16791	regions	_	
73-18	16792-16794	of	_	
73-19	16795-16806	significant	_	
73-20	16807-16810	SRM	_	
73-21	16811-16812	(	_	
73-22	16812-16817	R2246	_	
73-23	16817-16818	 	_	
73-24	16818-16819	=	_	
73-25	16820-16823	.04	_	
73-26	16823-16824	,	_	
73-27	16825-16826	p	_	
73-28	16826-16827	 	_	
73-29	16827-16828	=	_	
73-30	16829-16833	.002	_	
73-31	16833-16834	)	_	
73-32	16834-16835	;	_	
73-33	16836-16840	each	_	
73-34	16841-16844	dot	_	
73-35	16845-16855	represents	_	
73-36	16856-16857	1	_	
73-37	16858-16860	of	_	
73-38	16861-16864	248	_	
73-39	16865-16872	healthy	_	
73-40	16873-16879	people	_	
73-41	16880-16882	14	_	
73-42	16883-16885	to	_	
73-43	16886-16888	25	_	
73-44	16889-16894	years	_	
73-45	16895-16897	of	_	
73-46	16898-16901	age	_	
73-47	16901-16902	.	_	

#Text=(C) Scatterplots of SRM vs.
74-1	16903-16904	(	_	
74-2	16904-16905	C	_	
74-3	16905-16906	)	_	
74-4	16907-16919	Scatterplots	_	
74-5	16920-16922	of	_	
74-6	16923-16926	SRM	_	
74-7	16927-16929	vs	_	
74-8	16929-16930	.	_	

#Text=MT at 14 years of age (MT14) (left) (R267 = .34, permutation testing based on spherical rotations: p = .002) and SRM vs. change in magnetization 14 to 25 years of age (ΔMT) (right) (R267 = .28, permutation testing based on spherical rotations: p = .006).
75-1	16931-16933	MT	_	
75-2	16934-16936	at	_	
75-3	16937-16939	14	_	
75-4	16940-16945	years	_	
75-5	16946-16948	of	_	
75-6	16949-16952	age	_	
75-7	16953-16954	(	_	
75-8	16954-16958	MT14	_	
75-9	16958-16959	)	_	
75-10	16960-16961	(	_	
75-11	16961-16965	left	_	
75-12	16965-16966	)	_	
75-13	16967-16968	(	_	
75-14	16968-16972	R267	_	
75-15	16972-16973	 	_	
75-16	16973-16974	=	_	
75-17	16975-16978	.34	_	
75-18	16978-16979	,	_	
75-19	16980-16991	permutation	_	
75-20	16992-16999	testing	_	
75-21	17000-17005	based	_	
75-22	17006-17008	on	_	
75-23	17009-17018	spherical	_	
75-24	17019-17028	rotations	_	
75-25	17028-17029	:	_	
75-26	17030-17031	p	_	
75-27	17031-17032	 	_	
75-28	17032-17033	=	_	
75-29	17034-17038	.002	_	
75-30	17038-17039	)	_	
75-31	17040-17043	and	_	
75-32	17044-17047	SRM	_	
75-33	17048-17050	vs	_	
75-34	17050-17051	.	_	
75-35	17052-17058	change	_	
75-36	17059-17061	in	_	
75-37	17062-17075	magnetization	_	
75-38	17076-17078	14	_	
75-39	17079-17081	to	_	
75-40	17082-17084	25	_	
75-41	17085-17090	years	_	
75-42	17091-17093	of	_	
75-43	17094-17097	age	_	
75-44	17098-17099	(	_	
75-45	17099-17102	ΔMT	_	
75-46	17102-17103	)	_	
75-47	17104-17105	(	_	
75-48	17105-17110	right	_	
75-49	17110-17111	)	_	
75-50	17112-17113	(	_	
75-51	17113-17117	R267	_	
75-52	17117-17118	 	_	
75-53	17118-17119	=	_	
75-54	17120-17123	.28	_	
75-55	17123-17124	,	_	
75-56	17125-17136	permutation	_	
75-57	17137-17144	testing	_	
75-58	17145-17150	based	_	
75-59	17151-17153	on	_	
75-60	17154-17163	spherical	_	
75-61	17164-17173	rotations	_	
75-62	17173-17174	:	_	
75-63	17175-17176	p	_	
75-64	17176-17177	 	_	
75-65	17177-17178	=	_	
75-66	17179-17183	.006	_	
75-67	17183-17184	)	_	
75-68	17184-17185	.	_	

#Text=Each point represents a cortical region and colored points represent regions with significant SRM (pink: p < .05; red: false discovery rate < .05).
76-1	17186-17190	Each	_	
76-2	17191-17196	point	_	
76-3	17197-17207	represents	_	
76-4	17208-17209	a	_	
76-5	17210-17218	cortical	_	
76-6	17219-17225	region	_	
76-7	17226-17229	and	_	
76-8	17230-17237	colored	_	
76-9	17238-17244	points	_	
76-10	17245-17254	represent	_	
76-11	17255-17262	regions	_	
76-12	17263-17267	with	_	
76-13	17268-17279	significant	_	
76-14	17280-17283	SRM	_	
76-15	17284-17285	(	_	
76-16	17285-17289	pink	_	
76-17	17289-17290	:	_	
76-18	17291-17292	p	_	
76-19	17292-17293	 	_	
76-20	17293-17294	<	_	
76-21	17294-17295	 	_	
76-22	17295-17298	.05	_	
76-23	17298-17299	;	_	
76-24	17300-17303	red	_	
76-25	17303-17304	:	_	
76-26	17305-17310	false	_	
76-27	17311-17320	discovery	_	
76-28	17321-17325	rate	_	
76-29	17326-17327	<	_	
76-30	17328-17331	.05	_	
76-31	17331-17332	)	_	
76-32	17332-17333	.	_	

#Text=(D) Word cloud representing ontological terms most frequently associated with functional activation of the medial posterior cortical areas of significant SRM.
77-1	17334-17335	(	_	
77-2	17335-17336	D	_	
77-3	17336-17337	)	_	
77-4	17338-17342	Word	_	
77-5	17343-17348	cloud	_	
77-6	17349-17361	representing	_	
77-7	17362-17373	ontological	_	
77-8	17374-17379	terms	_	
77-9	17380-17384	most	_	
77-10	17385-17395	frequently	_	
77-11	17396-17406	associated	_	
77-12	17407-17411	with	_	
77-13	17412-17422	functional	_	
77-14	17423-17433	activation	_	
77-15	17434-17436	of	_	
77-16	17437-17440	the	_	
77-17	17441-17447	medial	_	
77-18	17448-17457	posterior	_	
77-19	17458-17466	cortical	_	
77-20	17467-17472	areas	_	
77-21	17473-17475	of	_	
77-22	17476-17487	significant	_	
77-23	17488-17491	SRM	_	
77-24	17491-17492	.	_	

#Text=(E) Cortical surface maps highlighting areas where scores on the disorganized factor of schizotypy was significantly positively correlated with regional MT after controlling for age by regression (pink, 2-tailed p < .05; red, false discovery rate < .05).
78-1	17493-17494	(	_	
78-2	17494-17495	E	_	
78-3	17495-17496	)	_	
78-4	17496-17497	 	_	
78-5	17497-17505	Cortical	_	
78-6	17506-17513	surface	_	
78-7	17514-17518	maps	_	
78-8	17519-17531	highlighting	_	
78-9	17532-17537	areas	_	
78-10	17538-17543	where	_	
78-11	17544-17550	scores	_	
78-12	17551-17553	on	_	
78-13	17554-17557	the	_	
78-14	17558-17570	disorganized	_	
78-15	17571-17577	factor	_	
78-16	17578-17580	of	_	
78-17	17581-17591	schizotypy	_	
78-18	17592-17595	was	_	
78-19	17596-17609	significantly	_	
78-20	17610-17620	positively	_	
78-21	17621-17631	correlated	_	
78-22	17632-17636	with	_	
78-23	17637-17645	regional	_	
78-24	17646-17648	MT	_	
78-25	17649-17654	after	_	
78-26	17655-17666	controlling	_	
78-27	17667-17670	for	_	
78-28	17671-17674	age	_	
78-29	17675-17677	by	_	
78-30	17678-17688	regression	_	
78-31	17689-17690	(	_	
78-32	17690-17694	pink	_	
78-33	17694-17695	,	_	
78-34	17696-17697	2	_	
78-35	17697-17698	-	_	
78-36	17698-17704	tailed	_	
78-37	17705-17706	p	_	
78-38	17707-17708	<	_	
78-39	17709-17712	.05	_	
78-40	17712-17713	;	_	
78-41	17714-17717	red	_	
78-42	17717-17718	,	_	
78-43	17719-17724	false	_	
78-44	17725-17734	discovery	_	
78-45	17735-17739	rate	_	
78-46	17740-17741	<	_	
78-47	17742-17745	.05	_	
78-48	17745-17746	)	_	
78-49	17746-17747	.	_	

#Text=SPQ total score was modestly positively correlated with global MT, estimated as the average MT over all 68 regions (R2 = .02, p = .015) (Figure S3).
79-1	17748-17751	SPQ	_	
79-2	17752-17757	total	_	
79-3	17758-17763	score	_	
79-4	17764-17767	was	_	
79-5	17768-17776	modestly	_	
79-6	17777-17787	positively	_	
79-7	17788-17798	correlated	_	
79-8	17799-17803	with	_	
79-9	17804-17810	global	_	
79-10	17811-17813	MT	_	
79-11	17813-17814	,	_	
79-12	17815-17824	estimated	_	
79-13	17825-17827	as	_	
79-14	17828-17831	the	_	
79-15	17832-17839	average	_	
79-16	17840-17842	MT	_	
79-17	17843-17847	over	_	
79-18	17848-17851	all	_	
79-19	17852-17854	68	_	
79-20	17855-17862	regions	_	
79-21	17863-17864	(	_	
79-22	17864-17866	R2	_	
79-23	17866-17867	 	_	
79-24	17867-17868	=	_	
79-25	17869-17872	.02	_	
79-26	17872-17873	,	_	
79-27	17874-17875	p	_	
79-28	17875-17876	 	_	
79-29	17876-17877	=	_	
79-30	17878-17882	.015	_	
79-31	17882-17883	)	_	
79-32	17884-17885	(	_	
79-33	17885-17891	Figure	_	
79-34	17891-17892	 	_	
79-35	17892-17894	S3	_	
79-36	17894-17895	)	_	
79-37	17895-17896	.	_	

#Text=SPQ total score was significantly correlated with age-corrected regional MT in 4 of 68 regions individually tested (R2 > .04, p < .05, FDR corrected) (Figure 1A, B and Table S4): the left isthmus cingulate, left posterior cingulate, left precuneus, and right isthmus cingulate.
80-1	17897-17900	SPQ	_	
80-2	17901-17906	total	_	
80-3	17907-17912	score	_	
80-4	17913-17916	was	_	
80-5	17917-17930	significantly	_	
80-6	17931-17941	correlated	_	
80-7	17942-17946	with	_	
80-8	17947-17960	age-corrected	_	
80-9	17961-17969	regional	_	
80-10	17970-17972	MT	_	
80-11	17973-17975	in	_	
80-12	17976-17977	4	_	
80-13	17978-17980	of	_	
80-14	17981-17983	68	_	
80-15	17984-17991	regions	_	
80-16	17992-18004	individually	_	
80-17	18005-18011	tested	_	
80-18	18012-18013	(	_	
80-19	18013-18015	R2	_	
80-20	18016-18017	>	_	
80-21	18018-18021	.04	_	
80-22	18021-18022	,	_	
80-23	18023-18024	p	_	
80-24	18025-18026	<	_	
80-25	18027-18030	.05	_	
80-26	18030-18031	,	_	
80-27	18032-18035	FDR	_	
80-28	18036-18045	corrected	_	
80-29	18045-18046	)	_	
80-30	18047-18048	(	_	
80-31	18048-18054	Figure	_	
80-32	18054-18055	 	_	
80-33	18055-18057	1A	_	
80-34	18057-18058	,	_	
80-35	18059-18060	B	_	
80-36	18061-18064	and	_	
80-37	18065-18070	Table	_	
80-38	18070-18071	 	_	
80-39	18071-18073	S4	_	
80-40	18073-18074	)	_	
80-41	18074-18075	:	_	
80-42	18076-18079	the	_	
80-43	18080-18084	left	_	
80-44	18085-18092	isthmus	_	
80-45	18093-18102	cingulate	_	
80-46	18102-18103	,	_	
80-47	18104-18108	left	_	
80-48	18109-18118	posterior	_	
80-49	18119-18128	cingulate	_	
80-50	18128-18129	,	_	
80-51	18130-18134	left	_	
80-52	18135-18144	precuneus	_	
80-53	18144-18145	,	_	
80-54	18146-18149	and	_	
80-55	18150-18155	right	_	
80-56	18156-18163	isthmus	_	
80-57	18164-18173	cingulate	_	
80-58	18173-18174	.	_	

#Text=These medial posterior cortical regions had high MT signals at 14 years of age (MT14) and relatively slow rates of increase in MT over the period of 14 to 25 years of age (ΔMT) (Figure 1C).
81-1	18175-18180	These	_	
81-2	18181-18187	medial	_	
81-3	18188-18197	posterior	_	
81-4	18198-18206	cortical	_	
81-5	18207-18214	regions	_	
81-6	18215-18218	had	_	
81-7	18219-18223	high	_	
81-8	18224-18226	MT	_	
81-9	18227-18234	signals	_	
81-10	18235-18237	at	_	
81-11	18238-18240	14	_	
81-12	18241-18246	years	_	
81-13	18247-18249	of	_	
81-14	18250-18253	age	_	
81-15	18254-18255	(	_	
81-16	18255-18259	MT14	_	
81-17	18259-18260	)	_	
81-18	18261-18264	and	_	
81-19	18265-18275	relatively	_	
81-20	18276-18280	slow	_	
81-21	18281-18286	rates	_	
81-22	18287-18289	of	_	
81-23	18290-18298	increase	_	
81-24	18299-18301	in	_	
81-25	18302-18304	MT	_	
81-26	18305-18309	over	_	
81-27	18310-18313	the	_	
81-28	18314-18320	period	_	
81-29	18321-18323	of	_	
81-30	18324-18326	14	_	
81-31	18327-18329	to	_	
81-32	18330-18332	25	_	
81-33	18333-18338	years	_	
81-34	18339-18341	of	_	
81-35	18342-18345	age	_	
81-36	18346-18347	(	_	
81-37	18347-18350	ΔMT	_	
81-38	18350-18351	)	_	
81-39	18352-18353	(	_	
81-40	18353-18359	Figure	_	
81-41	18359-18360	 	_	
81-42	18360-18362	1C	_	
81-43	18362-18363	)	_	
81-44	18363-18364	.	_	

#Text=We used prior functional MRI data to identify experimental task conditions that were most robustly associated with functional activation of these areas of significant SRM (Neurosynth [https://neurosynth.org/]): memory, social cognition or theory of mind, and executive functions (Figure 1D).
82-1	18365-18367	We	_	
82-2	18368-18372	used	_	
82-3	18373-18378	prior	_	
82-4	18379-18389	functional	_	
82-5	18390-18393	MRI	_	
82-6	18394-18398	data	_	
82-7	18399-18401	to	_	
82-8	18402-18410	identify	_	
82-9	18411-18423	experimental	_	
82-10	18424-18428	task	_	
82-11	18429-18439	conditions	_	
82-12	18440-18444	that	_	
82-13	18445-18449	were	_	
82-14	18450-18454	most	_	
82-15	18455-18463	robustly	_	
82-16	18464-18474	associated	_	
82-17	18475-18479	with	_	
82-18	18480-18490	functional	_	
82-19	18491-18501	activation	_	
82-20	18502-18504	of	_	
82-21	18505-18510	these	_	
82-22	18511-18516	areas	_	
82-23	18517-18519	of	_	
82-24	18520-18531	significant	_	
82-25	18532-18535	SRM	_	
82-26	18536-18537	(	_	
82-27	18537-18547	Neurosynth	_	
82-28	18548-18549	[	_	
82-29	18549-18554	https	_	
82-30	18554-18555	:	_	
82-31	18555-18556	/	_	
82-32	18556-18557	/	_	
82-33	18557-18571	neurosynth.org	_	
82-34	18571-18572	/	_	
82-35	18572-18573	]	_	
82-36	18573-18574	)	_	
82-37	18574-18575	:	_	
82-38	18576-18582	memory	_	
82-39	18582-18583	,	_	
82-40	18584-18590	social	_	
82-41	18591-18600	cognition	_	
82-42	18601-18603	or	_	
82-43	18604-18610	theory	_	
82-44	18611-18613	of	_	
82-45	18614-18618	mind	_	
82-46	18618-18619	,	_	
82-47	18620-18623	and	_	
82-48	18624-18633	executive	_	
82-49	18634-18643	functions	_	
82-50	18644-18645	(	_	
82-51	18645-18651	Figure	_	
82-52	18651-18652	 	_	
82-53	18652-18654	1D	_	
82-54	18654-18655	)	_	
82-55	18655-18656	.	_	

#Text=The posterior cingulate and medial parietal cortical areas of significant SRM were also enriched for default mode network–related terms in ontological analysis of prior functional MRI data.
83-1	18657-18660	The	_	
83-2	18661-18670	posterior	_	
83-3	18671-18680	cingulate	_	
83-4	18681-18684	and	_	
83-5	18685-18691	medial	_	
83-6	18692-18700	parietal	_	
83-7	18701-18709	cortical	_	
83-8	18710-18715	areas	_	
83-9	18716-18718	of	_	
83-10	18719-18730	significant	_	
83-11	18731-18734	SRM	_	
83-12	18735-18739	were	_	
83-13	18740-18744	also	_	
83-14	18745-18753	enriched	_	
83-15	18754-18757	for	_	
83-16	18758-18765	default	_	
83-17	18766-18770	mode	_	
83-18	18771-18786	network–related	_	
83-19	18787-18792	terms	_	
83-20	18793-18795	in	_	
83-21	18796-18807	ontological	_	
83-22	18808-18816	analysis	_	
83-23	18817-18819	of	_	
83-24	18820-18825	prior	_	
83-25	18826-18836	functional	_	
83-26	18837-18840	MRI	_	
83-27	18841-18845	data	_	
83-28	18845-18846	.	_	

#Text=Sensitivity Analyses of SRM
#Text=We used a linear model to control the association between SPQ and MT for the potentially confounding effects of age, gender, site, socioeconomic status, and total brain volume (Figure S4), and robust estimators to mitigate the influence of the small number of high SPQ scores on the estimation of SRM (Figure S5).
84-1	18847-18858	Sensitivity	_	
84-2	18859-18867	Analyses	_	
84-3	18868-18870	of	_	
84-4	18871-18874	SRM	_	
84-5	18875-18877	We	_	
84-6	18878-18882	used	_	
84-7	18883-18884	a	_	
84-8	18885-18891	linear	_	
84-9	18892-18897	model	_	
84-10	18898-18900	to	_	
84-11	18901-18908	control	_	
84-12	18909-18912	the	_	
84-13	18913-18924	association	_	
84-14	18925-18932	between	_	
84-15	18933-18936	SPQ	_	
84-16	18937-18940	and	_	
84-17	18941-18943	MT	_	
84-18	18944-18947	for	_	
84-19	18948-18951	the	_	
84-20	18952-18963	potentially	_	
84-21	18964-18975	confounding	_	
84-22	18976-18983	effects	_	
84-23	18984-18986	of	_	
84-24	18987-18990	age	_	
84-25	18990-18991	,	_	
84-26	18992-18998	gender	_	
84-27	18998-18999	,	_	
84-28	19000-19004	site	_	
84-29	19004-19005	,	_	
84-30	19006-19019	socioeconomic	_	
84-31	19020-19026	status	_	
84-32	19026-19027	,	_	
84-33	19028-19031	and	_	
84-34	19032-19037	total	_	
84-35	19038-19043	brain	_	
84-36	19044-19050	volume	_	
84-37	19051-19052	(	_	
84-38	19052-19058	Figure	_	
84-39	19058-19059	 	_	
84-40	19059-19061	S4	_	
84-41	19061-19062	)	_	
84-42	19062-19063	,	_	
84-43	19064-19067	and	_	
84-44	19068-19074	robust	_	
84-45	19075-19085	estimators	_	
84-46	19086-19088	to	_	
84-47	19089-19097	mitigate	_	
84-48	19098-19101	the	_	
84-49	19102-19111	influence	_	
84-50	19112-19114	of	_	
84-51	19115-19118	the	_	
84-52	19119-19124	small	_	
84-53	19125-19131	number	_	
84-54	19132-19134	of	_	
84-55	19135-19139	high	_	
84-56	19140-19143	SPQ	_	
84-57	19144-19150	scores	_	
84-58	19151-19153	on	_	
84-59	19154-19157	the	_	
84-60	19158-19168	estimation	_	
84-61	19169-19171	of	_	
84-62	19172-19175	SRM	_	
84-63	19176-19177	(	_	
84-64	19177-19183	Figure	_	
84-65	19183-19184	 	_	
84-66	19184-19186	S5	_	
84-67	19186-19187	)	_	
84-68	19187-19188	.	_	

#Text=In both cases, the key results were conserved: namely, significant SRM in default mode network areas and significant correlations between PLS1 weights and differential gene expression in schizophrenia.
85-1	19189-19191	In	_	
85-2	19192-19196	both	_	
85-3	19197-19202	cases	_	
85-4	19202-19203	,	_	
85-5	19204-19207	the	_	
85-6	19208-19211	key	_	
85-7	19212-19219	results	_	
85-8	19220-19224	were	_	
85-9	19225-19234	conserved	_	
85-10	19234-19235	:	_	
85-11	19236-19242	namely	_	
85-12	19242-19243	,	_	
85-13	19244-19255	significant	_	
85-14	19256-19259	SRM	_	
85-15	19260-19262	in	_	
85-16	19263-19270	default	_	
85-17	19271-19275	mode	_	
85-18	19276-19283	network	_	
85-19	19284-19289	areas	_	
85-20	19290-19293	and	_	
85-21	19294-19305	significant	_	
85-22	19306-19318	correlations	_	
85-23	19319-19326	between	_	
85-24	19327-19331	PLS1	_	
85-25	19332-19339	weights	_	
85-26	19340-19343	and	_	
85-27	19344-19356	differential	_	
85-28	19357-19361	gene	_	
85-29	19362-19372	expression	_	
85-30	19373-19375	in	_	
85-31	19376-19389	schizophrenia	_	
85-32	19389-19390	.	_	

#Text=We also noted a negative correlation between Euler number and global MT, indicating reduced MT in a minority of poor-quality images (ρ = −.14, p = .03).
86-1	19391-19393	We	_	
86-2	19394-19398	also	_	
86-3	19399-19404	noted	_	
86-4	19405-19406	a	_	
86-5	19407-19415	negative	_	
86-6	19416-19427	correlation	_	
86-7	19428-19435	between	_	
86-8	19436-19441	Euler	_	
86-9	19442-19448	number	_	
86-10	19449-19452	and	_	
86-11	19453-19459	global	_	
86-12	19460-19462	MT	_	
86-13	19462-19463	,	_	
86-14	19464-19474	indicating	_	
86-15	19475-19482	reduced	_	
86-16	19483-19485	MT	_	
86-17	19486-19488	in	_	
86-18	19489-19490	a	_	
86-19	19491-19499	minority	_	
86-20	19500-19502	of	_	
86-21	19503-19515	poor-quality	_	
86-22	19516-19522	images	_	
86-23	19523-19524	(	_	
86-24	19524-19525	ρ	_	
86-25	19525-19526	 	_	
86-26	19526-19527	=	_	
86-27	19527-19528	 	_	
86-28	19528-19529	−	_	
86-29	19529-19532	.14	_	
86-30	19532-19533	,	_	
86-31	19534-19535	p	_	
86-32	19535-19536	 	_	
86-33	19536-19537	=	_	
86-34	19538-19541	.03	_	
86-35	19541-19542	)	_	
86-36	19542-19543	.	_	

#Text=When we excluded the 10% of participants with the poorest image quality, the correlation between Euler number and MT was no longer significant (ρ = .04, p = .11), but the key results were conserved (Figure S6).
87-1	19544-19548	When	_	
87-2	19549-19551	we	_	
87-3	19552-19560	excluded	_	
87-4	19561-19564	the	_	
87-5	19565-19568	10%	_	
87-6	19569-19571	of	_	
87-7	19572-19584	participants	_	
87-8	19585-19589	with	_	
87-9	19590-19593	the	_	
87-10	19594-19601	poorest	_	
87-11	19602-19607	image	_	
87-12	19608-19615	quality	_	
87-13	19615-19616	,	_	
87-14	19617-19620	the	_	
87-15	19621-19632	correlation	_	
87-16	19633-19640	between	_	
87-17	19641-19646	Euler	_	
87-18	19647-19653	number	_	
87-19	19654-19657	and	_	
87-20	19658-19660	MT	_	
87-21	19661-19664	was	_	
87-22	19665-19667	no	_	
87-23	19668-19674	longer	_	
87-24	19675-19686	significant	_	
87-25	19687-19688	(	_	
87-26	19688-19689	ρ	_	
87-27	19689-19690	 	_	
87-28	19690-19691	=	_	
87-29	19692-19695	.04	_	
87-30	19695-19696	,	_	
87-31	19697-19698	p	_	
87-32	19698-19699	 	_	
87-33	19699-19700	=	_	
87-34	19701-19704	.11	_	
87-35	19704-19705	)	_	
87-36	19705-19706	,	_	
87-37	19707-19710	but	_	
87-38	19711-19714	the	_	
87-39	19715-19718	key	_	
87-40	19719-19726	results	_	
87-41	19727-19731	were	_	
87-42	19732-19741	conserved	_	
87-43	19742-19743	(	_	
87-44	19743-19749	Figure	_	
87-45	19749-19750	 	_	
87-46	19750-19752	S6	_	
87-47	19752-19753	)	_	
87-48	19753-19754	.	_	

#Text=Schizotypy is a complex trait comprising multiple dimensions of cognition, emotion, and behavior.
88-1	19755-19765	Schizotypy	_	
88-2	19766-19768	is	_	
88-3	19769-19770	a	_	
88-4	19771-19778	complex	_	
88-5	19779-19784	trait	_	
88-6	19785-19795	comprising	_	
88-7	19796-19804	multiple	_	
88-8	19805-19815	dimensions	_	
88-9	19816-19818	of	_	
88-10	19819-19828	cognition	_	
88-11	19828-19829	,	_	
88-12	19830-19837	emotion	_	
88-13	19837-19838	,	_	
88-14	19839-19842	and	_	
88-15	19843-19851	behavior	_	
88-16	19851-19852	.	_	

#Text=In addition to the principal analysis of SPQ total score, we also considered 2 possible decompositions of the schizotypal trait.
89-1	19853-19855	In	_	
89-2	19856-19864	addition	_	
89-3	19865-19867	to	_	
89-4	19868-19871	the	_	
89-5	19872-19881	principal	_	
89-6	19882-19890	analysis	_	
89-7	19891-19893	of	_	
89-8	19894-19897	SPQ	_	
89-9	19898-19903	total	_	
89-10	19904-19909	score	_	
89-11	19909-19910	,	_	
89-12	19911-19913	we	_	
89-13	19914-19918	also	_	
89-14	19919-19929	considered	_	
89-15	19930-19931	2	_	
89-16	19932-19940	possible	_	
89-17	19941-19955	decompositions	_	
89-18	19956-19958	of	_	
89-19	19959-19962	the	_	
89-20	19963-19974	schizotypal	_	
89-21	19975-19980	trait	_	
89-22	19980-19981	.	_	

#Text=Nine subscales of the SPQ defined by Raine were positively correlated with regional MT, but these associations were less robust than for SPQ total score (Figure S7).
90-1	19982-19986	Nine	_	
90-2	19987-19996	subscales	_	
90-3	19997-19999	of	_	
90-4	20000-20003	the	_	
90-5	20004-20007	SPQ	_	
90-6	20008-20015	defined	_	
90-7	20016-20018	by	_	
90-8	20019-20024	Raine	_	
90-9	20025-20029	were	_	
90-10	20030-20040	positively	_	
90-11	20041-20051	correlated	_	
90-12	20052-20056	with	_	
90-13	20057-20065	regional	_	
90-14	20066-20068	MT	_	
90-15	20068-20069	,	_	
90-16	20070-20073	but	_	
90-17	20074-20079	these	_	
90-18	20080-20092	associations	_	
90-19	20093-20097	were	_	
90-20	20098-20102	less	_	
90-21	20103-20109	robust	_	
90-22	20110-20114	than	_	
90-23	20115-20118	for	_	
90-24	20119-20122	SPQ	_	
90-25	20123-20128	total	_	
90-26	20129-20134	score	_	
90-27	20135-20136	(	_	
90-28	20136-20142	Figure	_	
90-29	20142-20143	 	_	
90-30	20143-20145	S7	_	
90-31	20145-20146	)	_	
90-32	20146-20147	.	_	

#Text=All 3 factors of schizotypy defined by Raine et al., i.e., positive, negative, and disorganized dimensions, were positively correlated with MT.
91-1	20148-20151	All	_	
91-2	20152-20153	3	_	
91-3	20154-20161	factors	_	
91-4	20162-20164	of	_	
91-5	20165-20175	schizotypy	_	
91-6	20176-20183	defined	_	
91-7	20184-20186	by	_	
91-8	20187-20192	Raine	_	
91-9	20193-20195	et	_	
91-10	20195-20196	 	_	
91-11	20196-20198	al	_	
91-12	20198-20199	.	_	
91-13	20199-20200	,	_	
91-14	20201-20204	i.e	_	
91-15	20204-20205	.	_	
91-16	20205-20206	,	_	
91-17	20207-20215	positive	_	
91-18	20215-20216	,	_	
91-19	20217-20225	negative	_	
91-20	20225-20226	,	_	
91-21	20227-20230	and	_	
91-22	20231-20243	disorganized	_	
91-23	20244-20254	dimensions	_	
91-24	20254-20255	,	_	
91-25	20256-20260	were	_	
91-26	20261-20271	positively	_	
91-27	20272-20282	correlated	_	
91-28	20283-20287	with	_	
91-29	20288-20290	MT	_	
91-30	20290-20291	.	_	

#Text=The correlation between disorganized schizotypy and MT was strongest and statistically significant when controlling for multiple comparisons (Figure 1E and Figure S8).
92-1	20292-20295	The	_	
92-2	20296-20307	correlation	_	
92-3	20308-20315	between	_	
92-4	20316-20328	disorganized	_	
92-5	20329-20339	schizotypy	_	
92-6	20340-20343	and	_	
92-7	20344-20346	MT	_	
92-8	20347-20350	was	_	
92-9	20351-20360	strongest	_	
92-10	20361-20364	and	_	
92-11	20365-20378	statistically	_	
92-12	20379-20390	significant	_	
92-13	20391-20395	when	_	
92-14	20396-20407	controlling	_	
92-15	20408-20411	for	_	
92-16	20412-20420	multiple	_	
92-17	20421-20432	comparisons	_	
92-18	20433-20434	(	_	
92-19	20434-20440	Figure	_	
92-20	20440-20441	 	_	
92-21	20441-20443	1E	_	
92-22	20444-20447	and	_	
92-23	20448-20454	Figure	_	
92-24	20454-20455	 	_	
92-25	20455-20457	S8	_	
92-26	20457-20458	)	_	
92-27	20458-20459	.	_	

#Text=We also measured cortical thickness for each of the same 68 regions, using R1 images collected as part of the same MRI sequence used to measure MT.
93-1	20460-20462	We	_	
93-2	20463-20467	also	_	
93-3	20468-20476	measured	_	
93-4	20477-20485	cortical	_	
93-5	20486-20495	thickness	_	
93-6	20496-20499	for	_	
93-7	20500-20504	each	_	
93-8	20505-20507	of	_	
93-9	20508-20511	the	_	
93-10	20512-20516	same	_	
93-11	20517-20519	68	_	
93-12	20520-20527	regions	_	
93-13	20527-20528	,	_	
93-14	20529-20534	using	_	
93-15	20535-20537	R1	_	
93-16	20538-20544	images	_	
93-17	20545-20554	collected	_	
93-18	20555-20557	as	_	
93-19	20558-20562	part	_	
93-20	20563-20565	of	_	
93-21	20566-20569	the	_	
93-22	20570-20574	same	_	
93-23	20575-20578	MRI	_	
93-24	20579-20587	sequence	_	
93-25	20588-20592	used	_	
93-26	20593-20595	to	_	
93-27	20596-20603	measure	_	
93-28	20604-20606	MT	_	
93-29	20606-20607	.	_	

#Text=SPQ scores were negatively correlated with cortical thickness in some regions, but the associations between schizotypy and cortical thickness were not significant when corrected for multiple tests (Figure S9).
94-1	20608-20611	SPQ	_	
94-2	20612-20618	scores	_	
94-3	20619-20623	were	_	
94-4	20624-20634	negatively	_	
94-5	20635-20645	correlated	_	
94-6	20646-20650	with	_	
94-7	20651-20659	cortical	_	
94-8	20660-20669	thickness	_	
94-9	20670-20672	in	_	
94-10	20673-20677	some	_	
94-11	20678-20685	regions	_	
94-12	20685-20686	,	_	
94-13	20687-20690	but	_	
94-14	20691-20694	the	_	
94-15	20695-20707	associations	_	
94-16	20708-20715	between	_	
94-17	20716-20726	schizotypy	_	
94-18	20727-20730	and	_	
94-19	20731-20739	cortical	_	
94-20	20740-20749	thickness	_	
94-21	20750-20754	were	_	
94-22	20755-20758	not	_	
94-23	20759-20770	significant	_	
94-24	20771-20775	when	_	
94-25	20776-20785	corrected	_	
94-26	20786-20789	for	_	
94-27	20790-20798	multiple	_	
94-28	20799-20804	tests	_	
94-29	20805-20806	(	_	
94-30	20806-20812	Figure	_	
94-31	20812-20813	 	_	
94-32	20813-20815	S9	_	
94-33	20815-20816	)	_	
94-34	20816-20817	.	_	

#Text=SRM and Gene Expression
#Text=Gene expression and schizotypy-related magnetization (SRM).
95-1	20818-20821	SRM	_	
95-2	20822-20825	and	_	
95-3	20826-20830	Gene	_	
95-4	20831-20841	Expression	_	
95-5	20842-20846	Gene	_	
95-6	20847-20857	expression	_	
95-7	20858-20861	and	_	
95-8	20862-20880	schizotypy-related	_	
95-9	20881-20894	magnetization	_	
95-10	20895-20896	(	_	
95-11	20896-20899	SRM	_	
95-12	20899-20900	)	_	
95-13	20900-20901	.	_	

#Text=(A) (Left panel) The first partial least squares component (PLS1) defined a linear combination of genes that had a similar cortical pattern of expression to the cortical map of SRM, representing the correlation between Schizotypal Personality Questionnaire and magnetization transfer at each of 68 cortical regions.
96-1	20902-20903	(	_	
96-2	20903-20904	A	_	
96-3	20904-20905	)	_	
96-4	20906-20907	(	_	
96-5	20907-20911	Left	_	
96-6	20912-20917	panel	_	
96-7	20917-20918	)	_	
96-8	20919-20922	The	_	
96-9	20923-20928	first	_	
96-10	20929-20936	partial	_	
96-11	20937-20942	least	_	
96-12	20943-20950	squares	_	
96-13	20951-20960	component	_	
96-14	20961-20962	(	_	
96-15	20962-20966	PLS1	_	
96-16	20966-20967	)	_	
96-17	20968-20975	defined	_	
96-18	20976-20977	a	_	
96-19	20978-20984	linear	_	
96-20	20985-20996	combination	_	
96-21	20997-20999	of	_	
96-22	21000-21005	genes	_	
96-23	21006-21010	that	_	
96-24	21011-21014	had	_	
96-25	21015-21016	a	_	
96-26	21017-21024	similar	_	
96-27	21025-21033	cortical	_	
96-28	21034-21041	pattern	_	
96-29	21042-21044	of	_	
96-30	21045-21055	expression	_	
96-31	21056-21058	to	_	
96-32	21059-21062	the	_	
96-33	21063-21071	cortical	_	
96-34	21072-21075	map	_	
96-35	21076-21078	of	_	
96-36	21079-21082	SRM	_	
96-37	21082-21083	,	_	
96-38	21084-21096	representing	_	
96-39	21097-21100	the	_	
96-40	21101-21112	correlation	_	
96-41	21113-21120	between	_	
96-42	21121-21132	Schizotypal	_	
96-43	21133-21144	Personality	_	
96-44	21145-21158	Questionnaire	_	
96-45	21159-21162	and	_	
96-46	21163-21176	magnetization	_	
96-47	21177-21185	transfer	_	
96-48	21186-21188	at	_	
96-49	21189-21193	each	_	
96-50	21194-21196	of	_	
96-51	21197-21199	68	_	
96-52	21200-21208	cortical	_	
96-53	21209-21216	regions	_	
96-54	21216-21217	.	_	

#Text=(Center panel) Scatterplot of PLS1 scores versus SRM; each point is a cortical region.
97-1	21218-21219	(	_	
97-2	21219-21225	Center	_	
97-3	21226-21231	panel	_	
97-4	21231-21232	)	_	
97-5	21233-21244	Scatterplot	_	
97-6	21245-21247	of	_	
97-7	21248-21252	PLS1	_	
97-8	21253-21259	scores	_	
97-9	21260-21266	versus	_	
97-10	21267-21270	SRM	_	
97-11	21270-21271	;	_	
97-12	21272-21276	each	_	
97-13	21277-21282	point	_	
97-14	21283-21285	is	_	
97-15	21286-21287	a	_	
97-16	21288-21296	cortical	_	
97-17	21297-21303	region	_	
97-18	21303-21304	.	_	

#Text=(Right panel) The combination of genes defined by PLS1 explains more of the variance in SRM (dotted line) than expected by chance (histogram of permutation distribution).
98-1	21305-21306	(	_	
98-2	21306-21311	Right	_	
98-3	21312-21317	panel	_	
98-4	21317-21318	)	_	
98-5	21319-21322	The	_	
98-6	21323-21334	combination	_	
98-7	21335-21337	of	_	
98-8	21338-21343	genes	_	
98-9	21344-21351	defined	_	
98-10	21352-21354	by	_	
98-11	21355-21359	PLS1	_	
98-12	21360-21368	explains	_	
98-13	21369-21373	more	_	
98-14	21374-21376	of	_	
98-15	21377-21380	the	_	
98-16	21381-21389	variance	_	
98-17	21390-21392	in	_	
98-18	21393-21396	SRM	_	
98-19	21397-21398	(	_	
98-20	21398-21404	dotted	_	
98-21	21405-21409	line	_	
98-22	21409-21410	)	_	
98-23	21411-21415	than	_	
98-24	21416-21424	expected	_	
98-25	21425-21427	by	_	
98-26	21428-21434	chance	_	
98-27	21435-21436	(	_	
98-28	21436-21445	histogram	_	
98-29	21446-21448	of	_	
98-30	21449-21460	permutation	_	
98-31	21461-21473	distribution	_	
98-32	21473-21474	)	_	
98-33	21474-21475	.	_	

#Text=(B) Illustrative example of the weights assigned to representative genes on PLS1.
99-1	21476-21477	(	_	
99-2	21477-21478	B	_	
99-3	21478-21479	)	_	
99-4	21480-21492	Illustrative	_	
99-5	21493-21500	example	_	
99-6	21501-21503	of	_	
99-7	21504-21507	the	_	
99-8	21508-21515	weights	_	
99-9	21516-21524	assigned	_	
99-10	21525-21527	to	_	
99-11	21528-21542	representative	_	
99-12	21543-21548	genes	_	
99-13	21549-21551	on	_	
99-14	21552-21556	PLS1	_	
99-15	21556-21557	.	_	

#Text=Genes with the highest positive weights are colored in pink, nonsignificantly weighted genes are shown in white, and the genes with the lowest negative weights are colored in blue.
100-1	21558-21563	Genes	_	
100-2	21564-21568	with	_	
100-3	21569-21572	the	_	
100-4	21573-21580	highest	_	
100-5	21581-21589	positive	_	
100-6	21590-21597	weights	_	
100-7	21598-21601	are	_	
100-8	21602-21609	colored	_	
100-9	21610-21612	in	_	
100-10	21613-21617	pink	_	
100-11	21617-21618	,	_	
100-12	21619-21635	nonsignificantly	_	
100-13	21636-21644	weighted	_	
100-14	21645-21650	genes	_	
100-15	21651-21654	are	_	
100-16	21655-21660	shown	_	
100-17	21661-21663	in	_	
100-18	21664-21669	white	_	
100-19	21669-21670	,	_	
100-20	21671-21674	and	_	
100-21	21675-21678	the	_	
100-22	21679-21684	genes	_	
100-23	21685-21689	with	_	
100-24	21690-21693	the	_	
100-25	21694-21700	lowest	_	
100-26	21701-21709	negative	_	
100-27	21710-21717	weights	_	
100-28	21718-21721	are	_	
100-29	21722-21729	colored	_	
100-30	21730-21732	in	_	
100-31	21733-21737	blue	_	
100-32	21737-21738	.	_	

#Text=Tables summarize p values by permutation testing for enrichment analysis by 4 lists of genes affiliated to specific cell types and 4 lists of genes associated with schizophrenia: Gandal and Fromer up-reg are lists of genes transcriptionally upregulated postmortem in schizophrenia; Gandal and Fromer down-reg are lists of genes transcriptionally downregulated in schizophrenia.
101-1	21739-21745	Tables	_	
101-2	21745-21746	 	_	
101-3	21746-21755	summarize	_	
101-4	21756-21757	p	_	
101-5	21758-21764	values	_	
101-6	21765-21767	by	_	
101-7	21768-21779	permutation	_	
101-8	21780-21787	testing	_	
101-9	21788-21791	for	_	
101-10	21792-21802	enrichment	_	
101-11	21803-21811	analysis	_	
101-12	21812-21814	by	_	
101-13	21815-21816	4	_	
101-14	21817-21822	lists	_	
101-15	21823-21825	of	_	
101-16	21826-21831	genes	_	
101-17	21832-21842	affiliated	_	
101-18	21843-21845	to	_	
101-19	21846-21854	specific	_	
101-20	21855-21859	cell	_	
101-21	21860-21865	types	_	
101-22	21866-21869	and	_	
101-23	21870-21871	4	_	
101-24	21872-21877	lists	_	
101-25	21878-21880	of	_	
101-26	21881-21886	genes	_	
101-27	21887-21897	associated	_	
101-28	21898-21902	with	_	
101-29	21903-21916	schizophrenia	_	
101-30	21916-21917	:	_	
101-31	21918-21924	Gandal	_	
101-32	21925-21928	and	_	
101-33	21929-21935	Fromer	_	
101-34	21936-21942	up-reg	_	
101-35	21943-21946	are	_	
101-36	21947-21952	lists	_	
101-37	21953-21955	of	_	
101-38	21956-21961	genes	_	
101-39	21962-21979	transcriptionally	_	
101-40	21980-21991	upregulated	_	
101-41	21992-22002	postmortem	_	
101-42	22003-22005	in	_	
101-43	22006-22019	schizophrenia	_	
101-44	22019-22020	;	_	
101-45	22021-22027	Gandal	_	
101-46	22028-22031	and	_	
101-47	22032-22038	Fromer	_	
101-48	22039-22047	down-reg	_	
101-49	22048-22051	are	_	
101-50	22052-22057	lists	_	
101-51	22058-22060	of	_	
101-52	22061-22066	genes	_	
101-53	22067-22084	transcriptionally	_	
101-54	22085-22098	downregulated	_	
101-55	22099-22101	in	_	
101-56	22102-22115	schizophrenia	_	
101-57	22115-22116	.	_	

#Text=Scatterplots and cortical maps illustrate that positively weighted genes, like ANK1, are overexpressed in cortical regions with high levels of schizotypy-related myelination, whereas negatively weighted genes, like PTPRC, are underexpressed in regions with high levels of SRM.
102-1	22117-22129	Scatterplots	_	
102-2	22130-22133	and	_	
102-3	22134-22142	cortical	_	
102-4	22143-22147	maps	_	
102-5	22148-22158	illustrate	_	
102-6	22159-22163	that	_	
102-7	22164-22174	positively	_	
102-8	22175-22183	weighted	_	
102-9	22184-22189	genes	_	
102-10	22189-22190	,	_	
102-11	22191-22195	like	_	
102-12	22196-22200	ANK1	_	
102-13	22200-22201	,	_	
102-14	22202-22205	are	_	
102-15	22206-22219	overexpressed	_	
102-16	22220-22222	in	_	
102-17	22223-22231	cortical	_	
102-18	22232-22239	regions	_	
102-19	22240-22244	with	_	
102-20	22245-22249	high	_	
102-21	22250-22256	levels	_	
102-22	22257-22259	of	_	
102-23	22260-22278	schizotypy-related	_	
102-24	22279-22290	myelination	_	
102-25	22290-22291	,	_	
102-26	22292-22299	whereas	_	
102-27	22300-22310	negatively	_	
102-28	22311-22319	weighted	_	
102-29	22320-22325	genes	_	
102-30	22325-22326	,	_	
102-31	22327-22331	like	_	
102-32	22332-22337	PTPRC	_	
102-33	22337-22338	,	_	
102-34	22339-22342	are	_	
102-35	22343-22357	underexpressed	_	
102-36	22358-22360	in	_	
102-37	22361-22368	regions	_	
102-38	22369-22373	with	_	
102-39	22374-22378	high	_	
102-40	22379-22385	levels	_	
102-41	22386-22388	of	_	
102-42	22389-22392	SRM	_	
102-43	22392-22393	.	_	

#Text=FDR, false discovery rate.
103-1	22394-22397	FDR	_	
103-2	22397-22398	,	_	
103-3	22399-22404	false	_	
103-4	22405-22414	discovery	_	
103-5	22415-22419	rate	_	
103-6	22419-22420	.	_	

#Text=PLS1 defined a weighted sum of whole-genome expression that accounted for ∼40% of the cortical patterning of SRM, significantly more than expected by chance (permutation testing based on spherical rotations: p = .027) (Figure 2A).
104-1	22421-22425	PLS1	_	
104-2	22426-22433	defined	_	
104-3	22434-22435	a	_	
104-4	22436-22444	weighted	_	
104-5	22445-22448	sum	_	
104-6	22449-22451	of	_	
104-7	22452-22464	whole-genome	_	
104-8	22465-22475	expression	_	
104-9	22476-22480	that	_	
104-10	22481-22490	accounted	_	
104-11	22491-22494	for	_	
104-12	22495-22496	∼	_	
104-13	22496-22499	40%	_	
104-14	22500-22502	of	_	
104-15	22503-22506	the	_	
104-16	22507-22515	cortical	_	
104-17	22516-22526	patterning	_	
104-18	22527-22529	of	_	
104-19	22530-22533	SRM	_	
104-20	22533-22534	,	_	
104-21	22535-22548	significantly	_	
104-22	22549-22553	more	_	
104-23	22554-22558	than	_	
104-24	22559-22567	expected	_	
104-25	22568-22570	by	_	
104-26	22571-22577	chance	_	
104-27	22578-22579	(	_	
104-28	22579-22590	permutation	_	
104-29	22591-22598	testing	_	
104-30	22599-22604	based	_	
104-31	22605-22607	on	_	
104-32	22608-22617	spherical	_	
104-33	22618-22627	rotations	_	
104-34	22627-22628	:	_	
104-35	22629-22630	p	_	
104-36	22630-22631	 	_	
104-37	22631-22632	=	_	
104-38	22633-22637	.027	_	
104-39	22637-22638	)	_	
104-40	22639-22640	(	_	
104-41	22640-22646	Figure	_	
104-42	22646-22647	 	_	
104-43	22647-22649	2A	_	
104-44	22649-22650	)	_	
104-45	22650-22651	.	_	

#Text=Multiple univariate Z tests were used to test the set of null hypotheses that the weight of each gene on PLS1 was zero.
105-1	22652-22660	Multiple	_	
105-2	22661-22671	univariate	_	
105-3	22672-22673	Z	_	
105-4	22674-22679	tests	_	
105-5	22680-22684	were	_	
105-6	22685-22689	used	_	
105-7	22690-22692	to	_	
105-8	22693-22697	test	_	
105-9	22698-22701	the	_	
105-10	22702-22705	set	_	
105-11	22706-22708	of	_	
105-12	22709-22713	null	_	
105-13	22714-22724	hypotheses	_	
105-14	22725-22729	that	_	
105-15	22730-22733	the	_	
105-16	22734-22740	weight	_	
105-17	22741-22743	of	_	
105-18	22744-22748	each	_	
105-19	22749-22753	gene	_	
105-20	22754-22756	on	_	
105-21	22757-22761	PLS1	_	
105-22	22762-22765	was	_	
105-23	22766-22770	zero	_	
105-24	22770-22771	.	_	

#Text=We found that this null hypothesis was refuted for 1932 positively weighted genes and 2153 negatively weighted genes (p < .05, FDR corrected for whole-genome testing at 20,647 genes) (Figure 2B).
106-1	22772-22774	We	_	
106-2	22775-22780	found	_	
106-3	22781-22785	that	_	
106-4	22786-22790	this	_	
106-5	22791-22795	null	_	
106-6	22796-22806	hypothesis	_	
106-7	22807-22810	was	_	
106-8	22811-22818	refuted	_	
106-9	22819-22822	for	_	
106-10	22823-22827	1932	_	
106-11	22828-22838	positively	_	
106-12	22839-22847	weighted	_	
106-13	22848-22853	genes	_	
106-14	22854-22857	and	_	
106-15	22858-22862	2153	_	
106-16	22863-22873	negatively	_	
106-17	22874-22882	weighted	_	
106-18	22883-22888	genes	_	
106-19	22889-22890	(	_	
106-20	22890-22891	p	_	
106-21	22891-22892	 	_	
106-22	22892-22893	<	_	
106-23	22894-22897	.05	_	
106-24	22897-22898	,	_	
106-25	22899-22902	FDR	_	
106-26	22903-22912	corrected	_	
106-27	22913-22916	for	_	
106-28	22917-22929	whole-genome	_	
106-29	22930-22937	testing	_	
106-30	22938-22940	at	_	
106-31	22941-22947	20,647	_	
106-32	22948-22953	genes	_	
106-33	22953-22954	)	_	
106-34	22955-22956	(	_	
106-35	22956-22962	Figure	_	
106-36	22962-22963	 	_	
106-37	22963-22965	2B	_	
106-38	22965-22966	)	_	
106-39	22966-22967	.	_	

#Text=Positively weighted genes were normally overexpressed, and negatively weighted genes were normally underexpressed, in cortical areas with high SRM.
107-1	22968-22978	Positively	_	
107-2	22979-22987	weighted	_	
107-3	22988-22993	genes	_	
107-4	22994-22998	were	_	
107-5	22999-23007	normally	_	
107-6	23008-23021	overexpressed	_	
107-7	23021-23022	,	_	
107-8	23023-23026	and	_	
107-9	23027-23037	negatively	_	
107-10	23038-23046	weighted	_	
107-11	23047-23052	genes	_	
107-12	23053-23057	were	_	
107-13	23058-23066	normally	_	
107-14	23067-23081	underexpressed	_	
107-15	23081-23082	,	_	
107-16	23083-23085	in	_	
107-17	23086-23094	cortical	_	
107-18	23095-23100	areas	_	
107-19	23101-23105	with	_	
107-20	23106-23110	high	_	
107-21	23111-23114	SRM	_	
107-22	23114-23115	.	_	

#Text=These 4085 genes constituted the SRM gene list.
108-1	23116-23121	These	_	
108-2	23122-23126	4085	_	
108-3	23127-23132	genes	_	
108-4	23133-23144	constituted	_	
108-5	23145-23148	the	_	
108-6	23149-23152	SRM	_	
108-7	23153-23157	gene	_	
108-8	23158-23162	list	_	
108-9	23162-23163	.	_	

#Text=Functional and Schizophrenia-Related Enrichment of SRM Genes
#Text=The SRM gene list was tested for enrichment by genes characteristic of specific cell types using 2 sets of prior criteria.
109-1	23164-23174	Functional	_	
109-2	23175-23178	and	_	
109-3	23179-23200	Schizophrenia-Related	_	
109-4	23201-23211	Enrichment	_	
109-5	23212-23214	of	_	
109-6	23215-23218	SRM	_	
109-7	23219-23224	Genes	_	
109-8	23225-23228	The	_	
109-9	23229-23232	SRM	_	
109-10	23233-23237	gene	_	
109-11	23238-23242	list	_	
109-12	23243-23246	was	_	
109-13	23247-23253	tested	_	
109-14	23254-23257	for	_	
109-15	23258-23268	enrichment	_	
109-16	23269-23271	by	_	
109-17	23272-23277	genes	_	
109-18	23278-23292	characteristic	_	
109-19	23293-23295	of	_	
109-20	23296-23304	specific	_	
109-21	23305-23309	cell	_	
109-22	23310-23315	types	_	
109-23	23316-23321	using	_	
109-24	23322-23323	2	_	
109-25	23324-23328	sets	_	
109-26	23329-23331	of	_	
109-27	23332-23337	prior	_	
109-28	23338-23346	criteria	_	
109-29	23346-23347	.	_	

#Text=Positively weighted SRM genes were enriched for neuronal affiliation (permutation test, p < 10−4) and, more specifically, for genes differentially expressed in fast-spiking parvalbumin (PVALB)-positive inhibitory interneurons (permutation test, FDR-corrected p < .01) (Table S2).
110-1	23348-23358	Positively	_	
110-2	23359-23367	weighted	_	
110-3	23368-23371	SRM	_	
110-4	23372-23377	genes	_	
110-5	23378-23382	were	_	
110-6	23383-23391	enriched	_	
110-7	23392-23395	for	_	
110-8	23396-23404	neuronal	_	
110-9	23405-23416	affiliation	_	
110-10	23417-23418	(	_	
110-11	23418-23429	permutation	_	
110-12	23430-23434	test	_	
110-13	23434-23435	,	_	
110-14	23436-23437	p	_	
110-15	23438-23439	<	_	
110-16	23440-23442	10	_	
110-17	23442-23443	−	_	
110-18	23443-23444	4	_	
110-19	23444-23445	)	_	
110-20	23446-23449	and	_	
110-21	23449-23450	,	_	
110-22	23451-23455	more	_	
110-23	23456-23468	specifically	_	
110-24	23468-23469	,	_	
110-25	23470-23473	for	_	
110-26	23474-23479	genes	_	
110-27	23480-23494	differentially	_	
110-28	23495-23504	expressed	_	
110-29	23505-23507	in	_	
110-30	23508-23520	fast-spiking	_	
110-31	23521-23532	parvalbumin	_	
110-32	23533-23534	(	_	
110-33	23534-23539	PVALB	_	
110-34	23539-23540	)	_	
110-35	23540-23541	-	_	
110-36	23541-23549	positive	_	
110-37	23550-23560	inhibitory	_	
110-38	23561-23573	interneurons	_	
110-39	23574-23575	(	_	
110-40	23575-23586	permutation	_	
110-41	23587-23591	test	_	
110-42	23591-23592	,	_	
110-43	23593-23606	FDR-corrected	_	
110-44	23607-23608	p	_	
110-45	23609-23610	<	_	
110-46	23611-23614	.01	_	
110-47	23614-23615	)	_	
110-48	23616-23617	(	_	
110-49	23617-23622	Table	_	
110-50	23622-23623	 	_	
110-51	23623-23625	S2	_	
110-52	23625-23626	)	_	
110-53	23626-23627	.	_	

#Text=Negatively weighted SRM genes were enriched for astrocytes, microglia, and neuronal affiliation (permutation tests, all ps < 10−4) (Figure 2B).
111-1	23628-23638	Negatively	_	
111-2	23639-23647	weighted	_	
111-3	23648-23651	SRM	_	
111-4	23652-23657	genes	_	
111-5	23658-23662	were	_	
111-6	23663-23671	enriched	_	
111-7	23672-23675	for	_	
111-8	23676-23686	astrocytes	_	
111-9	23686-23687	,	_	
111-10	23688-23697	microglia	_	
111-11	23697-23698	,	_	
111-12	23699-23702	and	_	
111-13	23703-23711	neuronal	_	
111-14	23712-23723	affiliation	_	
111-15	23724-23725	(	_	
111-16	23725-23736	permutation	_	
111-17	23737-23742	tests	_	
111-18	23742-23743	,	_	
111-19	23744-23747	all	_	
111-20	23748-23750	ps	_	
111-21	23751-23752	<	_	
111-22	23753-23755	10	_	
111-23	23755-23756	−	_	
111-24	23756-23757	4	_	
111-25	23757-23758	)	_	
111-26	23759-23760	(	_	
111-27	23760-23766	Figure	_	
111-28	23766-23767	 	_	
111-29	23767-23769	2B	_	
111-30	23769-23770	)	_	
111-31	23770-23771	.	_	

#Text=The positive or negative weighting of each SRM gene was strongly related to its differential expression in 2 postmortem studies of schizophrenia.
112-1	23772-23775	The	_	
112-2	23776-23784	positive	_	
112-3	23785-23787	or	_	
112-4	23788-23796	negative	_	
112-5	23797-23806	weighting	_	
112-6	23807-23809	of	_	
112-7	23810-23814	each	_	
112-8	23815-23818	SRM	_	
112-9	23819-23823	gene	_	
112-10	23824-23827	was	_	
112-11	23828-23836	strongly	_	
112-12	23837-23844	related	_	
112-13	23845-23847	to	_	
112-14	23848-23851	its	_	
112-15	23852-23864	differential	_	
112-16	23865-23875	expression	_	
112-17	23876-23878	in	_	
112-18	23879-23880	2	_	
112-19	23881-23891	postmortem	_	
112-20	23892-23899	studies	_	
112-21	23900-23902	of	_	
112-22	23903-23916	schizophrenia	_	
112-23	23916-23917	.	_	

#Text=Positively weighted SRM genes were enriched for genes that were significantly downregulated in both studies (Table S5) but not for significantly upregulated genes in either study.
113-1	23918-23928	Positively	_	
113-2	23929-23937	weighted	_	
113-3	23938-23941	SRM	_	
113-4	23942-23947	genes	_	
113-5	23948-23952	were	_	
113-6	23953-23961	enriched	_	
113-7	23962-23965	for	_	
113-8	23966-23971	genes	_	
113-9	23972-23976	that	_	
113-10	23977-23981	were	_	
113-11	23982-23995	significantly	_	
113-12	23996-24009	downregulated	_	
113-13	24010-24012	in	_	
113-14	24013-24017	both	_	
113-15	24018-24025	studies	_	
113-16	24026-24027	(	_	
113-17	24027-24032	Table	_	
113-18	24032-24033	 	_	
113-19	24033-24035	S5	_	
113-20	24035-24036	)	_	
113-21	24037-24040	but	_	
113-22	24041-24044	not	_	
113-23	24045-24048	for	_	
113-24	24049-24062	significantly	_	
113-25	24063-24074	upregulated	_	
113-26	24075-24080	genes	_	
113-27	24081-24083	in	_	
113-28	24084-24090	either	_	
113-29	24091-24096	study	_	
113-30	24096-24097	.	_	

#Text=Additionally, positively weighted SRM genes were also enriched for genes previously associated with white matter connectivity differences in schizophrenia described by Romme et al.
114-1	24098-24110	Additionally	_	
114-2	24110-24111	,	_	
114-3	24112-24122	positively	_	
114-4	24123-24131	weighted	_	
114-5	24132-24135	SRM	_	
114-6	24136-24141	genes	_	
114-7	24142-24146	were	_	
114-8	24147-24151	also	_	
114-9	24152-24160	enriched	_	
114-10	24161-24164	for	_	
114-11	24165-24170	genes	_	
114-12	24171-24181	previously	_	
114-13	24182-24192	associated	_	
114-14	24193-24197	with	_	
114-15	24198-24203	white	_	
114-16	24204-24210	matter	_	
114-17	24211-24223	connectivity	_	
114-18	24224-24235	differences	_	
114-19	24236-24238	in	_	
114-20	24239-24252	schizophrenia	_	
114-21	24253-24262	described	_	
114-22	24263-24265	by	_	
114-23	24266-24271	Romme	_	
114-24	24272-24274	et	_	
114-25	24274-24275	 	_	
114-26	24275-24277	al	_	
114-27	24277-24278	.	_	

#Text=(Figure S10).
115-1	24279-24280	(	_	
115-2	24280-24286	Figure	_	
115-3	24286-24287	 	_	
115-4	24287-24290	S10	_	
115-5	24290-24291	)	_	
115-6	24291-24292	.	_	

#Text=In contrast, negatively weighted SRM genes were enriched for genes that were significantly upregulated in both studies (permutation tests, all ps < 10−4) (Figure 2B and Table S6) but not for significantly downregulated genes.
116-1	24293-24295	In	_	
116-2	24296-24304	contrast	_	
116-3	24304-24305	,	_	
116-4	24306-24316	negatively	_	
116-5	24317-24325	weighted	_	
116-6	24326-24329	SRM	_	
116-7	24330-24335	genes	_	
116-8	24336-24340	were	_	
116-9	24341-24349	enriched	_	
116-10	24350-24353	for	_	
116-11	24354-24359	genes	_	
116-12	24360-24364	that	_	
116-13	24365-24369	were	_	
116-14	24370-24383	significantly	_	
116-15	24384-24395	upregulated	_	
116-16	24396-24398	in	_	
116-17	24399-24403	both	_	
116-18	24404-24411	studies	_	
116-19	24412-24413	(	_	
116-20	24413-24424	permutation	_	
116-21	24425-24430	tests	_	
116-22	24430-24431	,	_	
116-23	24432-24435	all	_	
116-24	24436-24438	ps	_	
116-25	24439-24440	<	_	
116-26	24441-24443	10	_	
116-27	24443-24444	−	_	
116-28	24444-24445	4	_	
116-29	24445-24446	)	_	
116-30	24447-24448	(	_	
116-31	24448-24454	Figure	_	
116-32	24454-24455	 	_	
116-33	24455-24457	2B	_	
116-34	24458-24461	and	_	
116-35	24462-24467	Table	_	
116-36	24467-24468	 	_	
116-37	24468-24470	S6	_	
116-38	24470-24471	)	_	
116-39	24472-24475	but	_	
116-40	24476-24479	not	_	
116-41	24480-24483	for	_	
116-42	24484-24497	significantly	_	
116-43	24498-24511	downregulated	_	
116-44	24512-24517	genes	_	
116-45	24517-24518	.	_	

#Text=Weights of gene expression from partial least squares (PLS) analysis of schizotypy-related magnetization (SRM) were related to histological measures of differential gene expression from case-control studies of schizophrenia and other disorders.
117-1	24519-24526	Weights	_	
117-2	24527-24529	of	_	
117-3	24530-24534	gene	_	
117-4	24535-24545	expression	_	
117-5	24546-24550	from	_	
117-6	24551-24558	partial	_	
117-7	24559-24564	least	_	
117-8	24565-24572	squares	_	
117-9	24573-24574	(	_	
117-10	24574-24577	PLS	_	
117-11	24577-24578	)	_	
117-12	24579-24587	analysis	_	
117-13	24588-24590	of	_	
117-14	24591-24609	schizotypy-related	_	
117-15	24610-24623	magnetization	_	
117-16	24624-24625	(	_	
117-17	24625-24628	SRM	_	
117-18	24628-24629	)	_	
117-19	24630-24634	were	_	
117-20	24635-24642	related	_	
117-21	24643-24645	to	_	
117-22	24646-24658	histological	_	
117-23	24659-24667	measures	_	
117-24	24668-24670	of	_	
117-25	24671-24683	differential	_	
117-26	24684-24688	gene	_	
117-27	24689-24699	expression	_	
117-28	24700-24704	from	_	
117-29	24705-24717	case-control	_	
117-30	24718-24725	studies	_	
117-31	24726-24728	of	_	
117-32	24729-24742	schizophrenia	_	
117-33	24743-24746	and	_	
117-34	24747-24752	other	_	
117-35	24753-24762	disorders	_	
117-36	24762-24763	.	_	

#Text=(A) The weight of each gene on the first PLS component was significantly negatively correlated with differential gene expression postmortem in schizophrenia according to prior data reported by Gandal et al.
118-1	24764-24765	(	_	
118-2	24765-24766	A	_	
118-3	24766-24767	)	_	
118-4	24768-24771	The	_	
118-5	24772-24778	weight	_	
118-6	24779-24781	of	_	
118-7	24782-24786	each	_	
118-8	24787-24791	gene	_	
118-9	24792-24794	on	_	
118-10	24795-24798	the	_	
118-11	24799-24804	first	_	
118-12	24805-24808	PLS	_	
118-13	24809-24818	component	_	
118-14	24819-24822	was	_	
118-15	24823-24836	significantly	_	
118-16	24837-24847	negatively	_	
118-17	24848-24858	correlated	_	
118-18	24859-24863	with	_	
118-19	24864-24876	differential	_	
118-20	24877-24881	gene	_	
118-21	24882-24892	expression	_	
118-22	24893-24903	postmortem	_	
118-23	24904-24906	in	_	
118-24	24907-24920	schizophrenia	_	
118-25	24921-24930	according	_	
118-26	24931-24933	to	_	
118-27	24934-24939	prior	_	
118-28	24940-24944	data	_	
118-29	24945-24953	reported	_	
118-30	24954-24956	by	_	
118-31	24957-24963	Gandal	_	
118-32	24964-24966	et	_	
118-33	24966-24967	 	_	
118-34	24967-24969	al	_	
118-35	24969-24970	.	_	

#Text=(Spearman’s rank correlation, ρ11111 = −.16, Bonferroni-corrected adjusted p11111 < 10−65) and by Fromer et al.
119-1	24971-24972	(	_	
119-2	24972-24980	Spearman	_	
119-3	24980-24981	’	_	
119-4	24981-24982	s	_	
119-5	24983-24987	rank	_	
119-6	24988-24999	correlation	_	
119-7	24999-25000	,	_	
119-8	25001-25007	ρ11111	_	
119-9	25007-25008	 	_	
119-10	25008-25009	=	_	
119-11	25009-25010	 	_	
119-12	25010-25011	−	_	
119-13	25011-25014	.16	_	
119-14	25014-25015	,	_	
119-15	25016-25036	Bonferroni-corrected	_	
119-16	25037-25045	adjusted	_	
119-17	25046-25052	p11111	_	
119-18	25053-25054	<	_	
119-19	25055-25057	10	_	
119-20	25057-25058	−	_	
119-21	25058-25060	65	_	
119-22	25060-25061	)	_	
119-23	25062-25065	and	_	
119-24	25066-25068	by	_	
119-25	25069-25075	Fromer	_	
119-26	25076-25078	et	_	
119-27	25078-25079	 	_	
119-28	25079-25081	al	_	
119-29	25081-25082	.	_	

#Text=[Spearman’s rank correlation, ρ586 = −.30, adjusted p586 < 10−12; for this dataset, only significantly different expression values have been reported ].
120-1	25083-25084	[	_	
120-2	25084-25092	Spearman	_	
120-3	25092-25093	’	_	
120-4	25093-25094	s	_	
120-5	25095-25099	rank	_	
120-6	25100-25111	correlation	_	
120-7	25111-25112	,	_	
120-8	25113-25117	ρ586	_	
120-9	25117-25118	 	_	
120-10	25118-25119	=	_	
120-11	25119-25120	 	_	
120-12	25120-25121	−	_	
120-13	25121-25124	.30	_	
120-14	25124-25125	,	_	
120-15	25126-25134	adjusted	_	
120-16	25135-25139	p586	_	
120-17	25140-25141	<	_	
120-18	25142-25144	10	_	
120-19	25144-25145	−	_	
120-20	25145-25147	12	_	
120-21	25147-25148	;	_	
120-22	25149-25152	for	_	
120-23	25153-25157	this	_	
120-24	25158-25165	dataset	_	
120-25	25165-25166	,	_	
120-26	25167-25171	only	_	
120-27	25172-25185	significantly	_	
120-28	25186-25195	different	_	
120-29	25196-25206	expression	_	
120-30	25207-25213	values	_	
120-31	25214-25218	have	_	
120-32	25219-25223	been	_	
120-33	25224-25232	reported	_	
120-34	25233-25234	]	_	
120-35	25234-25235	.	_	

#Text=(B) Correlations between PLS weights and differential expression were also evaluated for other conditions: inflammatory bowel disease (ρ586 = −.02, adjusted p586 = .10), major depressive disorder (ρ15281 = .007, adjusted p15281 = .37), bipolar disorder (ρ16064 = −.09, adjusted p16064 < 10−19 ), and autism spectrum disorder (ρ11131 = .11, adjusted p11131 < 10−35).
121-1	25236-25237	(	_	
121-2	25237-25238	B	_	
121-3	25238-25239	)	_	
121-4	25240-25252	Correlations	_	
121-5	25253-25260	between	_	
121-6	25261-25264	PLS	_	
121-7	25265-25272	weights	_	
121-8	25273-25276	and	_	
121-9	25277-25289	differential	_	
121-10	25290-25300	expression	_	
121-11	25301-25305	were	_	
121-12	25306-25310	also	_	
121-13	25311-25320	evaluated	_	
121-14	25321-25324	for	_	
121-15	25325-25330	other	_	
121-16	25331-25341	conditions	_	
121-17	25341-25342	:	_	
121-18	25343-25355	inflammatory	_	
121-19	25356-25361	bowel	_	
121-20	25362-25369	disease	_	
121-21	25370-25371	(	_	
121-22	25371-25375	ρ586	_	
121-23	25375-25376	 	_	
121-24	25376-25377	=	_	
121-25	25377-25378	 	_	
121-26	25378-25379	−	_	
121-27	25379-25382	.02	_	
121-28	25382-25383	,	_	
121-29	25384-25392	adjusted	_	
121-30	25393-25397	p586	_	
121-31	25397-25398	 	_	
121-32	25398-25399	=	_	
121-33	25400-25403	.10	_	
121-34	25403-25404	)	_	
121-35	25404-25405	,	_	
121-36	25406-25411	major	_	
121-37	25412-25422	depressive	_	
121-38	25423-25431	disorder	_	
121-39	25432-25433	(	_	
121-40	25433-25439	ρ15281	_	
121-41	25439-25440	 	_	
121-42	25440-25441	=	_	
121-43	25441-25442	 	_	
121-44	25442-25446	.007	_	
121-45	25446-25447	,	_	
121-46	25448-25456	adjusted	_	
121-47	25457-25463	p15281	_	
121-48	25463-25464	 	_	
121-49	25464-25465	=	_	
121-50	25466-25469	.37	_	
121-51	25469-25470	)	_	
121-52	25470-25471	,	_	
121-53	25472-25479	bipolar	_	
121-54	25480-25488	disorder	_	
121-55	25489-25490	(	_	
121-56	25490-25496	ρ16064	_	
121-57	25496-25497	 	_	
121-58	25497-25498	=	_	
121-59	25498-25499	 	_	
121-60	25499-25500	−	_	
121-61	25500-25503	.09	_	
121-62	25503-25504	,	_	
121-63	25505-25513	adjusted	_	
121-64	25514-25520	p16064	_	
121-65	25521-25522	<	_	
121-66	25523-25525	10	_	
121-67	25525-25526	−	_	
121-68	25526-25528	19	_	
121-69	25528-25529	 	_	
121-70	25529-25530	)	_	
121-71	25530-25531	,	_	
121-72	25532-25535	and	_	
121-73	25536-25542	autism	_	
121-74	25543-25551	spectrum	_	
121-75	25552-25560	disorder	_	
121-76	25561-25562	(	_	
121-77	25562-25568	ρ11131	_	
121-78	25568-25569	 	_	
121-79	25569-25570	=	_	
121-80	25571-25574	.11	_	
121-81	25574-25575	,	_	
121-82	25576-25584	adjusted	_	
121-83	25585-25591	p11131	_	
121-84	25591-25592	 	_	
121-85	25592-25593	<	_	
121-86	25593-25594	 	_	
121-87	25594-25596	10	_	
121-88	25596-25597	−	_	
121-89	25597-25599	35	_	
121-90	25599-25600	)	_	
121-91	25600-25601	.	_	

#Text=Red and blue points represent genes that are significantly up- and downregulated in postmortem data.
122-1	25602-25605	Red	_	
122-2	25606-25609	and	_	
122-3	25610-25614	blue	_	
122-4	25615-25621	points	_	
122-5	25622-25631	represent	_	
122-6	25632-25637	genes	_	
122-7	25638-25642	that	_	
122-8	25643-25646	are	_	
122-9	25647-25660	significantly	_	
122-10	25661-25663	up	_	
122-11	25663-25664	-	_	
122-12	25665-25668	and	_	
122-13	25669-25682	downregulated	_	
122-14	25683-25685	in	_	
122-15	25686-25696	postmortem	_	
122-16	25697-25701	data	_	
122-17	25701-25702	.	_	

#Text=Convergently, there was a significant negative correlation (Spearman’s ρ = −.16, p < 10−6) between the PLS1 weights of all genes in the genome and the differential expression values reported for all genes by Gandal et al. and Fromer et al.
123-1	25703-25715	Convergently	_	
123-2	25715-25716	,	_	
123-3	25717-25722	there	_	
123-4	25723-25726	was	_	
123-5	25727-25728	a	_	
123-6	25729-25740	significant	_	
123-7	25741-25749	negative	_	
123-8	25750-25761	correlation	_	
123-9	25762-25763	(	_	
123-10	25763-25771	Spearman	_	
123-11	25771-25772	’	_	
123-12	25772-25773	s	_	
123-13	25774-25775	ρ	_	
123-14	25775-25776	 	_	
123-15	25776-25777	=	_	
123-16	25777-25778	 	_	
123-17	25778-25779	−	_	
123-18	25779-25782	.16	_	
123-19	25782-25783	,	_	
123-20	25784-25785	p	_	
123-21	25786-25787	<	_	
123-22	25788-25790	10	_	
123-23	25790-25791	−	_	
123-24	25791-25792	6	_	
123-25	25792-25793	)	_	
123-26	25794-25801	between	_	
123-27	25802-25805	the	_	
123-28	25806-25810	PLS1	_	
123-29	25811-25818	weights	_	
123-30	25819-25821	of	_	
123-31	25822-25825	all	_	
123-32	25826-25831	genes	_	
123-33	25832-25834	in	_	
123-34	25835-25838	the	_	
123-35	25839-25845	genome	_	
123-36	25846-25849	and	_	
123-37	25850-25853	the	_	
123-38	25854-25866	differential	_	
123-39	25867-25877	expression	_	
123-40	25878-25884	values	_	
123-41	25885-25893	reported	_	
123-42	25894-25897	for	_	
123-43	25898-25901	all	_	
123-44	25902-25907	genes	_	
123-45	25908-25910	by	_	
123-46	25911-25917	Gandal	_	
123-47	25918-25920	et	_	
123-48	25920-25921	 	_	
123-49	25921-25923	al	_	
123-50	25923-25924	.	_	
123-51	25925-25928	and	_	
123-52	25929-25935	Fromer	_	
123-53	25936-25938	et	_	
123-54	25938-25939	 	_	
123-55	25939-25941	al	_	
123-56	25941-25942	.	_	

#Text=(Figure 3A).
124-1	25943-25944	(	_	
124-2	25944-25950	Figure	_	
124-3	25950-25951	 	_	
124-4	25951-25953	3A	_	
124-5	25953-25954	)	_	
124-6	25954-25955	.	_	

#Text=PLS1 gene weights were not correlated with differential expression in inflammatory bowel disease or major depressive disorder; however, they were negatively correlated with differential expression in BPD and ASD (Figure 3B).
125-1	25956-25960	PLS1	_	
125-2	25961-25965	gene	_	
125-3	25966-25973	weights	_	
125-4	25974-25978	were	_	
125-5	25979-25982	not	_	
125-6	25983-25993	correlated	_	
125-7	25994-25998	with	_	
125-8	25999-26011	differential	_	
125-9	26012-26022	expression	_	
125-10	26023-26025	in	_	
125-11	26026-26038	inflammatory	_	
125-12	26039-26044	bowel	_	
125-13	26045-26052	disease	_	
125-14	26053-26055	or	_	
125-15	26056-26061	major	_	
125-16	26062-26072	depressive	_	
125-17	26073-26081	disorder	_	
125-18	26081-26082	;	_	
125-19	26083-26090	however	_	
125-20	26090-26091	,	_	
125-21	26092-26096	they	_	
125-22	26097-26101	were	_	
125-23	26102-26112	negatively	_	
125-24	26113-26123	correlated	_	
125-25	26124-26128	with	_	
125-26	26129-26141	differential	_	
125-27	26142-26152	expression	_	
125-28	26153-26155	in	_	
125-29	26156-26159	BPD	_	
125-30	26160-26163	and	_	
125-31	26164-26167	ASD	_	
125-32	26168-26169	(	_	
125-33	26169-26175	Figure	_	
125-34	26175-26176	 	_	
125-35	26176-26178	3B	_	
125-36	26178-26179	)	_	
125-37	26179-26180	.	_	

#Text=Protein-protein interaction network for a set of 213 proteins coded by genes associated with both schizotypy-related magnetization and postmortem brain transcriptional dysregulation in schizophrenia.
126-1	26181-26196	Protein-protein	_	
126-2	26197-26208	interaction	_	
126-3	26209-26216	network	_	
126-4	26217-26220	for	_	
126-5	26221-26222	a	_	
126-6	26223-26226	set	_	
126-7	26227-26229	of	_	
126-8	26230-26233	213	_	
126-9	26234-26242	proteins	_	
126-10	26243-26248	coded	_	
126-11	26249-26251	by	_	
126-12	26252-26257	genes	_	
126-13	26258-26268	associated	_	
126-14	26269-26273	with	_	
126-15	26274-26278	both	_	
126-16	26279-26297	schizotypy-related	_	
126-17	26298-26311	magnetization	_	
126-18	26312-26315	and	_	
126-19	26316-26326	postmortem	_	
126-20	26327-26332	brain	_	
126-21	26333-26348	transcriptional	_	
126-22	26349-26362	dysregulation	_	
126-23	26363-26365	in	_	
126-24	26366-26379	schizophrenia	_	
126-25	26379-26380	.	_	

#Text=Nodes represent genes that were both 1) downregulated in brain tissue from 159 patients with schizophrenia and 2) positively weighted on the partial least squares component most strongly associated with schizotypy-related myelination in 248 healthy adolescents.
127-1	26381-26386	Nodes	_	
127-2	26387-26396	represent	_	
127-3	26397-26402	genes	_	
127-4	26403-26407	that	_	
127-5	26408-26412	were	_	
127-6	26413-26417	both	_	
127-7	26418-26419	1	_	
127-8	26419-26420	)	_	
127-9	26421-26434	downregulated	_	
127-10	26435-26437	in	_	
127-11	26438-26443	brain	_	
127-12	26444-26450	tissue	_	
127-13	26451-26455	from	_	
127-14	26456-26459	159	_	
127-15	26460-26468	patients	_	
127-16	26469-26473	with	_	
127-17	26474-26487	schizophrenia	_	
127-18	26488-26491	and	_	
127-19	26492-26493	2	_	
127-20	26493-26494	)	_	
127-21	26495-26505	positively	_	
127-22	26506-26514	weighted	_	
127-23	26515-26517	on	_	
127-24	26518-26521	the	_	
127-25	26522-26529	partial	_	
127-26	26530-26535	least	_	
127-27	26536-26543	squares	_	
127-28	26544-26553	component	_	
127-29	26554-26558	most	_	
127-30	26559-26567	strongly	_	
127-31	26568-26578	associated	_	
127-32	26579-26583	with	_	
127-33	26584-26602	schizotypy-related	_	
127-34	26603-26614	myelination	_	
127-35	26615-26617	in	_	
127-36	26618-26621	248	_	
127-37	26622-26629	healthy	_	
127-38	26630-26641	adolescents	_	
127-39	26641-26642	.	_	

#Text=Edges represent known protein-protein interactions.
128-1	26643-26648	Edges	_	
128-2	26649-26658	represent	_	
128-3	26659-26664	known	_	
128-4	26665-26680	protein-protein	_	
128-5	26681-26693	interactions	_	
128-6	26693-26694	.	_	

#Text=The color and size of each node represents its degree centrality or “hubness,” simply the number of interactions that protein has with the other proteins in the network.
129-1	26695-26698	The	_	
129-2	26699-26704	color	_	
129-3	26705-26708	and	_	
129-4	26709-26713	size	_	
129-5	26714-26716	of	_	
129-6	26717-26721	each	_	
129-7	26722-26726	node	_	
129-8	26727-26737	represents	_	
129-9	26738-26741	its	_	
129-10	26742-26748	degree	_	
129-11	26749-26759	centrality	_	
129-12	26760-26762	or	_	
129-13	26763-26764	“	_	
129-14	26764-26771	hubness	_	
129-15	26771-26772	,	_	
129-16	26772-26773	”	_	
129-17	26774-26780	simply	_	
129-18	26781-26784	the	_	
129-19	26785-26791	number	_	
129-20	26792-26794	of	_	
129-21	26795-26807	interactions	_	
129-22	26808-26812	that	_	
129-23	26813-26820	protein	_	
129-24	26821-26824	has	_	
129-25	26825-26829	with	_	
129-26	26830-26833	the	_	
129-27	26834-26839	other	_	
129-28	26840-26848	proteins	_	
129-29	26849-26851	in	_	
129-30	26852-26855	the	_	
129-31	26856-26863	network	_	
129-32	26863-26864	.	_	

#Text=The top 4 most highly connected hubs are highlighted: PPP3CC is a calmodulin dependent phosphatase, calcineurin; CAMK2G is a calcium/calmodulin dependent kinase; PVALB is a calcium binding protein, parvalbumin; ACTN4 is a microfilamentous protein, actinin-alpha-4.
130-1	26865-26868	The	_	
130-2	26869-26872	top	_	
130-3	26873-26874	4	_	
130-4	26875-26879	most	_	
130-5	26880-26886	highly	_	
130-6	26887-26896	connected	_	
130-7	26897-26901	hubs	_	
130-8	26902-26905	are	_	
130-9	26906-26917	highlighted	_	
130-10	26917-26918	:	_	
130-11	26919-26925	PPP3CC	_	
130-12	26926-26928	is	_	
130-13	26929-26930	a	_	
130-14	26931-26941	calmodulin	_	
130-15	26942-26951	dependent	_	
130-16	26952-26963	phosphatase	_	
130-17	26963-26964	,	_	
130-18	26965-26976	calcineurin	_	
130-19	26976-26977	;	_	
130-20	26978-26984	CAMK2G	_	
130-21	26985-26987	is	_	
130-22	26988-26989	a	_	
130-23	26990-26997	calcium	_	
130-24	26997-26998	/	_	
130-25	26998-27008	calmodulin	_	
130-26	27009-27018	dependent	_	
130-27	27019-27025	kinase	_	
130-28	27025-27026	;	_	
130-29	27027-27032	PVALB	_	
130-30	27033-27035	is	_	
130-31	27036-27037	a	_	
130-32	27038-27045	calcium	_	
130-33	27046-27053	binding	_	
130-34	27054-27061	protein	_	
130-35	27061-27062	,	_	
130-36	27063-27074	parvalbumin	_	
130-37	27074-27075	;	_	
130-38	27076-27081	ACTN4	_	
130-39	27082-27084	is	_	
130-40	27085-27086	a	_	
130-41	27087-27103	microfilamentous	_	
130-42	27104-27111	protein	_	
130-43	27111-27112	,	_	
130-44	27113-27126	actinin-alpha	_	
130-45	27126-27127	-	_	
130-46	27127-27128	4	_	
130-47	27128-27129	.	_	

#Text=This network is specialized for calcium-dependent processes that have been previously associated with interneurons and with pathogenesis of schizophrenia.
131-1	27130-27134	This	_	
131-2	27135-27142	network	_	
131-3	27143-27145	is	_	
131-4	27146-27157	specialized	_	
131-5	27158-27161	for	_	
131-6	27162-27179	calcium-dependent	_	
131-7	27180-27189	processes	_	
131-8	27190-27194	that	_	
131-9	27195-27199	have	_	
131-10	27200-27204	been	_	
131-11	27205-27215	previously	_	
131-12	27216-27226	associated	_	
131-13	27227-27231	with	_	
131-14	27232-27244	interneurons	_	
131-15	27245-27248	and	_	
131-16	27249-27253	with	_	
131-17	27254-27266	pathogenesis	_	
131-18	27267-27269	of	_	
131-19	27270-27283	schizophrenia	_	
131-20	27283-27284	.	_	

#Text=For the complete list of gene names on the protein-protein interaction network, see Figure S11 and see https://version-10-5.string-db.org/cgi/network.pl?
132-1	27285-27288	For	_	
132-2	27289-27292	the	_	
132-3	27292-27293	 	_	
132-4	27293-27301	complete	_	
132-5	27302-27306	list	_	
132-6	27307-27309	of	_	
132-7	27310-27314	gene	_	
132-8	27315-27320	names	_	
132-9	27321-27323	on	_	
132-10	27324-27327	the	_	
132-11	27328-27343	protein-protein	_	
132-12	27344-27355	interaction	_	
132-13	27356-27363	network	_	
132-14	27363-27364	,	_	
132-15	27365-27368	see	_	
132-16	27369-27375	Figure	_	
132-17	27375-27376	 	_	
132-18	27376-27379	S11	_	
132-19	27380-27383	and	_	
132-20	27384-27387	see	_	
132-21	27387-27388	 	_	
132-22	27388-27393	https	_	
132-23	27393-27394	:	_	
132-24	27394-27395	/	_	
132-25	27395-27396	/	_	
132-26	27396-27403	version	_	
132-27	27403-27404	-	_	
132-28	27404-27406	10	_	
132-29	27406-27407	-	_	
132-30	27407-27408	5	_	
132-31	27408-27409	.	_	
132-32	27409-27422	string-db.org	_	
132-33	27422-27423	/	_	
132-34	27423-27426	cgi	_	
132-35	27426-27427	/	_	
132-36	27427-27437	network.pl	_	
132-37	27437-27438	?	_	

#Text=taskId=RMpA04wbWG8k for a full interactive version of the protein-protein interaction network.
133-1	27438-27444	taskId	_	
133-2	27444-27445	=	_	
133-3	27445-27457	RMpA04wbWG8k	_	
133-4	27458-27461	for	_	
133-5	27462-27463	a	_	
133-6	27464-27468	full	_	
133-7	27469-27480	interactive	_	
133-8	27481-27488	version	_	
133-9	27489-27491	of	_	
133-10	27492-27495	the	_	
133-11	27496-27511	protein-protein	_	
133-12	27512-27523	interaction	_	
133-13	27524-27531	network	_	
133-14	27531-27532	.	_	

#Text=We analyzed the network of known protein-protein interactions [STRING (http://string-db.org) ] between proteins coded by the 213 genes that were significantly downregulated in schizophrenia and significantly positively weighted in the PLS analysis of SRM (Table S5).
134-1	27533-27535	We	_	
134-2	27536-27544	analyzed	_	
134-3	27545-27548	the	_	
134-4	27549-27556	network	_	
134-5	27557-27559	of	_	
134-6	27560-27565	known	_	
134-7	27566-27581	protein-protein	_	
134-8	27582-27594	interactions	_	
134-9	27595-27596	[	_	
134-10	27596-27602	STRING	_	
134-11	27603-27604	(	_	
134-12	27604-27608	http	_	
134-13	27608-27609	:	_	
134-14	27609-27610	/	_	
134-15	27610-27611	/	_	
134-16	27611-27624	string-db.org	_	
134-17	27624-27625	)	_	
134-18	27626-27627	]	_	
134-19	27628-27635	between	_	
134-20	27636-27644	proteins	_	
134-21	27645-27650	coded	_	
134-22	27651-27653	by	_	
134-23	27654-27657	the	_	
134-24	27658-27661	213	_	
134-25	27662-27667	genes	_	
134-26	27668-27672	that	_	
134-27	27673-27677	were	_	
134-28	27678-27691	significantly	_	
134-29	27692-27705	downregulated	_	
134-30	27706-27708	in	_	
134-31	27709-27722	schizophrenia	_	
134-32	27723-27726	and	_	
134-33	27727-27740	significantly	_	
134-34	27741-27751	positively	_	
134-35	27752-27760	weighted	_	
134-36	27761-27763	in	_	
134-37	27764-27767	the	_	
134-38	27768-27771	PLS	_	
134-39	27772-27780	analysis	_	
134-40	27781-27783	of	_	
134-41	27784-27787	SRM	_	
134-42	27788-27789	(	_	
134-43	27789-27794	Table	_	
134-44	27794-27795	 	_	
134-45	27795-27797	S5	_	
134-46	27797-27798	)	_	
134-47	27798-27799	.	_	

#Text=There were significantly more interactions (edges) between proteins coded by these genes than expected by chance (permutation test, p < 10−5) (Figure 4 and Figure S11).
135-1	27800-27805	There	_	
135-2	27806-27810	were	_	
135-3	27811-27824	significantly	_	
135-4	27825-27829	more	_	
135-5	27830-27842	interactions	_	
135-6	27843-27844	(	_	
135-7	27844-27849	edges	_	
135-8	27849-27850	)	_	
135-9	27851-27858	between	_	
135-10	27859-27867	proteins	_	
135-11	27868-27873	coded	_	
135-12	27874-27876	by	_	
135-13	27877-27882	these	_	
135-14	27883-27888	genes	_	
135-15	27889-27893	than	_	
135-16	27894-27902	expected	_	
135-17	27903-27905	by	_	
135-18	27906-27912	chance	_	
135-19	27913-27914	(	_	
135-20	27914-27925	permutation	_	
135-21	27926-27930	test	_	
135-22	27930-27931	,	_	
135-23	27932-27933	p	_	
135-24	27934-27935	<	_	
135-25	27936-27938	10	_	
135-26	27938-27939	−	_	
135-27	27939-27940	5	_	
135-28	27940-27941	)	_	
135-29	27942-27943	(	_	
135-30	27943-27949	Figure	_	
135-31	27949-27950	 	_	
135-32	27950-27951	4	_	
135-33	27952-27955	and	_	
135-34	27956-27962	Figure	_	
135-35	27962-27963	 	_	
135-36	27963-27966	S11	_	
135-37	27966-27967	)	_	
135-38	27967-27968	.	_	

#Text=Topologically, the network comprised several clusters of densely interconnected and functionally specialized proteins.
136-1	27969-27982	Topologically	_	
136-2	27982-27983	,	_	
136-3	27984-27987	the	_	
136-4	27988-27995	network	_	
136-5	27996-28005	comprised	_	
136-6	28006-28013	several	_	
136-7	28014-28022	clusters	_	
136-8	28023-28025	of	_	
136-9	28026-28033	densely	_	
136-10	28034-28048	interconnected	_	
136-11	28049-28052	and	_	
136-12	28053-28065	functionally	_	
136-13	28066-28077	specialized	_	
136-14	28078-28086	proteins	_	
136-15	28086-28087	.	_	

#Text=The biggest cluster was enriched for synaptic terms and centered around highly connected “hub” proteins (Figure 4).
137-1	28088-28091	The	_	
137-2	28092-28099	biggest	_	
137-3	28100-28107	cluster	_	
137-4	28108-28111	was	_	
137-5	28112-28120	enriched	_	
137-6	28121-28124	for	_	
137-7	28125-28133	synaptic	_	
137-8	28134-28139	terms	_	
137-9	28140-28143	and	_	
137-10	28144-28152	centered	_	
137-11	28153-28159	around	_	
137-12	28160-28166	highly	_	
137-13	28167-28176	connected	_	
137-14	28177-28178	“	_	
137-15	28178-28181	hub	_	
137-16	28181-28182	”	_	
137-17	28183-28191	proteins	_	
137-18	28192-28193	(	_	
137-19	28193-28199	Figure	_	
137-20	28199-28200	 	_	
137-21	28200-28201	4	_	
137-22	28201-28202	)	_	
137-23	28202-28203	.	_	

#Text=Discussion
#Text=Schizotypy was associated with intracortical magnetization of posterior cortical regions of the default mode network and colocated with a normative cortical pattern of weighted whole-genome expression.
138-1	28204-28214	Discussion	_	
138-2	28215-28225	Schizotypy	_	
138-3	28226-28229	was	_	
138-4	28230-28240	associated	_	
138-5	28241-28245	with	_	
138-6	28246-28259	intracortical	_	
138-7	28260-28273	magnetization	_	
138-8	28274-28276	of	_	
138-9	28277-28286	posterior	_	
138-10	28287-28295	cortical	_	
138-11	28296-28303	regions	_	
138-12	28304-28306	of	_	
138-13	28307-28310	the	_	
138-14	28311-28318	default	_	
138-15	28319-28323	mode	_	
138-16	28324-28331	network	_	
138-17	28332-28335	and	_	
138-18	28336-28345	colocated	_	
138-19	28346-28350	with	_	
138-20	28351-28352	a	_	
138-21	28353-28362	normative	_	
138-22	28363-28371	cortical	_	
138-23	28372-28379	pattern	_	
138-24	28380-28382	of	_	
138-25	28383-28391	weighted	_	
138-26	28392-28404	whole-genome	_	
138-27	28405-28415	expression	_	
138-28	28415-28416	.	_	

#Text=The gene transcripts most strongly weighted in association with this MRI map of SRM were significantly enriched for genes specifically expressed by neuronal and glial cells, especially PVALB-positive interneurons, and for genes that were transcriptionally dysregulated in 2 prior postmortem studies of schizophrenia.
139-1	28417-28420	The	_	
139-2	28421-28425	gene	_	
139-3	28426-28437	transcripts	_	
139-4	28438-28442	most	_	
139-5	28443-28451	strongly	_	
139-6	28452-28460	weighted	_	
139-7	28461-28463	in	_	
139-8	28464-28475	association	_	
139-9	28476-28480	with	_	
139-10	28481-28485	this	_	
139-11	28486-28489	MRI	_	
139-12	28490-28493	map	_	
139-13	28494-28496	of	_	
139-14	28497-28500	SRM	_	
139-15	28501-28505	were	_	
139-16	28506-28519	significantly	_	
139-17	28520-28528	enriched	_	
139-18	28529-28532	for	_	
139-19	28533-28538	genes	_	
139-20	28539-28551	specifically	_	
139-21	28552-28561	expressed	_	
139-22	28562-28564	by	_	
139-23	28565-28573	neuronal	_	
139-24	28574-28577	and	_	
139-25	28578-28583	glial	_	
139-26	28584-28589	cells	_	
139-27	28589-28590	,	_	
139-28	28591-28601	especially	_	
139-29	28602-28616	PVALB-positive	_	
139-30	28617-28629	interneurons	_	
139-31	28629-28630	,	_	
139-32	28631-28634	and	_	
139-33	28635-28638	for	_	
139-34	28639-28644	genes	_	
139-35	28645-28649	that	_	
139-36	28650-28654	were	_	
139-37	28655-28672	transcriptionally	_	
139-38	28673-28685	dysregulated	_	
139-39	28686-28688	in	_	
139-40	28689-28690	2	_	
139-41	28691-28696	prior	_	
139-42	28697-28707	postmortem	_	
139-43	28708-28715	studies	_	
139-44	28716-28718	of	_	
139-45	28719-28732	schizophrenia	_	
139-46	28732-28733	.	_	

#Text=Magnetization, Intracortical Myelination, and Schizotypy
#Text=MT is a microstructural MRI measurement that is sensitive to the ratio of fatty and watery tissue represented by each voxel, and in the brain, most of the fat is myelin.
140-1	28734-28747	Magnetization	_	
140-2	28747-28748	,	_	
140-3	28749-28762	Intracortical	_	
140-4	28763-28774	Myelination	_	
140-5	28774-28775	,	_	
140-6	28776-28779	and	_	
140-7	28780-28790	Schizotypy	_	
140-8	28791-28793	MT	_	
140-9	28794-28796	is	_	
140-10	28797-28798	a	_	
140-11	28799-28814	microstructural	_	
140-12	28815-28818	MRI	_	
140-13	28819-28830	measurement	_	
140-14	28831-28835	that	_	
140-15	28836-28838	is	_	
140-16	28839-28848	sensitive	_	
140-17	28849-28851	to	_	
140-18	28852-28855	the	_	
140-19	28856-28861	ratio	_	
140-20	28862-28864	of	_	
140-21	28865-28870	fatty	_	
140-22	28871-28874	and	_	
140-23	28875-28881	watery	_	
140-24	28882-28888	tissue	_	
140-25	28889-28900	represented	_	
140-26	28901-28903	by	_	
140-27	28904-28908	each	_	
140-28	28909-28914	voxel	_	
140-29	28914-28915	,	_	
140-30	28916-28919	and	_	
140-31	28920-28922	in	_	
140-32	28923-28926	the	_	
140-33	28927-28932	brain	_	
140-34	28932-28933	,	_	
140-35	28934-28938	most	_	
140-36	28939-28941	of	_	
140-37	28942-28945	the	_	
140-38	28946-28949	fat	_	
140-39	28950-28952	is	_	
140-40	28953-28959	myelin	_	
140-41	28959-28960	.	_	

#Text=Intracortical myelination, especially of the deeper layers of the cortex, has been recognized since seminal cytoarchitectonic and myeloarchitectonic studies in the early 20th century.
141-1	28961-28974	Intracortical	_	
141-2	28975-28986	myelination	_	
141-3	28986-28987	,	_	
141-4	28988-28998	especially	_	
141-5	28999-29001	of	_	
141-6	29002-29005	the	_	
141-7	29006-29012	deeper	_	
141-8	29013-29019	layers	_	
141-9	29020-29022	of	_	
141-10	29023-29026	the	_	
141-11	29027-29033	cortex	_	
141-12	29033-29034	,	_	
141-13	29035-29038	has	_	
141-14	29039-29043	been	_	
141-15	29044-29054	recognized	_	
141-16	29055-29060	since	_	
141-17	29061-29068	seminal	_	
141-18	29069-29086	cytoarchitectonic	_	
141-19	29087-29090	and	_	
141-20	29091-29109	myeloarchitectonic	_	
141-21	29110-29117	studies	_	
141-22	29118-29120	in	_	
141-23	29121-29124	the	_	
141-24	29125-29130	early	_	
141-25	29131-29135	20th	_	
141-26	29136-29143	century	_	
141-27	29143-29144	.	_	

#Text=MT images represent a stark contrast between the cortex and the central white matter as well as more nuanced variations across different cortical areas and layers.
142-1	29145-29147	MT	_	
142-2	29148-29154	images	_	
142-3	29155-29164	represent	_	
142-4	29165-29166	a	_	
142-5	29167-29172	stark	_	
142-6	29173-29181	contrast	_	
142-7	29182-29189	between	_	
142-8	29190-29193	the	_	
142-9	29194-29200	cortex	_	
142-10	29201-29204	and	_	
142-11	29205-29208	the	_	
142-12	29209-29216	central	_	
142-13	29217-29222	white	_	
142-14	29223-29229	matter	_	
142-15	29230-29232	as	_	
142-16	29233-29237	well	_	
142-17	29238-29240	as	_	
142-18	29241-29245	more	_	
142-19	29246-29253	nuanced	_	
142-20	29254-29264	variations	_	
142-21	29265-29271	across	_	
142-22	29272-29281	different	_	
142-23	29282-29290	cortical	_	
142-24	29291-29296	areas	_	
142-25	29297-29300	and	_	
142-26	29301-29307	layers	_	
142-27	29307-29308	.	_	

#Text=Histological measurements of myelin were positively correlated with MRI measurements of MT in postmortem brains.
143-1	29309-29321	Histological	_	
143-2	29322-29334	measurements	_	
143-3	29335-29337	of	_	
143-4	29338-29344	myelin	_	
143-5	29345-29349	were	_	
143-6	29350-29360	positively	_	
143-7	29361-29371	correlated	_	
143-8	29372-29376	with	_	
143-9	29377-29380	MRI	_	
143-10	29381-29393	measurements	_	
143-11	29394-29396	of	_	
143-12	29397-29399	MT	_	
143-13	29400-29402	in	_	
143-14	29403-29413	postmortem	_	
143-15	29414-29420	brains	_	
143-16	29420-29421	.	_	

#Text=Intracortical measurements of MT in humans have been validated as microstructural MRI markers of myelination in healthy volunteers and in patients with multiple sclerosis.
144-1	29422-29435	Intracortical	_	
144-2	29436-29448	measurements	_	
144-3	29449-29451	of	_	
144-4	29452-29454	MT	_	
144-5	29455-29457	in	_	
144-6	29458-29464	humans	_	
144-7	29465-29469	have	_	
144-8	29470-29474	been	_	
144-9	29475-29484	validated	_	
144-10	29485-29487	as	_	
144-11	29488-29503	microstructural	_	
144-12	29504-29507	MRI	_	
144-13	29508-29515	markers	_	
144-14	29516-29518	of	_	
144-15	29519-29530	myelination	_	
144-16	29531-29533	in	_	
144-17	29534-29541	healthy	_	
144-18	29542-29552	volunteers	_	
144-19	29553-29556	and	_	
144-20	29557-29559	in	_	
144-21	29560-29568	patients	_	
144-22	29569-29573	with	_	
144-23	29574-29582	multiple	_	
144-24	29583-29592	sclerosis	_	
144-25	29592-29593	.	_	

#Text=One plausible interpretation of SRM, therefore, is as a proxy marker for a biological state of schizotypy-related myelination.
145-1	29594-29597	One	_	
145-2	29598-29607	plausible	_	
145-3	29608-29622	interpretation	_	
145-4	29623-29625	of	_	
145-5	29626-29629	SRM	_	
145-6	29629-29630	,	_	
145-7	29631-29640	therefore	_	
145-8	29640-29641	,	_	
145-9	29642-29644	is	_	
145-10	29645-29647	as	_	
145-11	29648-29649	a	_	
145-12	29650-29655	proxy	_	
145-13	29656-29662	marker	_	
145-14	29663-29666	for	_	
145-15	29667-29668	a	_	
145-16	29669-29679	biological	_	
145-17	29680-29685	state	_	
145-18	29686-29688	of	_	
145-19	29689-29707	schizotypy-related	_	
145-20	29708-29719	myelination	_	
145-21	29719-29720	.	_	

#Text=On this assumption, the results are open to further interpretation at a cellular level.
146-1	29721-29723	On	_	
146-2	29724-29728	this	_	
146-3	29729-29739	assumption	_	
146-4	29739-29740	,	_	
146-5	29741-29744	the	_	
146-6	29745-29752	results	_	
146-7	29753-29756	are	_	
146-8	29757-29761	open	_	
146-9	29762-29764	to	_	
146-10	29765-29772	further	_	
146-11	29773-29787	interpretation	_	
146-12	29788-29790	at	_	
146-13	29791-29792	a	_	
146-14	29793-29801	cellular	_	
146-15	29802-29807	level	_	
146-16	29807-29808	.	_	

#Text=For example, greater “myelination” could imply a greater density of myelinated neurons per voxel (a neuronal process), or a greater density of myelin per neuron (an oligodendroglial process), or some combination of these and other cellular parameters.
147-1	29809-29812	For	_	
147-2	29813-29820	example	_	
147-3	29820-29821	,	_	
147-4	29822-29829	greater	_	
147-5	29830-29831	“	_	
147-6	29831-29842	myelination	_	
147-7	29842-29843	”	_	
147-8	29844-29849	could	_	
147-9	29850-29855	imply	_	
147-10	29856-29857	a	_	
147-11	29858-29865	greater	_	
147-12	29866-29873	density	_	
147-13	29874-29876	of	_	
147-14	29877-29887	myelinated	_	
147-15	29888-29895	neurons	_	
147-16	29896-29899	per	_	
147-17	29900-29905	voxel	_	
147-18	29906-29907	(	_	
147-19	29907-29908	a	_	
147-20	29909-29917	neuronal	_	
147-21	29918-29925	process	_	
147-22	29925-29926	)	_	
147-23	29926-29927	,	_	
147-24	29928-29930	or	_	
147-25	29931-29932	a	_	
147-26	29933-29940	greater	_	
147-27	29941-29948	density	_	
147-28	29949-29951	of	_	
147-29	29952-29958	myelin	_	
147-30	29959-29962	per	_	
147-31	29963-29969	neuron	_	
147-32	29970-29971	(	_	
147-33	29971-29973	an	_	
147-34	29974-29990	oligodendroglial	_	
147-35	29991-29998	process	_	
147-36	29998-29999	)	_	
147-37	29999-30000	,	_	
147-38	30001-30003	or	_	
147-39	30004-30008	some	_	
147-40	30009-30020	combination	_	
147-41	30021-30023	of	_	
147-42	30024-30029	these	_	
147-43	30030-30033	and	_	
147-44	30034-30039	other	_	
147-45	30040-30048	cellular	_	
147-46	30049-30059	parameters	_	
147-47	30059-30060	.	_	

#Text=The data available to us did not allow direct resolution of the relationships between SRM and myelination.
148-1	30061-30064	The	_	
148-2	30065-30069	data	_	
148-3	30070-30079	available	_	
148-4	30080-30082	to	_	
148-5	30083-30085	us	_	
148-6	30086-30089	did	_	
148-7	30090-30093	not	_	
148-8	30094-30099	allow	_	
148-9	30100-30106	direct	_	
148-10	30107-30117	resolution	_	
148-11	30118-30120	of	_	
148-12	30121-30124	the	_	
148-13	30125-30138	relationships	_	
148-14	30139-30146	between	_	
148-15	30147-30150	SRM	_	
148-16	30151-30154	and	_	
148-17	30155-30166	myelination	_	
148-18	30166-30167	.	_	

#Text=Instead, we used open data on human brain gene expression (n = 6, mean age = 42.5 years) to explore these questions more indirectly.
149-1	30168-30175	Instead	_	
149-2	30175-30176	,	_	
149-3	30177-30179	we	_	
149-4	30180-30184	used	_	
149-5	30185-30189	open	_	
149-6	30190-30194	data	_	
149-7	30195-30197	on	_	
149-8	30198-30203	human	_	
149-9	30204-30209	brain	_	
149-10	30210-30214	gene	_	
149-11	30215-30225	expression	_	
149-12	30226-30227	(	_	
149-13	30227-30228	n	_	
149-14	30228-30229	 	_	
149-15	30229-30230	=	_	
149-16	30231-30232	6	_	
149-17	30232-30233	,	_	
149-18	30234-30238	mean	_	
149-19	30239-30242	age	_	
149-20	30242-30243	 	_	
149-21	30243-30244	=	_	
149-22	30245-30249	42.5	_	
149-23	30250-30255	years	_	
149-24	30255-30256	)	_	
149-25	30257-30259	to	_	
149-26	30260-30267	explore	_	
149-27	30268-30273	these	_	
149-28	30274-30283	questions	_	
149-29	30284-30288	more	_	
149-30	30289-30299	indirectly	_	
149-31	30299-30300	.	_	

#Text=The adult brain gene expression profile that was most closely colocated with the adolescent brain map of SRM (n = 248, mean age = 19 years) was enriched for neuronal, but not oligodendroglial, affiliations.
150-1	30301-30304	The	_	
150-2	30305-30310	adult	_	
150-3	30311-30316	brain	_	
150-4	30317-30321	gene	_	
150-5	30322-30332	expression	_	
150-6	30333-30340	profile	_	
150-7	30341-30345	that	_	
150-8	30346-30349	was	_	
150-9	30350-30354	most	_	
150-10	30355-30362	closely	_	
150-11	30363-30372	colocated	_	
150-12	30373-30377	with	_	
150-13	30378-30381	the	_	
150-14	30382-30392	adolescent	_	
150-15	30393-30398	brain	_	
150-16	30399-30402	map	_	
150-17	30403-30405	of	_	
150-18	30406-30409	SRM	_	
150-19	30410-30411	(	_	
150-20	30411-30412	n	_	
150-21	30412-30413	 	_	
150-22	30413-30414	=	_	
150-23	30415-30418	248	_	
150-24	30418-30419	,	_	
150-25	30420-30424	mean	_	
150-26	30425-30428	age	_	
150-27	30428-30429	 	_	
150-28	30429-30430	=	_	
150-29	30431-30433	19	_	
150-30	30434-30439	years	_	
150-31	30439-30440	)	_	
150-32	30441-30444	was	_	
150-33	30445-30453	enriched	_	
150-34	30454-30457	for	_	
150-35	30458-30466	neuronal	_	
150-36	30466-30467	,	_	
150-37	30468-30471	but	_	
150-38	30472-30475	not	_	
150-39	30476-30492	oligodendroglial	_	
150-40	30492-30493	,	_	
150-41	30494-30506	affiliations	_	
150-42	30506-30507	.	_	

#Text=This pattern of results arguably favors the interpretation that higher MT indicates a greater density of myelinated neurons per voxel, rather than a greater density of myelin per neuron, in people with higher schizotypy scores.
151-1	30508-30512	This	_	
151-2	30513-30520	pattern	_	
151-3	30521-30523	of	_	
151-4	30524-30531	results	_	
151-5	30532-30540	arguably	_	
151-6	30541-30547	favors	_	
151-7	30548-30551	the	_	
151-8	30552-30566	interpretation	_	
151-9	30567-30571	that	_	
151-10	30572-30578	higher	_	
151-11	30579-30581	MT	_	
151-12	30582-30591	indicates	_	
151-13	30592-30593	a	_	
151-14	30594-30601	greater	_	
151-15	30602-30609	density	_	
151-16	30610-30612	of	_	
151-17	30613-30623	myelinated	_	
151-18	30624-30631	neurons	_	
151-19	30632-30635	per	_	
151-20	30636-30641	voxel	_	
151-21	30641-30642	,	_	
151-22	30643-30649	rather	_	
151-23	30650-30654	than	_	
151-24	30655-30656	a	_	
151-25	30657-30664	greater	_	
151-26	30665-30672	density	_	
151-27	30673-30675	of	_	
151-28	30676-30682	myelin	_	
151-29	30683-30686	per	_	
151-30	30687-30693	neuron	_	
151-31	30693-30694	,	_	
151-32	30695-30697	in	_	
151-33	30698-30704	people	_	
151-34	30705-30709	with	_	
151-35	30710-30716	higher	_	
151-36	30717-30727	schizotypy	_	
151-37	30728-30734	scores	_	
151-38	30734-30735	.	_	

#Text=However, the 20+-year age gap between the MRI measurements and the messenger RNA measurements precludes definitive resolution of these and other possible cellular interpretations of SRM.
152-1	30736-30743	However	_	
152-2	30743-30744	,	_	
152-3	30745-30748	the	_	
152-4	30749-30751	20	_	
152-5	30751-30752	+	_	
152-6	30752-30753	-	_	
152-7	30753-30757	year	_	
152-8	30758-30761	age	_	
152-9	30762-30765	gap	_	
152-10	30766-30773	between	_	
152-11	30774-30777	the	_	
152-12	30778-30781	MRI	_	
152-13	30782-30794	measurements	_	
152-14	30795-30798	and	_	
152-15	30799-30802	the	_	
152-16	30803-30812	messenger	_	
152-17	30813-30816	RNA	_	
152-18	30817-30829	measurements	_	
152-19	30830-30839	precludes	_	
152-20	30840-30850	definitive	_	
152-21	30851-30861	resolution	_	
152-22	30862-30864	of	_	
152-23	30865-30870	these	_	
152-24	30871-30874	and	_	
152-25	30875-30880	other	_	
152-26	30881-30889	possible	_	
152-27	30890-30898	cellular	_	
152-28	30899-30914	interpretations	_	
152-29	30915-30917	of	_	
152-30	30918-30921	SRM	_	
152-31	30921-30922	.	_	

#Text=Although the SRM gene set is not known to demonstrate major developmental changes in expression after childhood (Figure S12), in the future it will be important to colocate MT phenotypes in children and young people (and animal models) with more precisely age-matched data on brain gene expression and histology.
153-1	30923-30931	Although	_	
153-2	30932-30935	the	_	
153-3	30936-30939	SRM	_	
153-4	30940-30944	gene	_	
153-5	30945-30948	set	_	
153-6	30949-30951	is	_	
153-7	30952-30955	not	_	
153-8	30956-30961	known	_	
153-9	30962-30964	to	_	
153-10	30965-30976	demonstrate	_	
153-11	30977-30982	major	_	
153-12	30983-30996	developmental	_	
153-13	30997-31004	changes	_	
153-14	31005-31007	in	_	
153-15	31008-31018	expression	_	
153-16	31019-31024	after	_	
153-17	31025-31034	childhood	_	
153-18	31035-31036	(	_	
153-19	31036-31042	Figure	_	
153-20	31042-31043	 	_	
153-21	31043-31046	S12	_	
153-22	31046-31047	)	_	
153-23	31047-31048	,	_	
153-24	31049-31051	in	_	
153-25	31052-31055	the	_	
153-26	31056-31062	future	_	
153-27	31063-31065	it	_	
153-28	31066-31070	will	_	
153-29	31071-31073	be	_	
153-30	31074-31083	important	_	
153-31	31084-31086	to	_	
153-32	31087-31095	colocate	_	
153-33	31096-31098	MT	_	
153-34	31099-31109	phenotypes	_	
153-35	31110-31112	in	_	
153-36	31113-31121	children	_	
153-37	31122-31125	and	_	
153-38	31126-31131	young	_	
153-39	31132-31138	people	_	
153-40	31139-31140	(	_	
153-41	31140-31143	and	_	
153-42	31144-31150	animal	_	
153-43	31151-31157	models	_	
153-44	31157-31158	)	_	
153-45	31159-31163	with	_	
153-46	31164-31168	more	_	
153-47	31169-31178	precisely	_	
153-48	31179-31190	age-matched	_	
153-49	31191-31195	data	_	
153-50	31196-31198	on	_	
153-51	31199-31204	brain	_	
153-52	31205-31209	gene	_	
153-53	31210-31220	expression	_	
153-54	31221-31224	and	_	
153-55	31225-31234	histology	_	
153-56	31234-31235	.	_	

#Text=The macroscopic medial posterior cortical areas where MT was most strongly correlated with schizotypy in general—SPQ total score—are key components of the default mode network [as defined by functional MRI studies ] and specialized for memory, social cognitive, and theory-of-mind functions that are known to be abnormal in patients with schizophrenia.
154-1	31236-31239	The	_	
154-2	31240-31251	macroscopic	_	
154-3	31252-31258	medial	_	
154-4	31259-31268	posterior	_	
154-5	31269-31277	cortical	_	
154-6	31278-31283	areas	_	
154-7	31284-31289	where	_	
154-8	31290-31292	MT	_	
154-9	31293-31296	was	_	
154-10	31297-31301	most	_	
154-11	31302-31310	strongly	_	
154-12	31311-31321	correlated	_	
154-13	31322-31326	with	_	
154-14	31327-31337	schizotypy	_	
154-15	31338-31340	in	_	
154-16	31341-31352	general—SPQ	_	
154-17	31353-31358	total	_	
154-18	31359-31368	score—are	_	
154-19	31369-31372	key	_	
154-20	31373-31383	components	_	
154-21	31384-31386	of	_	
154-22	31387-31390	the	_	
154-23	31391-31398	default	_	
154-24	31399-31403	mode	_	
154-25	31404-31411	network	_	
154-26	31412-31413	[	_	
154-27	31413-31415	as	_	
154-28	31416-31423	defined	_	
154-29	31424-31426	by	_	
154-30	31427-31437	functional	_	
154-31	31438-31441	MRI	_	
154-32	31442-31449	studies	_	
154-33	31450-31451	]	_	
154-34	31452-31455	and	_	
154-35	31456-31467	specialized	_	
154-36	31468-31471	for	_	
154-37	31472-31478	memory	_	
154-38	31478-31479	,	_	
154-39	31480-31486	social	_	
154-40	31487-31496	cognitive	_	
154-41	31496-31497	,	_	
154-42	31498-31501	and	_	
154-43	31502-31516	theory-of-mind	_	
154-44	31517-31526	functions	_	
154-45	31527-31531	that	_	
154-46	31532-31535	are	_	
154-47	31536-31541	known	_	
154-48	31542-31544	to	_	
154-49	31545-31547	be	_	
154-50	31548-31556	abnormal	_	
154-51	31557-31559	in	_	
154-52	31560-31568	patients	_	
154-53	31569-31573	with	_	
154-54	31574-31587	schizophrenia	_	
154-55	31587-31588	.	_	

#Text=Interestingly, the schizotypal factor of disorganization was also correlated with MT in the medial prefrontal cortical areas that also form part of the default mode network.
155-1	31589-31602	Interestingly	_	
155-2	31602-31603	,	_	
155-3	31604-31607	the	_	
155-4	31608-31619	schizotypal	_	
155-5	31620-31626	factor	_	
155-6	31627-31629	of	_	
155-7	31630-31645	disorganization	_	
155-8	31646-31649	was	_	
155-9	31650-31654	also	_	
155-10	31655-31665	correlated	_	
155-11	31666-31670	with	_	
155-12	31671-31673	MT	_	
155-13	31674-31676	in	_	
155-14	31677-31680	the	_	
155-15	31681-31687	medial	_	
155-16	31688-31698	prefrontal	_	
155-17	31699-31707	cortical	_	
155-18	31708-31713	areas	_	
155-19	31714-31718	that	_	
155-20	31719-31723	also	_	
155-21	31724-31728	form	_	
155-22	31729-31733	part	_	
155-23	31734-31736	of	_	
155-24	31737-31740	the	_	
155-25	31741-31748	default	_	
155-26	31749-31753	mode	_	
155-27	31754-31761	network	_	
155-28	31761-31762	.	_	

#Text=All these regions had high levels of magnetization at 14 years of age and no significant subsequent change in magnetization over the period 14 to 25 years of age.
156-1	31763-31766	All	_	
156-2	31767-31772	these	_	
156-3	31773-31780	regions	_	
156-4	31781-31784	had	_	
156-5	31785-31789	high	_	
156-6	31790-31796	levels	_	
156-7	31797-31799	of	_	
156-8	31800-31813	magnetization	_	
156-9	31814-31816	at	_	
156-10	31817-31819	14	_	
156-11	31820-31825	years	_	
156-12	31826-31828	of	_	
156-13	31829-31832	age	_	
156-14	31833-31836	and	_	
156-15	31837-31839	no	_	
156-16	31840-31851	significant	_	
156-17	31852-31862	subsequent	_	
156-18	31863-31869	change	_	
156-19	31870-31872	in	_	
156-20	31873-31886	magnetization	_	
156-21	31887-31891	over	_	
156-22	31892-31895	the	_	
156-23	31896-31902	period	_	
156-24	31903-31905	14	_	
156-25	31906-31908	to	_	
156-26	31909-31911	25	_	
156-27	31912-31917	years	_	
156-28	31918-31920	of	_	
156-29	31921-31924	age	_	
156-30	31924-31925	.	_	

#Text=This contrasts with areas of the lateral association cortex, which have a low level of MT at 14 years of age but show significant increase in MT over the course of adolescence.
157-1	31926-31930	This	_	
157-2	31931-31940	contrasts	_	
157-3	31941-31945	with	_	
157-4	31946-31951	areas	_	
157-5	31952-31954	of	_	
157-6	31955-31958	the	_	
157-7	31959-31966	lateral	_	
157-8	31967-31978	association	_	
157-9	31979-31985	cortex	_	
157-10	31985-31986	,	_	
157-11	31987-31992	which	_	
157-12	31993-31997	have	_	
157-13	31998-31999	a	_	
157-14	32000-32003	low	_	
157-15	32004-32009	level	_	
157-16	32010-32012	of	_	
157-17	32013-32015	MT	_	
157-18	32016-32018	at	_	
157-19	32019-32021	14	_	
157-20	32022-32027	years	_	
157-21	32028-32030	of	_	
157-22	32031-32034	age	_	
157-23	32035-32038	but	_	
157-24	32039-32043	show	_	
157-25	32044-32055	significant	_	
157-26	32056-32064	increase	_	
157-27	32065-32067	in	_	
157-28	32068-32070	MT	_	
157-29	32071-32075	over	_	
157-30	32076-32079	the	_	
157-31	32080-32086	course	_	
157-32	32087-32089	of	_	
157-33	32090-32101	adolescence	_	
157-34	32101-32102	.	_	

#Text=We can infer that these medial posterior cortical areas matured as part of a preadolescent wave of cortical development, which would be compatible with the stable, traitlike properties of schizotypal personality in these data and in other studies of adolescents and adults.
158-1	32103-32105	We	_	
158-2	32106-32109	can	_	
158-3	32110-32115	infer	_	
158-4	32116-32120	that	_	
158-5	32121-32126	these	_	
158-6	32127-32133	medial	_	
158-7	32134-32143	posterior	_	
158-8	32144-32152	cortical	_	
158-9	32153-32158	areas	_	
158-10	32159-32166	matured	_	
158-11	32167-32169	as	_	
158-12	32170-32174	part	_	
158-13	32175-32177	of	_	
158-14	32178-32179	a	_	
158-15	32180-32193	preadolescent	_	
158-16	32194-32198	wave	_	
158-17	32199-32201	of	_	
158-18	32202-32210	cortical	_	
158-19	32211-32222	development	_	
158-20	32222-32223	,	_	
158-21	32224-32229	which	_	
158-22	32230-32235	would	_	
158-23	32236-32238	be	_	
158-24	32239-32249	compatible	_	
158-25	32250-32254	with	_	
158-26	32255-32258	the	_	
158-27	32259-32265	stable	_	
158-28	32265-32266	,	_	
158-29	32267-32276	traitlike	_	
158-30	32277-32287	properties	_	
158-31	32288-32290	of	_	
158-32	32291-32302	schizotypal	_	
158-33	32303-32314	personality	_	
158-34	32315-32317	in	_	
158-35	32318-32323	these	_	
158-36	32324-32328	data	_	
158-37	32329-32332	and	_	
158-38	32333-32335	in	_	
158-39	32336-32341	other	_	
158-40	32342-32349	studies	_	
158-41	32350-32352	of	_	
158-42	32353-32364	adolescents	_	
158-43	32365-32368	and	_	
158-44	32369-32375	adults	_	
158-45	32375-32376	.	_	

#Text=Cortical Gene Expression, Schizotypy-Related Myelination, and Schizophrenia
#Text=We wanted to identify which genes in the whole genome had a cortical expression pattern that was most similar to the cortical map of SRM.
159-1	32377-32385	Cortical	_	
159-2	32386-32390	Gene	_	
159-3	32391-32401	Expression	_	
159-4	32401-32402	,	_	
159-5	32403-32421	Schizotypy-Related	_	
159-6	32422-32433	Myelination	_	
159-7	32433-32434	,	_	
159-8	32435-32438	and	_	
159-9	32439-32452	Schizophrenia	_	
159-10	32453-32455	We	_	
159-11	32456-32462	wanted	_	
159-12	32463-32465	to	_	
159-13	32466-32474	identify	_	
159-14	32475-32480	which	_	
159-15	32481-32486	genes	_	
159-16	32487-32489	in	_	
159-17	32490-32493	the	_	
159-18	32494-32499	whole	_	
159-19	32500-32506	genome	_	
159-20	32507-32510	had	_	
159-21	32511-32512	a	_	
159-22	32513-32521	cortical	_	
159-23	32522-32532	expression	_	
159-24	32533-32540	pattern	_	
159-25	32541-32545	that	_	
159-26	32546-32549	was	_	
159-27	32550-32554	most	_	
159-28	32555-32562	similar	_	
159-29	32563-32565	to	_	
159-30	32566-32569	the	_	
159-31	32570-32578	cortical	_	
159-32	32579-32582	map	_	
159-33	32583-32585	of	_	
159-34	32586-32589	SRM	_	
159-35	32589-32590	.	_	

#Text=A large number (>20,000) of nonindependent statistical tests would be entailed in testing the association between each transcript’s spatially correlated cortical expression map and the cortical map of SRM.
160-1	32591-32592	A	_	
160-2	32593-32598	large	_	
160-3	32599-32605	number	_	
160-4	32606-32607	(	_	
160-5	32607-32608	>	_	
160-6	32608-32614	20,000	_	
160-7	32614-32615	)	_	
160-8	32616-32618	of	_	
160-9	32619-32633	nonindependent	_	
160-10	32634-32645	statistical	_	
160-11	32646-32651	tests	_	
160-12	32652-32657	would	_	
160-13	32658-32660	be	_	
160-14	32661-32669	entailed	_	
160-15	32670-32672	in	_	
160-16	32673-32680	testing	_	
160-17	32681-32684	the	_	
160-18	32685-32696	association	_	
160-19	32697-32704	between	_	
160-20	32705-32709	each	_	
160-21	32710-32720	transcript	_	
160-22	32720-32721	’	_	
160-23	32721-32722	s	_	
160-24	32723-32732	spatially	_	
160-25	32733-32743	correlated	_	
160-26	32744-32752	cortical	_	
160-27	32753-32763	expression	_	
160-28	32764-32767	map	_	
160-29	32768-32771	and	_	
160-30	32772-32775	the	_	
160-31	32776-32784	cortical	_	
160-32	32785-32788	map	_	
160-33	32789-32791	of	_	
160-34	32792-32795	SRM	_	
160-35	32795-32796	.	_	

#Text=Therefore, we favored a multivariate approach and used PLS to identify a cortical pattern of weighted whole-genome expression that was significantly colocated with the SRM map and to identify which particular gene transcripts were most positively or negatively weighted.
161-1	32797-32806	Therefore	_	
161-2	32806-32807	,	_	
161-3	32808-32810	we	_	
161-4	32811-32818	favored	_	
161-5	32819-32820	a	_	
161-6	32821-32833	multivariate	_	
161-7	32834-32842	approach	_	
161-8	32843-32846	and	_	
161-9	32847-32851	used	_	
161-10	32852-32855	PLS	_	
161-11	32856-32858	to	_	
161-12	32859-32867	identify	_	
161-13	32868-32869	a	_	
161-14	32870-32878	cortical	_	
161-15	32879-32886	pattern	_	
161-16	32887-32889	of	_	
161-17	32890-32898	weighted	_	
161-18	32899-32911	whole-genome	_	
161-19	32912-32922	expression	_	
161-20	32923-32927	that	_	
161-21	32928-32931	was	_	
161-22	32932-32945	significantly	_	
161-23	32946-32955	colocated	_	
161-24	32956-32960	with	_	
161-25	32961-32964	the	_	
161-26	32965-32968	SRM	_	
161-27	32969-32972	map	_	
161-28	32973-32976	and	_	
161-29	32977-32979	to	_	
161-30	32980-32988	identify	_	
161-31	32989-32994	which	_	
161-32	32995-33005	particular	_	
161-33	33006-33010	gene	_	
161-34	33011-33022	transcripts	_	
161-35	33023-33027	were	_	
161-36	33028-33032	most	_	
161-37	33033-33043	positively	_	
161-38	33044-33046	or	_	
161-39	33047-33057	negatively	_	
161-40	33058-33066	weighted	_	
161-41	33066-33067	.	_	

#Text=We found that the positively weighted genes (n = 1932) were overexpressed in cortical areas with high levels of SRM, whereas the negatively weighted genes (n = 2153) were overexpressed in cortical areas with low levels of SRM.
162-1	33068-33070	We	_	
162-2	33071-33076	found	_	
162-3	33077-33081	that	_	
162-4	33082-33085	the	_	
162-5	33086-33096	positively	_	
162-6	33097-33105	weighted	_	
162-7	33106-33111	genes	_	
162-8	33112-33113	(	_	
162-9	33113-33114	n	_	
162-10	33114-33115	 	_	
162-11	33115-33116	=	_	
162-12	33117-33121	1932	_	
162-13	33121-33122	)	_	
162-14	33123-33127	were	_	
162-15	33128-33141	overexpressed	_	
162-16	33142-33144	in	_	
162-17	33145-33153	cortical	_	
162-18	33154-33159	areas	_	
162-19	33160-33164	with	_	
162-20	33165-33169	high	_	
162-21	33170-33176	levels	_	
162-22	33177-33179	of	_	
162-23	33180-33183	SRM	_	
162-24	33183-33184	,	_	
162-25	33185-33192	whereas	_	
162-26	33193-33196	the	_	
162-27	33197-33207	negatively	_	
162-28	33208-33216	weighted	_	
162-29	33217-33222	genes	_	
162-30	33223-33224	(	_	
162-31	33224-33225	n	_	
162-32	33225-33226	 	_	
162-33	33226-33227	=	_	
162-34	33228-33232	2153	_	
162-35	33232-33233	)	_	
162-36	33234-33238	were	_	
162-37	33239-33252	overexpressed	_	
162-38	33253-33255	in	_	
162-39	33256-33264	cortical	_	
162-40	33265-33270	areas	_	
162-41	33271-33275	with	_	
162-42	33276-33279	low	_	
162-43	33280-33286	levels	_	
162-44	33287-33289	of	_	
162-45	33290-33293	SRM	_	
162-46	33293-33294	.	_	

#Text=Both positive and negative genes were enriched for neuronal, but not for oligodendroglial, affiliations.
163-1	33295-33299	Both	_	
163-2	33300-33308	positive	_	
163-3	33309-33312	and	_	
163-4	33313-33321	negative	_	
163-5	33322-33327	genes	_	
163-6	33328-33332	were	_	
163-7	33333-33341	enriched	_	
163-8	33342-33345	for	_	
163-9	33346-33354	neuronal	_	
163-10	33354-33355	,	_	
163-11	33356-33359	but	_	
163-12	33360-33363	not	_	
163-13	33364-33367	for	_	
163-14	33368-33384	oligodendroglial	_	
163-15	33384-33385	,	_	
163-16	33386-33398	affiliations	_	
163-17	33398-33399	.	_	

#Text=Positive genes were specifically enriched for PVALB-positive inhibitory interneurons; negative genes were enriched for astrocytes and microglia.
164-1	33400-33408	Positive	_	
164-2	33409-33414	genes	_	
164-3	33415-33419	were	_	
164-4	33420-33432	specifically	_	
164-5	33433-33441	enriched	_	
164-6	33442-33445	for	_	
164-7	33446-33460	PVALB-positive	_	
164-8	33461-33471	inhibitory	_	
164-9	33472-33484	interneurons	_	
164-10	33484-33485	;	_	
164-11	33486-33494	negative	_	
164-12	33495-33500	genes	_	
164-13	33501-33505	were	_	
164-14	33506-33514	enriched	_	
164-15	33515-33518	for	_	
164-16	33519-33529	astrocytes	_	
164-17	33530-33533	and	_	
164-18	33534-33543	microglia	_	
164-19	33543-33544	.	_	

#Text=We predicted hypothetically that the SRM gene set would be enriched for genes that are known to be transcriptionally dysregulated in schizophrenia.
165-1	33545-33547	We	_	
165-2	33548-33557	predicted	_	
165-3	33558-33572	hypothetically	_	
165-4	33573-33577	that	_	
165-5	33578-33581	the	_	
165-6	33582-33585	SRM	_	
165-7	33586-33590	gene	_	
165-8	33591-33594	set	_	
165-9	33595-33600	would	_	
165-10	33601-33603	be	_	
165-11	33604-33612	enriched	_	
165-12	33613-33616	for	_	
165-13	33617-33622	genes	_	
165-14	33623-33627	that	_	
165-15	33628-33631	are	_	
165-16	33632-33637	known	_	
165-17	33638-33640	to	_	
165-18	33641-33643	be	_	
165-19	33644-33661	transcriptionally	_	
165-20	33662-33674	dysregulated	_	
165-21	33675-33677	in	_	
165-22	33678-33691	schizophrenia	_	
165-23	33691-33692	.	_	

#Text=This prediction was supported by convergent results from enrichment analysis using two prior, independently discovered, and partially overlapping lists of genes differentially expressed in postmortem case-control studies of schizophrenia.
166-1	33693-33697	This	_	
166-2	33698-33708	prediction	_	
166-3	33709-33712	was	_	
166-4	33713-33722	supported	_	
166-5	33723-33725	by	_	
166-6	33726-33736	convergent	_	
166-7	33737-33744	results	_	
166-8	33745-33749	from	_	
166-9	33750-33760	enrichment	_	
166-10	33761-33769	analysis	_	
166-11	33770-33775	using	_	
166-12	33776-33779	two	_	
166-13	33780-33785	prior	_	
166-14	33785-33786	,	_	
166-15	33787-33800	independently	_	
166-16	33801-33811	discovered	_	
166-17	33811-33812	,	_	
166-18	33813-33816	and	_	
166-19	33817-33826	partially	_	
166-20	33827-33838	overlapping	_	
166-21	33839-33844	lists	_	
166-22	33845-33847	of	_	
166-23	33848-33853	genes	_	
166-24	33854-33868	differentially	_	
166-25	33869-33878	expressed	_	
166-26	33879-33881	in	_	
166-27	33882-33892	postmortem	_	
166-28	33893-33905	case-control	_	
166-29	33906-33913	studies	_	
166-30	33914-33916	of	_	
166-31	33917-33930	schizophrenia	_	
166-32	33930-33931	.	_	

#Text=In both cases, there were significantly more histologically downregulated genes in the list of positively weighted SRM genes, and significantly more upregulated genes in the list of negatively weighted SRM genes, than expected by chance.
167-1	33932-33934	In	_	
167-2	33935-33939	both	_	
167-3	33940-33945	cases	_	
167-4	33945-33946	,	_	
167-5	33947-33952	there	_	
167-6	33953-33957	were	_	
167-7	33958-33971	significantly	_	
167-8	33972-33976	more	_	
167-9	33977-33991	histologically	_	
167-10	33992-34005	downregulated	_	
167-11	34006-34011	genes	_	
167-12	34012-34014	in	_	
167-13	34015-34018	the	_	
167-14	34019-34023	list	_	
167-15	34024-34026	of	_	
167-16	34027-34037	positively	_	
167-17	34038-34046	weighted	_	
167-18	34047-34050	SRM	_	
167-19	34051-34056	genes	_	
167-20	34056-34057	,	_	
167-21	34058-34061	and	_	
167-22	34062-34075	significantly	_	
167-23	34076-34080	more	_	
167-24	34081-34092	upregulated	_	
167-25	34093-34098	genes	_	
167-26	34099-34101	in	_	
167-27	34102-34105	the	_	
167-28	34106-34110	list	_	
167-29	34111-34113	of	_	
167-30	34114-34124	negatively	_	
167-31	34125-34133	weighted	_	
167-32	34134-34137	SRM	_	
167-33	34138-34143	genes	_	
167-34	34143-34144	,	_	
167-35	34145-34149	than	_	
167-36	34150-34158	expected	_	
167-37	34159-34161	by	_	
167-38	34162-34168	chance	_	
167-39	34168-34169	.	_	

#Text=In other words, genes with reduced brain transcription postmortem in schizophrenia were normally more highly expressed in cortical areas with higher levels of SRM.
168-1	34170-34172	In	_	
168-2	34173-34178	other	_	
168-3	34179-34184	words	_	
168-4	34184-34185	,	_	
168-5	34186-34191	genes	_	
168-6	34192-34196	with	_	
168-7	34197-34204	reduced	_	
168-8	34205-34210	brain	_	
168-9	34211-34224	transcription	_	
168-10	34225-34235	postmortem	_	
168-11	34236-34238	in	_	
168-12	34239-34252	schizophrenia	_	
168-13	34253-34257	were	_	
168-14	34258-34266	normally	_	
168-15	34267-34271	more	_	
168-16	34272-34278	highly	_	
168-17	34279-34288	expressed	_	
168-18	34289-34291	in	_	
168-19	34292-34300	cortical	_	
168-20	34301-34306	areas	_	
168-21	34307-34311	with	_	
168-22	34312-34318	higher	_	
168-23	34319-34325	levels	_	
168-24	34326-34328	of	_	
168-25	34329-34332	SRM	_	
168-26	34332-34333	.	_	

#Text=A subset of the positively weighted SRM genes has been previously associated with white matter dysconnectivity in schizophrenia, suggesting that SRM of cortex and schizophrenia-related disruption of central white matter tracts may be different imaging phenotypes related to expression of genes in common.
169-1	34334-34335	A	_	
169-2	34336-34342	subset	_	
169-3	34343-34345	of	_	
169-4	34346-34349	the	_	
169-5	34350-34360	positively	_	
169-6	34361-34369	weighted	_	
169-7	34370-34373	SRM	_	
169-8	34374-34379	genes	_	
169-9	34380-34383	has	_	
169-10	34384-34388	been	_	
169-11	34389-34399	previously	_	
169-12	34400-34410	associated	_	
169-13	34411-34415	with	_	
169-14	34416-34421	white	_	
169-15	34422-34428	matter	_	
169-16	34429-34444	dysconnectivity	_	
169-17	34445-34447	in	_	
169-18	34448-34461	schizophrenia	_	
169-19	34461-34462	,	_	
169-20	34463-34473	suggesting	_	
169-21	34474-34478	that	_	
169-22	34479-34482	SRM	_	
169-23	34483-34485	of	_	
169-24	34486-34492	cortex	_	
169-25	34493-34496	and	_	
169-26	34497-34518	schizophrenia-related	_	
169-27	34519-34529	disruption	_	
169-28	34530-34532	of	_	
169-29	34533-34540	central	_	
169-30	34541-34546	white	_	
169-31	34547-34553	matter	_	
169-32	34554-34560	tracts	_	
169-33	34561-34564	may	_	
169-34	34565-34567	be	_	
169-35	34568-34577	different	_	
169-36	34578-34585	imaging	_	
169-37	34586-34596	phenotypes	_	
169-38	34597-34604	related	_	
169-39	34605-34607	to	_	
169-40	34608-34618	expression	_	
169-41	34619-34621	of	_	
169-42	34622-34627	genes	_	
169-43	34628-34630	in	_	
169-44	34631-34637	common	_	
169-45	34637-34638	.	_	

#Text=The subset of 213 SRM-positive genes that were also significantly downregulated in one or both of the prior histological studies coded for a protein-protein interaction network comprising a small number of highly connected hub proteins (ACTN4 [alpha-actinin-4], CAMK2G [calcium/calmodulin-dependent protein kinase II gamma], PPP3CC [protein phosphatase 3 catalytic subunit gamma], and PVALB), each hub having up to 14 known biochemical interactions with other proteins in the network.
170-1	34639-34642	The	_	
170-2	34643-34649	subset	_	
170-3	34650-34652	of	_	
170-4	34653-34656	213	_	
170-5	34657-34669	SRM-positive	_	
170-6	34670-34675	genes	_	
170-7	34676-34680	that	_	
170-8	34681-34685	were	_	
170-9	34686-34690	also	_	
170-10	34691-34704	significantly	_	
170-11	34705-34718	downregulated	_	
170-12	34719-34721	in	_	
170-13	34722-34725	one	_	
170-14	34726-34728	or	_	
170-15	34729-34733	both	_	
170-16	34734-34736	of	_	
170-17	34737-34740	the	_	
170-18	34741-34746	prior	_	
170-19	34747-34759	histological	_	
170-20	34760-34767	studies	_	
170-21	34768-34773	coded	_	
170-22	34774-34777	for	_	
170-23	34778-34779	a	_	
170-24	34780-34795	protein-protein	_	
170-25	34796-34807	interaction	_	
170-26	34808-34815	network	_	
170-27	34816-34826	comprising	_	
170-28	34827-34828	a	_	
170-29	34829-34834	small	_	
170-30	34835-34841	number	_	
170-31	34842-34844	of	_	
170-32	34845-34851	highly	_	
170-33	34852-34861	connected	_	
170-34	34862-34865	hub	_	
170-35	34866-34874	proteins	_	
170-36	34875-34876	(	_	
170-37	34876-34881	ACTN4	_	
170-38	34882-34883	[	_	
170-39	34883-34896	alpha-actinin	_	
170-40	34896-34897	-	_	
170-41	34897-34898	4	_	
170-42	34898-34899	]	_	
170-43	34899-34900	,	_	
170-44	34901-34907	CAMK2G	_	
170-45	34908-34909	[	_	
170-46	34909-34916	calcium	_	
170-47	34916-34917	/	_	
170-48	34917-34937	calmodulin-dependent	_	
170-49	34938-34945	protein	_	
170-50	34946-34952	kinase	_	
170-51	34953-34955	II	_	
170-52	34956-34961	gamma	_	
170-53	34961-34962	]	_	
170-54	34962-34963	,	_	
170-55	34964-34970	PPP3CC	_	
170-56	34971-34972	[	_	
170-57	34972-34979	protein	_	
170-58	34980-34991	phosphatase	_	
170-59	34992-34993	3	_	
170-60	34994-35003	catalytic	_	
170-61	35004-35011	subunit	_	
170-62	35012-35017	gamma	_	
170-63	35017-35018	]	_	
170-64	35018-35019	,	_	
170-65	35020-35023	and	_	
170-66	35024-35029	PVALB	_	
170-67	35029-35030	)	_	
170-68	35030-35031	,	_	
170-69	35032-35036	each	_	
170-70	35037-35040	hub	_	
170-71	35041-35047	having	_	
170-72	35048-35050	up	_	
170-73	35051-35053	to	_	
170-74	35054-35056	14	_	
170-75	35057-35062	known	_	
170-76	35063-35074	biochemical	_	
170-77	35075-35087	interactions	_	
170-78	35088-35092	with	_	
170-79	35093-35098	other	_	
170-80	35099-35107	proteins	_	
170-81	35108-35110	in	_	
170-82	35111-35114	the	_	
170-83	35115-35122	network	_	
170-84	35122-35123	.	_	

#Text=CAMK2G is one of a family of serine/threonine kinases that mediate many of the second messenger effects of Ca2+ that are crucial for plasticity at glutamatergic synapses.
171-1	35124-35130	CAMK2G	_	
171-2	35131-35133	is	_	
171-3	35134-35137	one	_	
171-4	35138-35140	of	_	
171-5	35141-35142	a	_	
171-6	35143-35149	family	_	
171-7	35150-35152	of	_	
171-8	35153-35159	serine	_	
171-9	35159-35160	/	_	
171-10	35160-35169	threonine	_	
171-11	35170-35177	kinases	_	
171-12	35178-35182	that	_	
171-13	35183-35190	mediate	_	
171-14	35191-35195	many	_	
171-15	35196-35198	of	_	
171-16	35199-35202	the	_	
171-17	35203-35209	second	_	
171-18	35210-35219	messenger	_	
171-19	35220-35227	effects	_	
171-20	35228-35230	of	_	
171-21	35231-35234	Ca2	_	
171-22	35234-35235	+	_	
171-23	35236-35240	that	_	
171-24	35241-35244	are	_	
171-25	35245-35252	crucial	_	
171-26	35253-35256	for	_	
171-27	35257-35267	plasticity	_	
171-28	35268-35270	at	_	
171-29	35271-35284	glutamatergic	_	
171-30	35285-35293	synapses	_	
171-31	35293-35294	.	_	

#Text=PVALB is a calcium-binding albumin protein that is expressed particularly by the fast-spiking class of GABAergic (gamma-aminobutyric acidergic) interneurons that has been strongly implicated in the pathogenesis of schizophrenia (Figure 4).
172-1	35295-35300	PVALB	_	
172-2	35301-35303	is	_	
172-3	35304-35305	a	_	
172-4	35306-35321	calcium-binding	_	
172-5	35322-35329	albumin	_	
172-6	35330-35337	protein	_	
172-7	35338-35342	that	_	
172-8	35343-35345	is	_	
172-9	35346-35355	expressed	_	
172-10	35356-35368	particularly	_	
172-11	35369-35371	by	_	
172-12	35372-35375	the	_	
172-13	35376-35388	fast-spiking	_	
172-14	35389-35394	class	_	
172-15	35395-35397	of	_	
172-16	35398-35407	GABAergic	_	
172-17	35408-35409	(	_	
172-18	35409-35427	gamma-aminobutyric	_	
172-19	35428-35437	acidergic	_	
172-20	35437-35438	)	_	
172-21	35439-35451	interneurons	_	
172-22	35452-35456	that	_	
172-23	35457-35460	has	_	
172-24	35461-35465	been	_	
172-25	35466-35474	strongly	_	
172-26	35475-35485	implicated	_	
172-27	35486-35488	in	_	
172-28	35489-35492	the	_	
172-29	35493-35505	pathogenesis	_	
172-30	35506-35508	of	_	
172-31	35509-35522	schizophrenia	_	
172-32	35523-35524	(	_	
172-33	35524-35530	Figure	_	
172-34	35530-35531	 	_	
172-35	35531-35532	4	_	
172-36	35532-35533	)	_	
172-37	35533-35534	.	_	

#Text=We found that the SRM gene list was also enriched by genes differentially expressed in ASD and BPD.
173-1	35535-35537	We	_	
173-2	35538-35543	found	_	
173-3	35544-35548	that	_	
173-4	35549-35552	the	_	
173-5	35553-35556	SRM	_	
173-6	35557-35561	gene	_	
173-7	35562-35566	list	_	
173-8	35567-35570	was	_	
173-9	35571-35575	also	_	
173-10	35576-35584	enriched	_	
173-11	35585-35587	by	_	
173-12	35588-35593	genes	_	
173-13	35594-35608	differentially	_	
173-14	35609-35618	expressed	_	
173-15	35619-35621	in	_	
173-16	35622-35625	ASD	_	
173-17	35626-35629	and	_	
173-18	35630-35633	BPD	_	
173-19	35633-35634	.	_	

#Text=These results are consistent with the postmortem evidence that the differential gene expression profile of schizophrenia (compared with healthy controls) is strongly correlated with the case-control differences of transcription in BPD and ASD (ρ > .45, p < .001).
174-1	35635-35640	These	_	
174-2	35641-35648	results	_	
174-3	35649-35652	are	_	
174-4	35653-35663	consistent	_	
174-5	35664-35668	with	_	
174-6	35669-35672	the	_	
174-7	35673-35683	postmortem	_	
174-8	35684-35692	evidence	_	
174-9	35693-35697	that	_	
174-10	35698-35701	the	_	
174-11	35702-35714	differential	_	
174-12	35715-35719	gene	_	
174-13	35720-35730	expression	_	
174-14	35731-35738	profile	_	
174-15	35739-35741	of	_	
174-16	35742-35755	schizophrenia	_	
174-17	35756-35757	(	_	
174-18	35757-35765	compared	_	
174-19	35766-35770	with	_	
174-20	35771-35778	healthy	_	
174-21	35779-35787	controls	_	
174-22	35787-35788	)	_	
174-23	35789-35791	is	_	
174-24	35792-35800	strongly	_	
174-25	35801-35811	correlated	_	
174-26	35812-35816	with	_	
174-27	35817-35820	the	_	
174-28	35821-35833	case-control	_	
174-29	35834-35845	differences	_	
174-30	35846-35848	of	_	
174-31	35849-35862	transcription	_	
174-32	35863-35865	in	_	
174-33	35866-35869	BPD	_	
174-34	35870-35873	and	_	
174-35	35874-35877	ASD	_	
174-36	35878-35879	(	_	
174-37	35879-35880	ρ	_	
174-38	35881-35882	>	_	
174-39	35883-35886	.45	_	
174-40	35886-35887	,	_	
174-41	35888-35889	p	_	
174-42	35890-35891	<	_	
174-43	35892-35896	.001	_	
174-44	35896-35897	)	_	
174-45	35897-35898	.	_	

#Text=They are also consistent with clinical evidence that both ASD and BPD are associated with increased schizotypal traits.
175-1	35899-35903	They	_	
175-2	35904-35907	are	_	
175-3	35908-35912	also	_	
175-4	35913-35923	consistent	_	
175-5	35924-35928	with	_	
175-6	35929-35937	clinical	_	
175-7	35938-35946	evidence	_	
175-8	35947-35951	that	_	
175-9	35952-35956	both	_	
175-10	35957-35960	ASD	_	
175-11	35961-35964	and	_	
175-12	35965-35968	BPD	_	
175-13	35969-35972	are	_	
175-14	35973-35983	associated	_	
175-15	35984-35988	with	_	
175-16	35989-35998	increased	_	
175-17	35999-36010	schizotypal	_	
175-18	36011-36017	traits	_	
175-19	36017-36018	.	_	

#Text=Methodological Issues
#Text=The brain tissue samples used for RNA sequencing in the AHBA were not homogeneously distributed across the cortex, so estimates of regional expression are based on different numbers of experimental measurements in each of the 68 regions.
176-1	36019-36033	Methodological	_	
176-2	36034-36040	Issues	_	
176-3	36041-36044	The	_	
176-4	36045-36050	brain	_	
176-5	36051-36057	tissue	_	
176-6	36058-36065	samples	_	
176-7	36066-36070	used	_	
176-8	36071-36074	for	_	
176-9	36075-36078	RNA	_	
176-10	36079-36089	sequencing	_	
176-11	36090-36092	in	_	
176-12	36093-36096	the	_	
176-13	36097-36101	AHBA	_	
176-14	36102-36106	were	_	
176-15	36107-36110	not	_	
176-16	36111-36124	homogeneously	_	
176-17	36125-36136	distributed	_	
176-18	36137-36143	across	_	
176-19	36144-36147	the	_	
176-20	36148-36154	cortex	_	
176-21	36154-36155	,	_	
176-22	36156-36158	so	_	
176-23	36159-36168	estimates	_	
176-24	36169-36171	of	_	
176-25	36172-36180	regional	_	
176-26	36181-36191	expression	_	
176-27	36192-36195	are	_	
176-28	36196-36201	based	_	
176-29	36202-36204	on	_	
176-30	36205-36214	different	_	
176-31	36215-36222	numbers	_	
176-32	36223-36225	of	_	
176-33	36226-36238	experimental	_	
176-34	36239-36251	measurements	_	
176-35	36252-36254	in	_	
176-36	36255-36259	each	_	
176-37	36260-36262	of	_	
176-38	36263-36266	the	_	
176-39	36267-36269	68	_	
176-40	36270-36277	regions	_	
176-41	36277-36278	.	_	

#Text=The case-control differences in frontal or parietal lobar gene transcription reported by Gandal et al. and Fromer et al., although based on a relatively large number of patients, are not as precisely localized or representative of the whole brain as the AHBA and MRI data.
177-1	36279-36282	The	_	
177-2	36283-36295	case-control	_	
177-3	36296-36307	differences	_	
177-4	36308-36310	in	_	
177-5	36311-36318	frontal	_	
177-6	36319-36321	or	_	
177-7	36322-36330	parietal	_	
177-8	36331-36336	lobar	_	
177-9	36337-36341	gene	_	
177-10	36342-36355	transcription	_	
177-11	36356-36364	reported	_	
177-12	36365-36367	by	_	
177-13	36368-36374	Gandal	_	
177-14	36375-36377	et	_	
177-15	36377-36378	 	_	
177-16	36378-36380	al	_	
177-17	36380-36381	.	_	
177-18	36382-36385	and	_	
177-19	36386-36392	Fromer	_	
177-20	36393-36395	et	_	
177-21	36395-36396	 	_	
177-22	36396-36398	al	_	
177-23	36398-36399	.	_	
177-24	36399-36400	,	_	
177-25	36401-36409	although	_	
177-26	36410-36415	based	_	
177-27	36416-36418	on	_	
177-28	36419-36420	a	_	
177-29	36421-36431	relatively	_	
177-30	36432-36437	large	_	
177-31	36438-36444	number	_	
177-32	36445-36447	of	_	
177-33	36448-36456	patients	_	
177-34	36456-36457	,	_	
177-35	36458-36461	are	_	
177-36	36462-36465	not	_	
177-37	36466-36468	as	_	
177-38	36469-36478	precisely	_	
177-39	36479-36488	localized	_	
177-40	36489-36491	or	_	
177-41	36492-36506	representative	_	
177-42	36507-36509	of	_	
177-43	36510-36513	the	_	
177-44	36514-36519	whole	_	
177-45	36520-36525	brain	_	
177-46	36526-36528	as	_	
177-47	36529-36532	the	_	
177-48	36533-36537	AHBA	_	
177-49	36538-36541	and	_	
177-50	36542-36545	MRI	_	
177-51	36546-36550	data	_	
177-52	36550-36551	.	_	

#Text=This study has a considerably larger sample size than any previously reported MRI study of schizotypy, and it is the first to evaluate a microstructural MRI marker, which was more strongly related to schizotypy than the more conventional macrostructural MRI marker of cortical thickness.
178-1	36552-36556	This	_	
178-2	36557-36562	study	_	
178-3	36563-36566	has	_	
178-4	36567-36568	a	_	
178-5	36569-36581	considerably	_	
178-6	36582-36588	larger	_	
178-7	36589-36595	sample	_	
178-8	36596-36600	size	_	
178-9	36601-36605	than	_	
178-10	36606-36609	any	_	
178-11	36610-36620	previously	_	
178-12	36621-36629	reported	_	
178-13	36630-36633	MRI	_	
178-14	36634-36639	study	_	
178-15	36640-36642	of	_	
178-16	36643-36653	schizotypy	_	
178-17	36653-36654	,	_	
178-18	36655-36658	and	_	
178-19	36659-36661	it	_	
178-20	36662-36664	is	_	
178-21	36665-36668	the	_	
178-22	36669-36674	first	_	
178-23	36675-36677	to	_	
178-24	36678-36686	evaluate	_	
178-25	36687-36688	a	_	
178-26	36689-36704	microstructural	_	
178-27	36705-36708	MRI	_	
178-28	36709-36715	marker	_	
178-29	36715-36716	,	_	
178-30	36717-36722	which	_	
178-31	36723-36726	was	_	
178-32	36727-36731	more	_	
178-33	36732-36740	strongly	_	
178-34	36741-36748	related	_	
178-35	36749-36751	to	_	
178-36	36752-36762	schizotypy	_	
178-37	36763-36767	than	_	
178-38	36768-36771	the	_	
178-39	36772-36776	more	_	
178-40	36777-36789	conventional	_	
178-41	36790-36805	macrostructural	_	
178-42	36806-36809	MRI	_	
178-43	36810-36816	marker	_	
178-44	36817-36819	of	_	
178-45	36820-36828	cortical	_	
178-46	36829-36838	thickness	_	
178-47	36838-36839	.	_	

#Text=Nonetheless, it is theoretically surprising that there was limited evidence for significant SRM of the frontal and lateral temporal cortex (although magnetization of the medial prefrontal cortex was significantly associated with the disorganized component of schizotypy) (Figure 1E), possibly reflecting limited statistical power.
179-1	36840-36851	Nonetheless	_	
179-2	36851-36852	,	_	
179-3	36853-36855	it	_	
179-4	36856-36858	is	_	
179-5	36859-36872	theoretically	_	
179-6	36873-36883	surprising	_	
179-7	36884-36888	that	_	
179-8	36889-36894	there	_	
179-9	36895-36898	was	_	
179-10	36899-36906	limited	_	
179-11	36907-36915	evidence	_	
179-12	36916-36919	for	_	
179-13	36920-36931	significant	_	
179-14	36932-36935	SRM	_	
179-15	36936-36938	of	_	
179-16	36939-36942	the	_	
179-17	36943-36950	frontal	_	
179-18	36951-36954	and	_	
179-19	36955-36962	lateral	_	
179-20	36963-36971	temporal	_	
179-21	36972-36978	cortex	_	
179-22	36979-36980	(	_	
179-23	36980-36988	although	_	
179-24	36989-37002	magnetization	_	
179-25	37003-37005	of	_	
179-26	37006-37009	the	_	
179-27	37010-37016	medial	_	
179-28	37017-37027	prefrontal	_	
179-29	37028-37034	cortex	_	
179-30	37035-37038	was	_	
179-31	37039-37052	significantly	_	
179-32	37053-37063	associated	_	
179-33	37064-37068	with	_	
179-34	37069-37072	the	_	
179-35	37073-37085	disorganized	_	
179-36	37086-37095	component	_	
179-37	37096-37098	of	_	
179-38	37099-37109	schizotypy	_	
179-39	37109-37110	)	_	
179-40	37111-37112	(	_	
179-41	37112-37118	Figure	_	
179-42	37118-37119	 	_	
179-43	37119-37121	1E	_	
179-44	37121-37122	)	_	
179-45	37122-37123	,	_	
179-46	37124-37132	possibly	_	
179-47	37133-37143	reflecting	_	
179-48	37144-37151	limited	_	
179-49	37152-37163	statistical	_	
179-50	37164-37169	power	_	
179-51	37169-37170	.	_	

#Text=The SPQ is a self-report questionnaire measure of schizotypy; more refined and objective assessments of schizotypal traits would likely add value to future studies.
180-1	37171-37174	The	_	
180-2	37175-37178	SPQ	_	
180-3	37179-37181	is	_	
180-4	37182-37183	a	_	
180-5	37184-37195	self-report	_	
180-6	37196-37209	questionnaire	_	
180-7	37210-37217	measure	_	
180-8	37218-37220	of	_	
180-9	37221-37231	schizotypy	_	
180-10	37231-37232	;	_	
180-11	37233-37237	more	_	
180-12	37238-37245	refined	_	
180-13	37246-37249	and	_	
180-14	37250-37259	objective	_	
180-15	37260-37271	assessments	_	
180-16	37272-37274	of	_	
180-17	37275-37286	schizotypal	_	
180-18	37287-37293	traits	_	
180-19	37294-37299	would	_	
180-20	37300-37306	likely	_	
180-21	37307-37310	add	_	
180-22	37311-37316	value	_	
180-23	37317-37319	to	_	
180-24	37320-37326	future	_	
180-25	37327-37334	studies	_	
180-26	37334-37335	.	_	

#Text=Conclusions
#Text=Overall, these correlational results do not unambiguously resolve questions of causality, but they are consistent with the interpretation that SRM, putatively an imaging marker of intracortical density of myelinated neurons, represents cellular processes determined in part by transcription of genes related to schizophrenia and other neuropsychiatric disorders.
181-1	37336-37347	Conclusions	_	
181-2	37348-37355	Overall	_	
181-3	37355-37356	,	_	
181-4	37357-37362	these	_	
181-5	37363-37376	correlational	_	
181-6	37377-37384	results	_	
181-7	37385-37387	do	_	
181-8	37388-37391	not	_	
181-9	37392-37405	unambiguously	_	
181-10	37406-37413	resolve	_	
181-11	37414-37423	questions	_	
181-12	37424-37426	of	_	
181-13	37427-37436	causality	_	
181-14	37436-37437	,	_	
181-15	37438-37441	but	_	
181-16	37442-37446	they	_	
181-17	37447-37450	are	_	
181-18	37451-37461	consistent	_	
181-19	37462-37466	with	_	
181-20	37467-37470	the	_	
181-21	37471-37485	interpretation	_	
181-22	37486-37490	that	_	
181-23	37491-37494	SRM	_	
181-24	37494-37495	,	_	
181-25	37496-37506	putatively	_	
181-26	37507-37509	an	_	
181-27	37510-37517	imaging	_	
181-28	37518-37524	marker	_	
181-29	37525-37527	of	_	
181-30	37528-37541	intracortical	_	
181-31	37542-37549	density	_	
181-32	37550-37552	of	_	
181-33	37553-37563	myelinated	_	
181-34	37564-37571	neurons	_	
181-35	37571-37572	,	_	
181-36	37573-37583	represents	_	
181-37	37584-37592	cellular	_	
181-38	37593-37602	processes	_	
181-39	37603-37613	determined	_	
181-40	37614-37616	in	_	
181-41	37617-37621	part	_	
181-42	37622-37624	by	_	
181-43	37625-37638	transcription	_	
181-44	37639-37641	of	_	
181-45	37642-37647	genes	_	
181-46	37648-37655	related	_	
181-47	37656-37658	to	_	
181-48	37659-37672	schizophrenia	_	
181-49	37673-37676	and	_	
181-50	37677-37682	other	_	
181-51	37683-37699	neuropsychiatric	_	
181-52	37700-37709	disorders	_	
181-53	37709-37710	.	_	

#Text=References
#Text=Genetic consideration of schizotypal traits: A review
#Text=Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients
#Text=Biological insights from 108 schizophrenia-associated genetic loci
#Text=Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
#Text=Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap
#Text=Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls
#Text=Trends and properties of human cerebral cortex: Correlations with cortical myelin content
#Text=Quantitative multi-parameter mapping of R1, PD(*), MT, and R2(*) at 3T: A multi-center validation
#Text=Gray matter myelination of 1555 human brains using partial volume corrected MRI images
#Text=The radial diffusivity and magnetization transfer pool size ratio are sensitive markers for demyelination in a rat model of type III multiple sclerosis (MS) lesions
#Text=Magnetization transfer SWIFT MRI consistently detects histologically verified myelin loss in the thalamocortical pathway after a traumatic brain injury in rat
#Text=In vivo quantitative magnetization transfer imaging correlates with histology during de- and remyelination in cuprizone-treated mice
#Text=Monitoring demyelination and remyelination by magnetization transfer imaging in the mouse brain at 9.4 T
#Text=Die myeloarchitektonische Felderung des menschlichen Stirnhirns
#Text=Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome
#Text=Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups
#Text=Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis
#Text=Surface-based analysis reveals regions of reduced cortical magnetization transfer ratio in patients with multiple sclerosis: A proposed method for imaging subpial demyelination
#Text=Neuropathological abnormalities in schizophrenia: Evidence from magnetization transfer imaging
#Text=Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging
#Text=Myelin and axon abnormalities in schizophrenia measured with magnetic resonance imaging techniques
#Text=DTI and MTR abnormalities in schizophrenia: Analysis of white matter integrity
#Text=DTI and MTR abnormalities in schizophrenia — Voxel wise analysis of white matter integrity
#Text=Combined white matter imaging suggests myelination defects in visual processing regions in schizophrenia
#Text=Magnetization transfer imaging in chronic schizophrenia
#Text=Cortical magnetization transfer abnormalities and connectome dysconnectivity in schizophrenia
#Text=Hierarchy of transcriptomic specialization across human cortex captured by structural neuroimaging topography
#Text=Cohort profile: The NSPN 2400 Cohort: A developmental sample supporting the Wellcome Trust Neuro Science in Psychiatry Network
#Text=The SPQ: A scale for the assessment of schizotypal personality based on DSM-III-R criteria
#Text=Morphometric similarity networks detect microscale cortical organization and predict inter-individual cognitive variation
#Text=Adolescent tuning of association cortex in human structural brain networks
#Text=Quantitative assessment of structural image quality
#Text=An anatomically comprehensive atlas of the adult human brain transcriptome
#Text=A practical guide to linking brain-wide gene expression and neuroimaging data
#Text=Re-Annotator: Annotation pipeline for microarray probe sequences
#Text=BRAIN NETWORKS.
182-1	37711-37721	References	_	
182-2	37722-37729	Genetic	_	
182-3	37730-37743	consideration	_	
182-4	37744-37746	of	_	
182-5	37747-37758	schizotypal	_	
182-6	37759-37765	traits	_	
182-7	37765-37766	:	_	
182-8	37767-37768	A	_	
182-9	37769-37775	review	_	
182-10	37776-37784	Multiple	_	
182-11	37785-37795	dimensions	_	
182-12	37796-37798	of	_	
182-13	37799-37809	schizotypy	_	
182-14	37810-37812	in	_	
182-15	37813-37818	first	_	
182-16	37819-37825	degree	_	
182-17	37826-37836	biological	_	
182-18	37837-37846	relatives	_	
182-19	37847-37849	of	_	
182-20	37850-37863	schizophrenia	_	
182-21	37864-37872	patients	_	
182-22	37873-37883	Biological	_	
182-23	37884-37892	insights	_	
182-24	37893-37897	from	_	
182-25	37898-37901	108	_	
182-26	37902-37926	schizophrenia-associated	_	
182-27	37927-37934	genetic	_	
182-28	37935-37939	loci	_	
182-29	37940-37946	Common	_	
182-30	37947-37956	polygenic	_	
182-31	37957-37966	variation	_	
182-32	37967-37978	contributes	_	
182-33	37979-37981	to	_	
182-34	37982-37986	risk	_	
182-35	37987-37989	of	_	
182-36	37990-38003	schizophrenia	_	
182-37	38004-38007	and	_	
182-38	38008-38015	bipolar	_	
182-39	38016-38024	disorder	_	
182-40	38025-38031	Shared	_	
182-41	38032-38041	molecular	_	
182-42	38042-38056	neuropathology	_	
182-43	38057-38063	across	_	
182-44	38064-38069	major	_	
182-45	38070-38081	psychiatric	_	
182-46	38082-38091	disorders	_	
182-47	38092-38101	parallels	_	
182-48	38102-38111	polygenic	_	
182-49	38112-38119	overlap	_	
182-50	38120-38132	Associations	_	
182-51	38133-38135	of	_	
182-52	38136-38144	cortical	_	
182-53	38145-38154	thickness	_	
182-54	38155-38158	and	_	
182-55	38159-38168	cognition	_	
182-56	38169-38171	in	_	
182-57	38172-38180	patients	_	
182-58	38181-38185	with	_	
182-59	38186-38199	schizophrenia	_	
182-60	38200-38203	and	_	
182-61	38204-38211	healthy	_	
182-62	38212-38220	controls	_	
182-63	38221-38227	Trends	_	
182-64	38228-38231	and	_	
182-65	38232-38242	properties	_	
182-66	38243-38245	of	_	
182-67	38246-38251	human	_	
182-68	38252-38260	cerebral	_	
182-69	38261-38267	cortex	_	
182-70	38267-38268	:	_	
182-71	38269-38281	Correlations	_	
182-72	38282-38286	with	_	
182-73	38287-38295	cortical	_	
182-74	38296-38302	myelin	_	
182-75	38303-38310	content	_	
182-76	38311-38323	Quantitative	_	
182-77	38324-38339	multi-parameter	_	
182-78	38340-38347	mapping	_	
182-79	38348-38350	of	_	
182-80	38351-38353	R1	_	
182-81	38353-38354	,	_	
182-82	38355-38357	PD	_	
182-83	38357-38358	(	_	
182-84	38358-38359	*	_	
182-85	38359-38360	)	_	
182-86	38360-38361	,	_	
182-87	38362-38364	MT	_	
182-88	38364-38365	,	_	
182-89	38366-38369	and	_	
182-90	38370-38372	R2	_	
182-91	38372-38373	(	_	
182-92	38373-38374	*	_	
182-93	38374-38375	)	_	
182-94	38376-38378	at	_	
182-95	38379-38381	3T	_	
182-96	38381-38382	:	_	
182-97	38383-38384	A	_	
182-98	38385-38397	multi-center	_	
182-99	38398-38408	validation	_	
182-100	38409-38413	Gray	_	
182-101	38414-38420	matter	_	
182-102	38421-38432	myelination	_	
182-103	38433-38435	of	_	
182-104	38436-38440	1555	_	
182-105	38441-38446	human	_	
182-106	38447-38453	brains	_	
182-107	38454-38459	using	_	
182-108	38460-38467	partial	_	
182-109	38468-38474	volume	_	
182-110	38475-38484	corrected	_	
182-111	38485-38488	MRI	_	
182-112	38489-38495	images	_	
182-113	38496-38499	The	_	
182-114	38500-38506	radial	_	
182-115	38507-38518	diffusivity	_	
182-116	38519-38522	and	_	
182-117	38523-38536	magnetization	_	
182-118	38537-38545	transfer	_	
182-119	38546-38550	pool	_	
182-120	38551-38555	size	_	
182-121	38556-38561	ratio	_	
182-122	38562-38565	are	_	
182-123	38566-38575	sensitive	_	
182-124	38576-38583	markers	_	
182-125	38584-38587	for	_	
182-126	38588-38601	demyelination	_	
182-127	38602-38604	in	_	
182-128	38605-38606	a	_	
182-129	38607-38610	rat	_	
182-130	38611-38616	model	_	
182-131	38617-38619	of	_	
182-132	38620-38624	type	_	
182-133	38625-38628	III	_	
182-134	38629-38637	multiple	_	
182-135	38638-38647	sclerosis	_	
182-136	38648-38649	(	_	
182-137	38649-38651	MS	_	
182-138	38651-38652	)	_	
182-139	38653-38660	lesions	_	
182-140	38661-38674	Magnetization	_	
182-141	38675-38683	transfer	_	
182-142	38684-38689	SWIFT	_	
182-143	38690-38693	MRI	_	
182-144	38694-38706	consistently	_	
182-145	38707-38714	detects	_	
182-146	38715-38729	histologically	_	
182-147	38730-38738	verified	_	
182-148	38739-38745	myelin	_	
182-149	38746-38750	loss	_	
182-150	38751-38753	in	_	
182-151	38754-38757	the	_	
182-152	38758-38773	thalamocortical	_	
182-153	38774-38781	pathway	_	
182-154	38782-38787	after	_	
182-155	38788-38789	a	_	
182-156	38790-38799	traumatic	_	
182-157	38800-38805	brain	_	
182-158	38806-38812	injury	_	
182-159	38813-38815	in	_	
182-160	38816-38819	rat	_	
182-161	38820-38822	In	_	
182-162	38822-38823	 	_	
182-163	38823-38827	vivo	_	
182-164	38828-38840	quantitative	_	
182-165	38841-38854	magnetization	_	
182-166	38855-38863	transfer	_	
182-167	38864-38871	imaging	_	
182-168	38872-38882	correlates	_	
182-169	38883-38887	with	_	
182-170	38888-38897	histology	_	
182-171	38898-38904	during	_	
182-172	38905-38907	de	_	
182-173	38907-38908	-	_	
182-174	38909-38912	and	_	
182-175	38913-38926	remyelination	_	
182-176	38927-38929	in	_	
182-177	38930-38947	cuprizone-treated	_	
182-178	38948-38952	mice	_	
182-179	38953-38963	Monitoring	_	
182-180	38964-38977	demyelination	_	
182-181	38978-38981	and	_	
182-182	38982-38995	remyelination	_	
182-183	38996-38998	by	_	
182-184	38999-39012	magnetization	_	
182-185	39013-39021	transfer	_	
182-186	39022-39029	imaging	_	
182-187	39030-39032	in	_	
182-188	39033-39036	the	_	
182-189	39037-39042	mouse	_	
182-190	39043-39048	brain	_	
182-191	39049-39051	at	_	
182-192	39052-39055	9.4	_	
182-193	39056-39057	T	_	
182-194	39058-39061	Die	_	
182-195	39062-39083	myeloarchitektonische	_	
182-196	39084-39093	Felderung	_	
182-197	39094-39097	des	_	
182-198	39098-39110	menschlichen	_	
182-199	39111-39121	Stirnhirns	_	
182-200	39122-39133	Adolescence	_	
182-201	39134-39136	is	_	
182-202	39137-39147	associated	_	
182-203	39148-39152	with	_	
182-204	39153-39164	genomically	_	
182-205	39165-39174	patterned	_	
182-206	39175-39188	consolidation	_	
182-207	39189-39191	of	_	
182-208	39192-39195	the	_	
182-209	39196-39200	hubs	_	
182-210	39201-39203	of	_	
182-211	39204-39207	the	_	
182-212	39208-39213	human	_	
182-213	39214-39219	brain	_	
182-214	39220-39230	connectome	_	
182-215	39231-39244	Investigation	_	
182-216	39245-39247	of	_	
182-217	39248-39253	outer	_	
182-218	39254-39262	cortical	_	
182-219	39263-39276	magnetisation	_	
182-220	39277-39285	transfer	_	
182-221	39286-39291	ratio	_	
182-222	39292-39305	abnormalities	_	
182-223	39306-39308	in	_	
182-224	39309-39317	multiple	_	
182-225	39318-39327	sclerosis	_	
182-226	39328-39336	clinical	_	
182-227	39337-39346	subgroups	_	
182-228	39347-39359	Relationship	_	
182-229	39360-39362	of	_	
182-230	39363-39367	grey	_	
182-231	39368-39371	and	_	
182-232	39372-39377	white	_	
182-233	39378-39384	matter	_	
182-234	39385-39398	abnormalities	_	
182-235	39399-39403	with	_	
182-236	39404-39412	distance	_	
182-237	39413-39417	from	_	
182-238	39418-39421	the	_	
182-239	39422-39429	surface	_	
182-240	39430-39432	of	_	
182-241	39433-39436	the	_	
182-242	39437-39442	brain	_	
182-243	39443-39445	in	_	
182-244	39446-39454	multiple	_	
182-245	39455-39464	sclerosis	_	
182-246	39465-39478	Surface-based	_	
182-247	39479-39487	analysis	_	
182-248	39488-39495	reveals	_	
182-249	39496-39503	regions	_	
182-250	39504-39506	of	_	
182-251	39507-39514	reduced	_	
182-252	39515-39523	cortical	_	
182-253	39524-39537	magnetization	_	
182-254	39538-39546	transfer	_	
182-255	39547-39552	ratio	_	
182-256	39553-39555	in	_	
182-257	39556-39564	patients	_	
182-258	39565-39569	with	_	
182-259	39570-39578	multiple	_	
182-260	39579-39588	sclerosis	_	
182-261	39588-39589	:	_	
182-262	39590-39591	A	_	
182-263	39592-39600	proposed	_	
182-264	39601-39607	method	_	
182-265	39608-39611	for	_	
182-266	39612-39619	imaging	_	
182-267	39620-39627	subpial	_	
182-268	39628-39641	demyelination	_	
182-269	39642-39659	Neuropathological	_	
182-270	39660-39673	abnormalities	_	
182-271	39674-39676	in	_	
182-272	39677-39690	schizophrenia	_	
182-273	39690-39691	:	_	
182-274	39692-39700	Evidence	_	
182-275	39701-39705	from	_	
182-276	39706-39719	magnetization	_	
182-277	39720-39728	transfer	_	
182-278	39729-39736	imaging	_	
182-279	39737-39741	Gray	_	
182-280	39742-39745	and	_	
182-281	39746-39751	white	_	
182-282	39752-39758	matter	_	
182-283	39759-39764	brain	_	
182-284	39765-39778	abnormalities	_	
182-285	39779-39781	in	_	
182-286	39782-39795	first-episode	_	
182-287	39796-39809	schizophrenia	_	
182-288	39810-39818	inferred	_	
182-289	39819-39823	from	_	
182-290	39824-39837	magnetization	_	
182-291	39838-39846	transfer	_	
182-292	39847-39854	imaging	_	
182-293	39855-39861	Myelin	_	
182-294	39862-39865	and	_	
182-295	39866-39870	axon	_	
182-296	39871-39884	abnormalities	_	
182-297	39885-39887	in	_	
182-298	39888-39901	schizophrenia	_	
182-299	39902-39910	measured	_	
182-300	39911-39915	with	_	
182-301	39916-39924	magnetic	_	
182-302	39925-39934	resonance	_	
182-303	39935-39942	imaging	_	
182-304	39943-39953	techniques	_	
182-305	39954-39957	DTI	_	
182-306	39958-39961	and	_	
182-307	39962-39965	MTR	_	
182-308	39966-39979	abnormalities	_	
182-309	39980-39982	in	_	
182-310	39983-39996	schizophrenia	_	
182-311	39996-39997	:	_	
182-312	39998-40006	Analysis	_	
182-313	40007-40009	of	_	
182-314	40010-40015	white	_	
182-315	40016-40022	matter	_	
182-316	40023-40032	integrity	_	
182-317	40033-40036	DTI	_	
182-318	40037-40040	and	_	
182-319	40041-40044	MTR	_	
182-320	40045-40058	abnormalities	_	
182-321	40059-40061	in	_	
182-322	40062-40075	schizophrenia	_	
182-323	40076-40077	—	_	
182-324	40078-40083	Voxel	_	
182-325	40084-40088	wise	_	
182-326	40089-40097	analysis	_	
182-327	40098-40100	of	_	
182-328	40101-40106	white	_	
182-329	40107-40113	matter	_	
182-330	40114-40123	integrity	_	
182-331	40124-40132	Combined	_	
182-332	40133-40138	white	_	
182-333	40139-40145	matter	_	
182-334	40146-40153	imaging	_	
182-335	40154-40162	suggests	_	
182-336	40163-40174	myelination	_	
182-337	40175-40182	defects	_	
182-338	40183-40185	in	_	
182-339	40186-40192	visual	_	
182-340	40193-40203	processing	_	
182-341	40204-40211	regions	_	
182-342	40212-40214	in	_	
182-343	40215-40228	schizophrenia	_	
182-344	40229-40242	Magnetization	_	
182-345	40243-40251	transfer	_	
182-346	40252-40259	imaging	_	
182-347	40260-40262	in	_	
182-348	40263-40270	chronic	_	
182-349	40271-40284	schizophrenia	_	
182-350	40285-40293	Cortical	_	
182-351	40294-40307	magnetization	_	
182-352	40308-40316	transfer	_	
182-353	40317-40330	abnormalities	_	
182-354	40331-40334	and	_	
182-355	40335-40345	connectome	_	
182-356	40346-40361	dysconnectivity	_	
182-357	40362-40364	in	_	
182-358	40365-40378	schizophrenia	_	
182-359	40379-40388	Hierarchy	_	
182-360	40389-40391	of	_	
182-361	40392-40406	transcriptomic	_	
182-362	40407-40421	specialization	_	
182-363	40422-40428	across	_	
182-364	40429-40434	human	_	
182-365	40435-40441	cortex	_	
182-366	40442-40450	captured	_	
182-367	40451-40453	by	_	
182-368	40454-40464	structural	_	
182-369	40465-40477	neuroimaging	_	
182-370	40478-40488	topography	_	
182-371	40489-40495	Cohort	_	
182-372	40496-40503	profile	_	
182-373	40503-40504	:	_	
182-374	40505-40508	The	_	
182-375	40509-40513	NSPN	_	
182-376	40514-40518	2400	_	
182-377	40519-40525	Cohort	_	
182-378	40525-40526	:	_	
182-379	40527-40528	A	_	
182-380	40529-40542	developmental	_	
182-381	40543-40549	sample	_	
182-382	40550-40560	supporting	_	
182-383	40561-40564	the	_	
182-384	40565-40573	Wellcome	_	
182-385	40574-40579	Trust	_	
182-386	40580-40585	Neuro	_	
182-387	40586-40593	Science	_	
182-388	40594-40596	in	_	
182-389	40597-40607	Psychiatry	_	
182-390	40608-40615	Network	_	
182-391	40616-40619	The	_	
182-392	40620-40623	SPQ	_	
182-393	40623-40624	:	_	
182-394	40625-40626	A	_	
182-395	40627-40632	scale	_	
182-396	40633-40636	for	_	
182-397	40637-40640	the	_	
182-398	40641-40651	assessment	_	
182-399	40652-40654	of	_	
182-400	40655-40666	schizotypal	_	
182-401	40667-40678	personality	_	
182-402	40679-40684	based	_	
182-403	40685-40687	on	_	
182-404	40688-40697	DSM-III-R	_	
182-405	40698-40706	criteria	_	
182-406	40707-40719	Morphometric	_	
182-407	40720-40730	similarity	_	
182-408	40731-40739	networks	_	
182-409	40740-40746	detect	_	
182-410	40747-40757	microscale	_	
182-411	40758-40766	cortical	_	
182-412	40767-40779	organization	_	
182-413	40780-40783	and	_	
182-414	40784-40791	predict	_	
182-415	40792-40808	inter-individual	_	
182-416	40809-40818	cognitive	_	
182-417	40819-40828	variation	_	
182-418	40829-40839	Adolescent	_	
182-419	40840-40846	tuning	_	
182-420	40847-40849	of	_	
182-421	40850-40861	association	_	
182-422	40862-40868	cortex	_	
182-423	40869-40871	in	_	
182-424	40872-40877	human	_	
182-425	40878-40888	structural	_	
182-426	40889-40894	brain	_	
182-427	40895-40903	networks	_	
182-428	40904-40916	Quantitative	_	
182-429	40917-40927	assessment	_	
182-430	40928-40930	of	_	
182-431	40931-40941	structural	_	
182-432	40942-40947	image	_	
182-433	40948-40955	quality	_	
182-434	40956-40958	An	_	
182-435	40959-40971	anatomically	_	
182-436	40972-40985	comprehensive	_	
182-437	40986-40991	atlas	_	
182-438	40992-40994	of	_	
182-439	40995-40998	the	_	
182-440	40999-41004	adult	_	
182-441	41005-41010	human	_	
182-442	41011-41016	brain	_	
182-443	41017-41030	transcriptome	_	
182-444	41031-41032	A	_	
182-445	41032-41033	 	_	
182-446	41033-41042	practical	_	
182-447	41043-41048	guide	_	
182-448	41049-41051	to	_	
182-449	41052-41059	linking	_	
182-450	41060-41070	brain-wide	_	
182-451	41071-41075	gene	_	
182-452	41076-41086	expression	_	
182-453	41087-41090	and	_	
182-454	41091-41103	neuroimaging	_	
182-455	41104-41108	data	_	
182-456	41109-41121	Re-Annotator	_	
182-457	41121-41122	:	_	
182-458	41123-41133	Annotation	_	
182-459	41134-41142	pipeline	_	
182-460	41143-41146	for	_	
182-461	41147-41157	microarray	_	
182-462	41158-41163	probe	_	
182-463	41164-41173	sequences	_	
182-464	41174-41179	BRAIN	_	
182-465	41180-41188	NETWORKS	_	
182-466	41188-41189	.	_	

#Text=Correlated gene expression supports synchronous activity in brain networks
#Text=Strategies for aggregating gene expression data: The collapseRows R function
#Text=Structural covariance networks are coupled to expression of genes enriched in supragranular layers of the human cortex
#Text=A comparison of partial least squares (PLS) and ordinary least squares (OLS) regressions in predicting of couples mental health based on their communicational patterns
#Text=
#Text=Brain regions showing white matter loss in Huntington’s disease are enriched for synaptic and metabolic genes
#Text=Synaptic and transcriptionally downregulated genes are associated with cortical thickness differences in autism
#Text=Cortical patterning of abnormal morphometric similarity in psychosis is associated with brain expression of schizophrenia-related genes
#Text=Gene transcription profiles associated with inter-modular hubs and connection distance in human functional magnetic resonance imaging networks
#Text=Variation among intact tissue samples reveals the core transcriptional features of human CNS cell classes
#Text=Transcriptomic evidence for alterations in astrocytes and parvalbumin interneurons in subjects with bipolar disorder and schizophrenia
#Text=Gene expression elucidates functional impact of polygenic risk for schizophrenia
#Text=
#Text=Yarkoni T, Poldrack R, Nichols T, Van Essen D, Wager T (2011): NeuroSynth: A new platform for large-scale automated synthesis of human functional neuroimaging data.
183-1	41190-41200	Correlated	_	
183-2	41201-41205	gene	_	
183-3	41206-41216	expression	_	
183-4	41217-41225	supports	_	
183-5	41226-41237	synchronous	_	
183-6	41238-41246	activity	_	
183-7	41247-41249	in	_	
183-8	41250-41255	brain	_	
183-9	41256-41264	networks	_	
183-10	41265-41275	Strategies	_	
183-11	41276-41279	for	_	
183-12	41280-41291	aggregating	_	
183-13	41292-41296	gene	_	
183-14	41297-41307	expression	_	
183-15	41308-41312	data	_	
183-16	41312-41313	:	_	
183-17	41314-41317	The	_	
183-18	41318-41330	collapseRows	_	
183-19	41331-41332	R	_	
183-20	41333-41341	function	_	
183-21	41342-41352	Structural	_	
183-22	41353-41363	covariance	_	
183-23	41364-41372	networks	_	
183-24	41373-41376	are	_	
183-25	41377-41384	coupled	_	
183-26	41385-41387	to	_	
183-27	41388-41398	expression	_	
183-28	41399-41401	of	_	
183-29	41402-41407	genes	_	
183-30	41408-41416	enriched	_	
183-31	41417-41419	in	_	
183-32	41420-41433	supragranular	_	
183-33	41434-41440	layers	_	
183-34	41441-41443	of	_	
183-35	41444-41447	the	_	
183-36	41448-41453	human	_	
183-37	41454-41460	cortex	_	
183-38	41461-41462	A	_	
183-39	41462-41463	 	_	
183-40	41463-41473	comparison	_	
183-41	41474-41476	of	_	
183-42	41477-41484	partial	_	
183-43	41485-41490	least	_	
183-44	41491-41498	squares	_	
183-45	41499-41500	(	_	
183-46	41500-41503	PLS	_	
183-47	41503-41504	)	_	
183-48	41505-41508	and	_	
183-49	41509-41517	ordinary	_	
183-50	41518-41523	least	_	
183-51	41524-41531	squares	_	
183-52	41532-41533	(	_	
183-53	41533-41536	OLS	_	
183-54	41536-41537	)	_	
183-55	41538-41549	regressions	_	
183-56	41550-41552	in	_	
183-57	41553-41563	predicting	_	
183-58	41564-41566	of	_	
183-59	41567-41574	couples	_	
183-60	41575-41581	mental	_	
183-61	41582-41588	health	_	
183-62	41589-41594	based	_	
183-63	41595-41597	on	_	
183-64	41598-41603	their	_	
183-65	41604-41619	communicational	_	
183-66	41620-41628	patterns	_	
183-67	41630-41635	Brain	_	
183-68	41636-41643	regions	_	
183-69	41644-41651	showing	_	
183-70	41652-41657	white	_	
183-71	41658-41664	matter	_	
183-72	41665-41669	loss	_	
183-73	41670-41672	in	_	
183-74	41673-41683	Huntington	_	
183-75	41683-41684	’	_	
183-76	41684-41685	s	_	
183-77	41686-41693	disease	_	
183-78	41694-41697	are	_	
183-79	41698-41706	enriched	_	
183-80	41707-41710	for	_	
183-81	41711-41719	synaptic	_	
183-82	41720-41723	and	_	
183-83	41724-41733	metabolic	_	
183-84	41734-41739	genes	_	
183-85	41740-41748	Synaptic	_	
183-86	41749-41752	and	_	
183-87	41753-41770	transcriptionally	_	
183-88	41771-41784	downregulated	_	
183-89	41785-41790	genes	_	
183-90	41791-41794	are	_	
183-91	41795-41805	associated	_	
183-92	41806-41810	with	_	
183-93	41811-41819	cortical	_	
183-94	41820-41829	thickness	_	
183-95	41830-41841	differences	_	
183-96	41842-41844	in	_	
183-97	41845-41851	autism	_	
183-98	41852-41860	Cortical	_	
183-99	41861-41871	patterning	_	
183-100	41872-41874	of	_	
183-101	41875-41883	abnormal	_	
183-102	41884-41896	morphometric	_	
183-103	41897-41907	similarity	_	
183-104	41908-41910	in	_	
183-105	41911-41920	psychosis	_	
183-106	41921-41923	is	_	
183-107	41924-41934	associated	_	
183-108	41935-41939	with	_	
183-109	41940-41945	brain	_	
183-110	41946-41956	expression	_	
183-111	41957-41959	of	_	
183-112	41960-41981	schizophrenia-related	_	
183-113	41982-41987	genes	_	
183-114	41988-41992	Gene	_	
183-115	41993-42006	transcription	_	
183-116	42007-42015	profiles	_	
183-117	42016-42026	associated	_	
183-118	42027-42031	with	_	
183-119	42032-42045	inter-modular	_	
183-120	42046-42050	hubs	_	
183-121	42051-42054	and	_	
183-122	42055-42065	connection	_	
183-123	42066-42074	distance	_	
183-124	42075-42077	in	_	
183-125	42078-42083	human	_	
183-126	42084-42094	functional	_	
183-127	42095-42103	magnetic	_	
183-128	42104-42113	resonance	_	
183-129	42114-42121	imaging	_	
183-130	42122-42130	networks	_	
183-131	42131-42140	Variation	_	
183-132	42141-42146	among	_	
183-133	42147-42153	intact	_	
183-134	42154-42160	tissue	_	
183-135	42161-42168	samples	_	
183-136	42169-42176	reveals	_	
183-137	42177-42180	the	_	
183-138	42181-42185	core	_	
183-139	42186-42201	transcriptional	_	
183-140	42202-42210	features	_	
183-141	42211-42213	of	_	
183-142	42214-42219	human	_	
183-143	42220-42223	CNS	_	
183-144	42224-42228	cell	_	
183-145	42229-42236	classes	_	
183-146	42237-42251	Transcriptomic	_	
183-147	42252-42260	evidence	_	
183-148	42261-42264	for	_	
183-149	42265-42276	alterations	_	
183-150	42277-42279	in	_	
183-151	42280-42290	astrocytes	_	
183-152	42291-42294	and	_	
183-153	42295-42306	parvalbumin	_	
183-154	42307-42319	interneurons	_	
183-155	42320-42322	in	_	
183-156	42323-42331	subjects	_	
183-157	42332-42336	with	_	
183-158	42337-42344	bipolar	_	
183-159	42345-42353	disorder	_	
183-160	42354-42357	and	_	
183-161	42358-42371	schizophrenia	_	
183-162	42372-42376	Gene	_	
183-163	42377-42387	expression	_	
183-164	42388-42398	elucidates	_	
183-165	42399-42409	functional	_	
183-166	42410-42416	impact	_	
183-167	42417-42419	of	_	
183-168	42420-42429	polygenic	_	
183-169	42430-42434	risk	_	
183-170	42435-42438	for	_	
183-171	42439-42452	schizophrenia	_	
183-172	42454-42461	Yarkoni	_	
183-173	42462-42463	T	_	
183-174	42463-42464	,	_	
183-175	42465-42473	Poldrack	_	
183-176	42474-42475	R	_	
183-177	42475-42476	,	_	
183-178	42477-42484	Nichols	_	
183-179	42485-42486	T	_	
183-180	42486-42487	,	_	
183-181	42488-42491	Van	_	
183-182	42492-42497	Essen	_	
183-183	42498-42499	D	_	
183-184	42499-42500	,	_	
183-185	42501-42506	Wager	_	
183-186	42507-42508	T	_	
183-187	42509-42510	(	_	
183-188	42510-42514	2011	_	
183-189	42514-42515	)	_	
183-190	42515-42516	:	_	
183-191	42517-42527	NeuroSynth	_	
183-192	42527-42528	:	_	
183-193	42529-42530	A	_	
183-194	42531-42534	new	_	
183-195	42535-42543	platform	_	
183-196	42544-42547	for	_	
183-197	42548-42559	large-scale	_	
183-198	42560-42569	automated	_	
183-199	42570-42579	synthesis	_	
183-200	42580-42582	of	_	
183-201	42583-42588	human	_	
183-202	42589-42599	functional	_	
183-203	42600-42612	neuroimaging	_	
183-204	42613-42617	data	_	
183-205	42617-42618	.	_	

#Text=Presented at the 4th INCF Congress of Neuroinformatics, September 4–6, Boston, Massachusetts.
184-1	42619-42628	Presented	_	
184-2	42629-42631	at	_	
184-3	42632-42635	the	_	
184-4	42636-42639	4th	_	
184-5	42640-42644	INCF	_	
184-6	42645-42653	Congress	_	
184-7	42654-42656	of	_	
184-8	42657-42673	Neuroinformatics	_	
184-9	42673-42674	,	_	
184-10	42675-42684	September	_	
184-11	42685-42686	4	_	
184-12	42686-42687	–	_	
184-13	42687-42688	6	_	
184-14	42688-42689	,	_	
184-15	42690-42696	Boston	_	
184-16	42696-42697	,	_	
184-17	42698-42711	Massachusetts	_	
184-18	42711-42712	.	_	

#Text=Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality
#Text=Connectome disconnectivity and cortical gene expression in patients with schizophrenia
#Text=STRING v10: Protein-protein interaction networks, integrated over the tree of life
#Text=Studying neuroanatomy using MRI
#Text=Myelin and iron concentration in the human brain: A quantitative study of MRI contrast
#Text=Quantitative MRI provides markers of intra-, inter-regional, and age-related differences in young adult cortical microstructure
#Text=Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain
#Text=The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: Evidence from a partial correlation network analysis
#Text=White matter abnormalities in schizophrenia and schizotypal personality disorder
#Text=Waves of maturation and senescence in micro-structural MRI markers of human cortical myelination over the lifespan
#Text=Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia
#Text=Overlap of autistic and schizotypal traits in adolescents with Autism Spectrum Disorders
#Text=Schizotypal dimensions: Continuity between schizophrenia and bipolar disorders
#Text=Neural substrates of a schizotypal spectrum in typically developing children: Further evidence of a normal-pathological continuum
#Text=Brain structural correlates of schizotypy and psychosis proneness in a non-clinical healthy volunteer sample
#Text=Neurobiological changes of schizotypy: Evidence from both volume-based morphometric analysis and resting-state functional connectivity
#Text=Evidence from structural and diffusion tensor imaging for frontotemporal deficits in psychometric schizotypy
#Text=Higher prefrontal cortical thickness in high schizotypal personality trait
#Text=Association between brain structure and psychometric schizotypy in healthy individuals
#Text=Schizotypy and brain structure: A voxel-based morphometry study
#Text=Progressive temporal lobe grey matter loss in adolescents with schizotypal traits and mild intellectual impairment
#Text=Increased right prefrontal cortical folding in adolescents at risk of schizophrenia for cognitive reasons
#Text=Supplementary Material
#Text=NSPN Consortium member list: Principal investigators: Edward Bullmore (Chief Investigator from January 1, 2017), Raymond Dolan, Ian Goodyer (Chief Investigator until January 1, 2017), Peter Fonagy, Peter Jones; NSPN (funded) staff: Matilde Vaghi, Michael Moutoussis, Tobias Hauser, Sharon Neufeld, Rafael Romero-Garcia, Michelle St Clair, Kirstie Whitaker, Becky Inkster, Gita Prabhu, Cinly Ooi, Umar Toseeb, Barry Widmer, Junaid Bhatti, Laura Villis, Ayesha Alrumaithi, Sarah Birt, Aislinn Bowler, Kalia Cleridou, Hina Dadabhoy, Emma Davies, Ashlyn Firkins, Sian Granville, Elizabeth Harding, Alexandra Hopkins, Daniel Isaacs, Janchai King, Danae Kokorikou, Christina Maurice, Cleo McIntosh, Jessica Memarzia, Harriet Mills, Ciara O’Donnell, Sara Pantaleone, Jenny Scott; Affiliated scientists: Pasco Fearon, John Suckling, Anne-Laura van Harmelen, Rogier Kievit, Petra Vértes; full member list available in the Supplement.
185-1	42713-42733	Cognitive-perceptual	_	
185-2	42733-42734	,	_	
185-3	42735-42748	interpersonal	_	
185-4	42748-42749	,	_	
185-5	42750-42753	and	_	
185-6	42754-42766	disorganized	_	
185-7	42767-42775	features	_	
185-8	42776-42778	of	_	
185-9	42779-42790	schizotypal	_	
185-10	42791-42802	personality	_	
185-11	42803-42813	Connectome	_	
185-12	42814-42829	disconnectivity	_	
185-13	42830-42833	and	_	
185-14	42834-42842	cortical	_	
185-15	42843-42847	gene	_	
185-16	42848-42858	expression	_	
185-17	42859-42861	in	_	
185-18	42862-42870	patients	_	
185-19	42871-42875	with	_	
185-20	42876-42889	schizophrenia	_	
185-21	42890-42896	STRING	_	
185-22	42897-42900	v10	_	
185-23	42900-42901	:	_	
185-24	42902-42917	Protein-protein	_	
185-25	42918-42929	interaction	_	
185-26	42930-42938	networks	_	
185-27	42938-42939	,	_	
185-28	42940-42950	integrated	_	
185-29	42951-42955	over	_	
185-30	42956-42959	the	_	
185-31	42960-42964	tree	_	
185-32	42965-42967	of	_	
185-33	42968-42972	life	_	
185-34	42973-42981	Studying	_	
185-35	42982-42994	neuroanatomy	_	
185-36	42995-43000	using	_	
185-37	43001-43004	MRI	_	
185-38	43005-43011	Myelin	_	
185-39	43012-43015	and	_	
185-40	43016-43020	iron	_	
185-41	43021-43034	concentration	_	
185-42	43035-43037	in	_	
185-43	43038-43041	the	_	
185-44	43042-43047	human	_	
185-45	43048-43053	brain	_	
185-46	43053-43054	:	_	
185-47	43055-43056	A	_	
185-48	43057-43069	quantitative	_	
185-49	43070-43075	study	_	
185-50	43076-43078	of	_	
185-51	43079-43082	MRI	_	
185-52	43083-43091	contrast	_	
185-53	43092-43104	Quantitative	_	
185-54	43105-43108	MRI	_	
185-55	43109-43117	provides	_	
185-56	43118-43125	markers	_	
185-57	43126-43128	of	_	
185-58	43129-43134	intra	_	
185-59	43134-43135	-	_	
185-60	43135-43136	,	_	
185-61	43137-43151	inter-regional	_	
185-62	43151-43152	,	_	
185-63	43153-43156	and	_	
185-64	43157-43168	age-related	_	
185-65	43169-43180	differences	_	
185-66	43181-43183	in	_	
185-67	43184-43189	young	_	
185-68	43190-43195	adult	_	
185-69	43196-43204	cortical	_	
185-70	43205-43219	microstructure	_	
185-71	43220-43233	Magnetization	_	
185-72	43234-43242	transfer	_	
185-73	43243-43248	ratio	_	
185-74	43249-43252	and	_	
185-75	43253-43259	myelin	_	
185-76	43260-43262	in	_	
185-77	43263-43273	postmortem	_	
185-78	43274-43282	multiple	_	
185-79	43283-43292	sclerosis	_	
185-80	43293-43298	brain	_	
185-81	43299-43302	The	_	
185-82	43303-43312	precuneus	_	
185-83	43312-43313	/	_	
185-84	43313-43322	posterior	_	
185-85	43323-43332	cingulate	_	
185-86	43333-43339	cortex	_	
185-87	43340-43345	plays	_	
185-88	43346-43347	a	_	
185-89	43348-43355	pivotal	_	
185-90	43356-43360	role	_	
185-91	43361-43363	in	_	
185-92	43364-43367	the	_	
185-93	43368-43375	default	_	
185-94	43376-43380	mode	_	
185-95	43381-43388	network	_	
185-96	43388-43389	:	_	
185-97	43390-43398	Evidence	_	
185-98	43399-43403	from	_	
185-99	43404-43405	a	_	
185-100	43406-43413	partial	_	
185-101	43414-43425	correlation	_	
185-102	43426-43433	network	_	
185-103	43434-43442	analysis	_	
185-104	43443-43448	White	_	
185-105	43449-43455	matter	_	
185-106	43456-43469	abnormalities	_	
185-107	43470-43472	in	_	
185-108	43473-43486	schizophrenia	_	
185-109	43487-43490	and	_	
185-110	43491-43502	schizotypal	_	
185-111	43503-43514	personality	_	
185-112	43515-43523	disorder	_	
185-113	43524-43529	Waves	_	
185-114	43530-43532	of	_	
185-115	43533-43543	maturation	_	
185-116	43544-43547	and	_	
185-117	43548-43558	senescence	_	
185-118	43559-43561	in	_	
185-119	43562-43578	micro-structural	_	
185-120	43579-43582	MRI	_	
185-121	43583-43590	markers	_	
185-122	43591-43593	of	_	
185-123	43594-43599	human	_	
185-124	43600-43608	cortical	_	
185-125	43609-43620	myelination	_	
185-126	43621-43625	over	_	
185-127	43626-43629	the	_	
185-128	43630-43638	lifespan	_	
185-129	43639-43643	Gene	_	
185-130	43644-43654	expression	_	
185-131	43655-43663	deficits	_	
185-132	43664-43666	in	_	
185-133	43667-43668	a	_	
185-134	43669-43677	subclass	_	
185-135	43678-43680	of	_	
185-136	43681-43685	GABA	_	
185-137	43686-43693	neurons	_	
185-138	43694-43696	in	_	
185-139	43697-43700	the	_	
185-140	43701-43711	prefrontal	_	
185-141	43712-43718	cortex	_	
185-142	43719-43721	of	_	
185-143	43722-43730	subjects	_	
185-144	43731-43735	with	_	
185-145	43736-43749	schizophrenia	_	
185-146	43750-43757	Overlap	_	
185-147	43758-43760	of	_	
185-148	43761-43769	autistic	_	
185-149	43770-43773	and	_	
185-150	43774-43785	schizotypal	_	
185-151	43786-43792	traits	_	
185-152	43793-43795	in	_	
185-153	43796-43807	adolescents	_	
185-154	43808-43812	with	_	
185-155	43813-43819	Autism	_	
185-156	43820-43828	Spectrum	_	
185-157	43829-43838	Disorders	_	
185-158	43839-43850	Schizotypal	_	
185-159	43851-43861	dimensions	_	
185-160	43861-43862	:	_	
185-161	43863-43873	Continuity	_	
185-162	43874-43881	between	_	
185-163	43882-43895	schizophrenia	_	
185-164	43896-43899	and	_	
185-165	43900-43907	bipolar	_	
185-166	43908-43917	disorders	_	
185-167	43918-43924	Neural	_	
185-168	43925-43935	substrates	_	
185-169	43936-43938	of	_	
185-170	43939-43940	a	_	
185-171	43941-43952	schizotypal	_	
185-172	43953-43961	spectrum	_	
185-173	43962-43964	in	_	
185-174	43965-43974	typically	_	
185-175	43975-43985	developing	_	
185-176	43986-43994	children	_	
185-177	43994-43995	:	_	
185-178	43996-44003	Further	_	
185-179	44004-44012	evidence	_	
185-180	44013-44015	of	_	
185-181	44016-44017	a	_	
185-182	44018-44037	normal-pathological	_	
185-183	44038-44047	continuum	_	
185-184	44048-44053	Brain	_	
185-185	44054-44064	structural	_	
185-186	44065-44075	correlates	_	
185-187	44076-44078	of	_	
185-188	44079-44089	schizotypy	_	
185-189	44090-44093	and	_	
185-190	44094-44103	psychosis	_	
185-191	44104-44113	proneness	_	
185-192	44114-44116	in	_	
185-193	44117-44118	a	_	
185-194	44119-44131	non-clinical	_	
185-195	44132-44139	healthy	_	
185-196	44140-44149	volunteer	_	
185-197	44150-44156	sample	_	
185-198	44157-44172	Neurobiological	_	
185-199	44173-44180	changes	_	
185-200	44181-44183	of	_	
185-201	44184-44194	schizotypy	_	
185-202	44194-44195	:	_	
185-203	44196-44204	Evidence	_	
185-204	44205-44209	from	_	
185-205	44210-44214	both	_	
185-206	44215-44227	volume-based	_	
185-207	44228-44240	morphometric	_	
185-208	44241-44249	analysis	_	
185-209	44250-44253	and	_	
185-210	44254-44267	resting-state	_	
185-211	44268-44278	functional	_	
185-212	44279-44291	connectivity	_	
185-213	44292-44300	Evidence	_	
185-214	44301-44305	from	_	
185-215	44306-44316	structural	_	
185-216	44317-44320	and	_	
185-217	44321-44330	diffusion	_	
185-218	44331-44337	tensor	_	
185-219	44338-44345	imaging	_	
185-220	44346-44349	for	_	
185-221	44350-44364	frontotemporal	_	
185-222	44365-44373	deficits	_	
185-223	44374-44376	in	_	
185-224	44377-44389	psychometric	_	
185-225	44390-44400	schizotypy	_	
185-226	44401-44407	Higher	_	
185-227	44408-44418	prefrontal	_	
185-228	44419-44427	cortical	_	
185-229	44428-44437	thickness	_	
185-230	44438-44440	in	_	
185-231	44441-44445	high	_	
185-232	44446-44457	schizotypal	_	
185-233	44458-44469	personality	_	
185-234	44470-44475	trait	_	
185-235	44476-44487	Association	_	
185-236	44488-44495	between	_	
185-237	44496-44501	brain	_	
185-238	44502-44511	structure	_	
185-239	44512-44515	and	_	
185-240	44516-44528	psychometric	_	
185-241	44529-44539	schizotypy	_	
185-242	44540-44542	in	_	
185-243	44543-44550	healthy	_	
185-244	44551-44562	individuals	_	
185-245	44563-44573	Schizotypy	_	
185-246	44574-44577	and	_	
185-247	44578-44583	brain	_	
185-248	44584-44593	structure	_	
185-249	44593-44594	:	_	
185-250	44595-44596	A	_	
185-251	44597-44608	voxel-based	_	
185-252	44609-44620	morphometry	_	
185-253	44621-44626	study	_	
185-254	44627-44638	Progressive	_	
185-255	44639-44647	temporal	_	
185-256	44648-44652	lobe	_	
185-257	44653-44657	grey	_	
185-258	44658-44664	matter	_	
185-259	44665-44669	loss	_	
185-260	44670-44672	in	_	
185-261	44673-44684	adolescents	_	
185-262	44685-44689	with	_	
185-263	44690-44701	schizotypal	_	
185-264	44702-44708	traits	_	
185-265	44709-44712	and	_	
185-266	44713-44717	mild	_	
185-267	44718-44730	intellectual	_	
185-268	44731-44741	impairment	_	
185-269	44742-44751	Increased	_	
185-270	44752-44757	right	_	
185-271	44758-44768	prefrontal	_	
185-272	44769-44777	cortical	_	
185-273	44778-44785	folding	_	
185-274	44786-44788	in	_	
185-275	44789-44800	adolescents	_	
185-276	44801-44803	at	_	
185-277	44804-44808	risk	_	
185-278	44809-44811	of	_	
185-279	44812-44825	schizophrenia	_	
185-280	44826-44829	for	_	
185-281	44830-44839	cognitive	_	
185-282	44840-44847	reasons	_	
185-283	44848-44861	Supplementary	_	
185-284	44862-44870	Material	_	
185-285	44871-44875	NSPN	_	
185-286	44876-44886	Consortium	_	
185-287	44887-44893	member	_	
185-288	44894-44898	list	_	
185-289	44898-44899	:	_	
185-290	44900-44909	Principal	_	
185-291	44910-44923	investigators	_	
185-292	44923-44924	:	_	
185-293	44925-44931	Edward	_	
185-294	44932-44940	Bullmore	_	
185-295	44941-44942	(	_	
185-296	44942-44947	Chief	_	
185-297	44948-44960	Investigator	_	
185-298	44961-44965	from	_	
185-299	44966-44973	January	_	
185-300	44974-44975	1	_	
185-301	44975-44976	,	_	
185-302	44977-44981	2017	_	
185-303	44981-44982	)	_	
185-304	44982-44983	,	_	
185-305	44984-44991	Raymond	_	
185-306	44992-44997	Dolan	_	
185-307	44997-44998	,	_	
185-308	44999-45002	Ian	_	
185-309	45003-45010	Goodyer	_	
185-310	45011-45012	(	_	
185-311	45012-45017	Chief	_	
185-312	45018-45030	Investigator	_	
185-313	45031-45036	until	_	
185-314	45037-45044	January	_	
185-315	45045-45046	1	_	
185-316	45046-45047	,	_	
185-317	45048-45052	2017	_	
185-318	45052-45053	)	_	
185-319	45053-45054	,	_	
185-320	45055-45060	Peter	_	
185-321	45061-45067	Fonagy	_	
185-322	45067-45068	,	_	
185-323	45069-45074	Peter	_	
185-324	45075-45080	Jones	_	
185-325	45080-45081	;	_	
185-326	45082-45086	NSPN	_	
185-327	45087-45088	(	_	
185-328	45088-45094	funded	_	
185-329	45094-45095	)	_	
185-330	45096-45101	staff	_	
185-331	45101-45102	:	_	
185-332	45103-45110	Matilde	_	
185-333	45111-45116	Vaghi	_	
185-334	45116-45117	,	_	
185-335	45118-45125	Michael	_	
185-336	45126-45136	Moutoussis	_	
185-337	45136-45137	,	_	
185-338	45138-45144	Tobias	_	
185-339	45145-45151	Hauser	_	
185-340	45151-45152	,	_	
185-341	45153-45159	Sharon	_	
185-342	45160-45167	Neufeld	_	
185-343	45167-45168	,	_	
185-344	45169-45175	Rafael	_	
185-345	45176-45189	Romero-Garcia	_	
185-346	45189-45190	,	_	
185-347	45191-45199	Michelle	_	
185-348	45200-45202	St	_	
185-349	45203-45208	Clair	_	
185-350	45208-45209	,	_	
185-351	45210-45217	Kirstie	_	
185-352	45218-45226	Whitaker	_	
185-353	45226-45227	,	_	
185-354	45228-45233	Becky	_	
185-355	45234-45241	Inkster	_	
185-356	45241-45242	,	_	
185-357	45243-45247	Gita	_	
185-358	45248-45254	Prabhu	_	
185-359	45254-45255	,	_	
185-360	45256-45261	Cinly	_	
185-361	45262-45265	Ooi	_	
185-362	45265-45266	,	_	
185-363	45267-45271	Umar	_	
185-364	45272-45278	Toseeb	_	
185-365	45278-45279	,	_	
185-366	45280-45285	Barry	_	
185-367	45286-45292	Widmer	_	
185-368	45292-45293	,	_	
185-369	45294-45300	Junaid	_	
185-370	45301-45307	Bhatti	_	
185-371	45307-45308	,	_	
185-372	45309-45314	Laura	_	
185-373	45315-45321	Villis	_	
185-374	45321-45322	,	_	
185-375	45323-45329	Ayesha	_	
185-376	45330-45340	Alrumaithi	_	
185-377	45340-45341	,	_	
185-378	45342-45347	Sarah	_	
185-379	45348-45352	Birt	_	
185-380	45352-45353	,	_	
185-381	45354-45361	Aislinn	_	
185-382	45362-45368	Bowler	_	
185-383	45368-45369	,	_	
185-384	45370-45375	Kalia	_	
185-385	45376-45384	Cleridou	_	
185-386	45384-45385	,	_	
185-387	45386-45390	Hina	_	
185-388	45391-45399	Dadabhoy	_	
185-389	45399-45400	,	_	
185-390	45401-45405	Emma	_	
185-391	45406-45412	Davies	_	
185-392	45412-45413	,	_	
185-393	45414-45420	Ashlyn	_	
185-394	45421-45428	Firkins	_	
185-395	45428-45429	,	_	
185-396	45430-45434	Sian	_	
185-397	45435-45444	Granville	_	
185-398	45444-45445	,	_	
185-399	45446-45455	Elizabeth	_	
185-400	45456-45463	Harding	_	
185-401	45463-45464	,	_	
185-402	45465-45474	Alexandra	_	
185-403	45475-45482	Hopkins	_	
185-404	45482-45483	,	_	
185-405	45484-45490	Daniel	_	
185-406	45491-45497	Isaacs	_	
185-407	45497-45498	,	_	
185-408	45499-45506	Janchai	_	
185-409	45507-45511	King	_	
185-410	45511-45512	,	_	
185-411	45513-45518	Danae	_	
185-412	45519-45528	Kokorikou	_	
185-413	45528-45529	,	_	
185-414	45530-45539	Christina	_	
185-415	45540-45547	Maurice	_	
185-416	45547-45548	,	_	
185-417	45549-45553	Cleo	_	
185-418	45554-45562	McIntosh	_	
185-419	45562-45563	,	_	
185-420	45564-45571	Jessica	_	
185-421	45572-45580	Memarzia	_	
185-422	45580-45581	,	_	
185-423	45582-45589	Harriet	_	
185-424	45590-45595	Mills	_	
185-425	45595-45596	,	_	
185-426	45597-45602	Ciara	_	
185-427	45603-45604	O	_	
185-428	45604-45605	’	_	
185-429	45605-45612	Donnell	_	
185-430	45612-45613	,	_	
185-431	45614-45618	Sara	_	
185-432	45619-45629	Pantaleone	_	
185-433	45629-45630	,	_	
185-434	45631-45636	Jenny	_	
185-435	45637-45642	Scott	_	
185-436	45642-45643	;	_	
185-437	45644-45654	Affiliated	_	
185-438	45655-45665	scientists	_	
185-439	45665-45666	:	_	
185-440	45667-45672	Pasco	_	
185-441	45673-45679	Fearon	_	
185-442	45679-45680	,	_	
185-443	45681-45685	John	_	
185-444	45686-45694	Suckling	_	
185-445	45694-45695	,	_	
185-446	45696-45706	Anne-Laura	_	
185-447	45707-45710	van	_	
185-448	45711-45719	Harmelen	_	
185-449	45719-45720	,	_	
185-450	45721-45727	Rogier	_	
185-451	45728-45734	Kievit	_	
185-452	45734-45735	,	_	
185-453	45736-45741	Petra	_	
185-454	45742-45748	Vértes	_	
185-455	45748-45749	;	_	
185-456	45750-45754	full	_	
185-457	45755-45761	member	_	
185-458	45762-45766	list	_	
185-459	45767-45776	available	_	
185-460	45777-45779	in	_	
185-461	45780-45783	the	_	
185-462	45784-45794	Supplement	_	
185-463	45794-45795	.	_	

#Text=Supplementary material cited in this article is available online at https://doi.org/10.1016/j.biopsych.2019.12.005.
186-1	45796-45809	Supplementary	_	
186-2	45810-45818	material	_	
186-3	45819-45824	cited	_	
186-4	45825-45827	in	_	
186-5	45828-45832	this	_	
186-6	45833-45840	article	_	
186-7	45841-45843	is	_	
186-8	45844-45853	available	_	
186-9	45854-45860	online	_	
186-10	45861-45863	at	_	
186-11	45864-45869	https	_	
186-12	45869-45870	:	_	
186-13	45870-45871	/	_	
186-14	45871-45872	/	_	
186-15	45872-45879	doi.org	_	
186-16	45879-45880	/	_	
186-17	45880-45887	10.1016	_	
186-18	45887-45888	/	_	
186-19	45888-45898	j.biopsych	_	
186-20	45898-45910	.2019.12.005	_	
186-21	45910-45911	.	_	
